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1 Introduction 
Due to international concerted cancer research nowadays patients can be offered 
individually tailored antineoplastic therapies. Systemic therapies are part of most 
therapeutic strategies and for some malignancies they even seem to be the only 
option. More cancers are curable or can be halted in a chronic state which goes along 
with changing patient needs. This is why in recent years a paradigm shift occurred 
towards a patient-focused rather than a disease-focused approach. Patients’ quality of 
life and patients’ satisfaction during and after the antineoplastic treatment emerged to 
be important outcome parameters alongside the tumour response. Supportive therapy 
became an integral part of the antineoplastic therapy to limit the therapy-associated 
toxicity. Moreover the significance of complementary therapy options for cancer 
patients became evident. However, not only anticancer drugs have to be taken into 
consideration. The patient often has to take additional medication against other 
underlying conditions such as asthma, diabetes etc. Altogether it is crucial striving for 
offering the patient an appropriately indicated, effective, safe and convenient drug 
therapy. 
1.1 Gynaecological malignancies and their therapies 
1.1.1 Breast cancer 
1.1.1.1 Epidemiology 
Approximately 10% of all women in the western industrialised countries develop 
breast cancer in their lives (Engel et al., 2001). Risk factors have been determined 
which may account for breast cancer (Tab. 1-1). Age still seems to be the most 
important risk factor. 
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Tab. 1-1 Established risk factors for breast cancer (Armstrong et al., 2000) 
Risk factor Relative risk  
(data compiled from various studies) 
Age (≥ 50 vs. < 50 yr) 6.5 
Family history of breast cancer  
 First-degree relative 1.4 - 13.6 
 Second-degree relative 1.5 - 1.8 
Age at menarche (< 12 vs. ≥ 14 yr) 1.2 - 1.5 
Age at menopause (≥ 55 vs. < 55 yr) 1.5 - 2.0 
Age at first live birth (> 30 vs. < 20 yr) 1.3 - 2.2 
Benign breast disease  
 Breast biopsy (any histologic finding) 1.5 - 1.8 
 Atypical hyperplasia 4.0 - 4.4 
 
Breast cancer is the most common type of cancer in women in the western 
industrialised countries. In Germany approximately 46,000 women are newly 
diagnosed with breast cancer every year. 19,000 are younger than 60 years old. The 
incidence of breast cancer increased continuously over the past 25 years (Batzler et 
al., 2002b). In 2001 17,504 women in Germany died of breast cancer (Statistisches 
Bundesamt, 2003). As a comparison in 1997 there were 18,378 cases of death. 
Malignant tumours of the breast are classified according to the ‘International 
Statistical Classification of Diseases and Related Health Problems’, ICD 10, C50. 
Depending on the location of the carcinoma subgroups are differentiated. The WHO 
distinguishes between non-invasive and invasive carcinomas depending on the 
histological phenotype. 
To ascertain the malignancy of a tumour mammography is performed in 
combination with ultrasound scans. Uncertain findings are ensured by vacuum stamp 
biopsy in order to obtain tissue which can be assessed histological. If, after these 
measures, a tumour is found to be malignant, the further staging can only be done 
after surgery. 
The tumour size, nodal status and distant metastases are categorised in the TNM 
system (see Tab. A-2 of the appendix). The grade of differentiation is determined 
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according to Elston and Ellis (2002). A sum score integrating histological parameters 
such as architectural pattern of the cell, nuclear polymorphism and mitotic count leads 
to one of the following three categories: 
G1 well differentiated 
G2 moderately differentiated 
G3 poorly differentiated 
Moreover, the hormone receptor (estrogene and progesterone) and the HER2 status 
contribute to the staging and influence the treatment decision. 
 
1.1.1.2 Treatment concepts 
The appropriate treatment should be tailored to the individual patient. The choice of 
treatment depends on the staging of the tumour and the individual patient 
characteristics. Surgery, radiotherapy and systemic therapy (e.g. chemotherapy) are 
the main pillars of the therapy of breast cancer. Breast conserving surgery with 
mandatory subsequent radiation therapy can be an alternative to the formerly used 
standard modified radical mastectomy. Chemotherapy, endocrine therapy and 
monoclonal antibodies are options of the systemic therapy, which can be administered 
either alone or in combination. Curative and palliative treatment concepts are 
distinguished. Within the curative treatment concepts the systemic therapy can be 
neo-adjuvant (before the surgery) or adjuvant (to support the success of the surgical 
measure). The commonly applied substances are the anthracyclines epirubicin (E) and 
doxorubicin (A), cyclophosphamide (C), methotrexate (M), fluorouracil (F) and the 
taxanes paclitaxel and docetaxel. The current recommendations of the St. Gallen 
consensus conference for the adjuvant treatment suggest either  
 4 cycles EC/AC or 6 cycles CMF 
or 6 cycles of an anthracycline-containing chemotherapy regimen (e.g. FEC) 
or a taxane-containing chemotherapy regimen (Nitz and Mohrmann, 2003). 
If patients have an increased risk for a relapse an anthracycline-containiing regimen 
including 3 substances is recommended. In St. Gallen the algorithm for the treatment 
decisions in the adjuvant situation has been updated as shown in Tab. 1-2. 
Depending on the menopausal status and the hormone receptor status, the 
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nodal status and the individual’s prognostic factors the decision is made whether 
chemotherapy is administered at all, alone or in combination with an endocrine 
therapy. Trastuzumab is not yet registered for the use in the adjuvant situation. Studies 
are currently being conducted which survey the value of trastuzumab in the adjuvant 
situation (German Adjuvant Breast Cancer Group, 2002). 
Tab. 1-2 Adjuvant treatment options St. Gallen 2003 (Nitz and Mohrmann, 2003) 
Nodal negative 
 Hormone-receptor positive Hormone-receptor negative 
 Pre-menopausal Post-
menopausal 
Pre-
menopausal 
Post-
menopausal 
Minimal risk 
T1a,b,c, N0, G1 
and ER/PR+ 
and 35 years ≥
Tamoxifen  
or nothing 
Tamoxifena  
or nothing 
No available 
data 
No available 
data 
All other 
constellations 
Ovarian 
suppression + 
Tamoxifen /  
Chemotherapyb 
+ Tamoxifen 
Tamoxifena or  
Chemotherapyb 
+ Tamoxifen 
Chemotherapy
b
Chemotherapy
b
 a Anastrozole if tamoxifen is contraindicated (only for postmenopausal women) 
b Containing anthracyclines, CMF only with minimal risk  
Nodal positive 
 Hormone-receptor positive Hormone-receptor negative 
 Pre-menopausal Post-
menopausal 
Pre-
menopausal 
Post-
menopausal 
Increased risk Ovarian 
suppression + 
Tamoxifen /  
Chemotherapyb 
+ Tamoxifen 
Tamoxifena or  
Chemotherapyb 
+ Tamoxifen 
Chemotherapy
b
Chemotherapy
b
 a Anastrozole if tamoxifen is contraindicated (only for postmenopausal women) 
b Containing anthracyclines 
 
Combination of epirubicin and cyclophosphamide 
As mentioned above a variety of chemotherapy regimens are approved for the use in 
the adjuvant treatment of breast cancer. Since Fisher et al. showed that four cycles of 
an anthracycline-containing regimen have equal efficiency in terms of relapse-free and 
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overall survival compared to six cycles CMF, combination regimens of 
cyclophosphamide combined with either doxorubicine (AC) or epirubicin (EC) 
became a standard in the adjuvant treatment of breast cancer (Fisher et al., 1990). It is 
suitable for the ambulatory application and also presents with a tolerable toxicity 
profile.  
Epirubicin 
Epirubicin is a stereoisomer of doxorubicin with an inverse stereochemistry of the 
hydroxyl group in the C-4' position of the amino sugar. Like other anthracyclines, the 
precise mechanism of action of epirubicin is unknown, but it is primarily related to 
intercalation of the planar ring with DNA and subsequent steric inhibition of DNA and 
RNA synthesis. The intercalation seems to interfere with the topoisomerase-DNA-
‘cleavable complex’. Other discussed potential mechanisms of action are the 
formation of free radicals and chelate complexes with metal ions. Epirubicin acts cell 
cycle phase-nonspecific. Still the maximum effects appear to be in the S- and G2-phase 
of the cell cycle (Roth und Fenner, 2000, Pharmacia 2003). 
O
H3C
O
O OH
OH
OH
O
OH
O
NH2
O
CH3
HO
 
Fig. 1-1 Chemical structure of epirubicin 
Epirubicin is approved for the indications breast cancer, gastric cancer, small cell lung 
cancer, ovarian cancer and soft tissue sarcoma. Epirubicin is mainly excreted by the 
biliary route (40% in 72 h). The active metaboltite is epirubicinol and as inactive 
metabolites two glucuronides and 4 aglycones are known. 
 5
[1] Introduction 
Its pharmacokinetic properties are listed in (Tab 1-3). 
Tab. 1-3 Pharmacokinetics of epirubicin 
Pharmacokinetic parameter Epirubicin 
Vd 32 - 46 L/kg 
CL 30 - 100 L/h 
t½α 3.0 - 4.8 min 
t½β 1.1 - 2.6 h 
t½γ 18 - 45 h 
 
The dosing depends on the protocol by which the patient is being treated. Numerous 
dosing schedules exist and depend on disease, response and concomitant therapy. 
Guidelines for dosing also include consideration of white blood cell count. In 
combination with cyclophosphamide in the treatment of breast cancer it is dosed at 
90 mg/m2 BSA. 
The acute dose-limiting toxicity is myelosuppression (febrile neutropenia and 
granulocytopenia) with a nadir between day 10 and 14 post-chemotherapy. Epirubicin 
is associated with cardiac toxicity. Serious, irreversible cardiomyopathy with delayed 
congestive heart failure often unresponsive to therapy may be encountered as the 
cumulative dose approaches 1000 mg/m2. Cardiac monitoring is advised when the 
cumulative dose exceeds 650 mg/m2. Observed dermatologic toxicity comprises 
rashes and an epirubicin flare due to histamine release. Practically all patients 
experience a complete alopecia which is reversible two to three months after the end 
of chemotherapy. In some cases mucositis (stomatitis and esophagitis) has been 
reported. The emetogenic potential of the substance is moderate to high (ESMO 
guidelines task force, 2001). Epirubicin is a vesicant and can cause tissue necrosis after 
extravasation. Immediate measures have to be initiated to interrupt the tissue damage. 
Other adverse effects are diarrhea, fever, amenorrhea, conjunctivitis and fatigue. 
Cyclophosphamide 
Cyclophosphamide is an oxazaphosphorine, an inactive cyclic phosphamide ester of 
mechlorethamine (Fig. 1-2). 
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NH
P
O
O
N
Cl Cl
 
Fig. 1-2 Chemical structure of cyclophosphamide 
It is converted by hepatic and intracellular enzymes to its active alkylating metabolites 
4-hydroxycyclophosphamide, aldophosphamide, acrolein and phosphoramide 
mustard. Cyclophosphamide causes prevention of cell division primarily by cross-
linking DNA strands. It is considered to be cell cycle-phase non-specific, but cell cycle 
specific. It has an almost complete bioavailability (ca. 70-90%) after oral 
administration. The maximum plasma levels are reached after approximately one hour 
and after six to eight hours half of the substance is eliminated. Of the unmodified 
cyclophosphamide 10-20% are eliminated renally (Roth and Fenner, 2000).  
Toxicity caused by cyclophosphamide is dose-dependent and usually reversible. 
Myelosuppression presents with leukocytopenia, thrombocytopenia and anemia. The 
nadir is observed between day 8 and 15 following administration and is associated 
with immunosuppression and the risk of severe infections and fever. 
Gastrointestinal adverse effects such as diarrhea, constipation, stomatitis and 
anorexia occur rarely. The emetogenic potential is considered moderate to high 
depending on the dose (ESMO guidelines task force, 2001). Dose-related hemorrhagic 
cystitis occurs due to direct contact of toxic metabolites accumulating in concentrated 
urine with the bladder mucosa. This occurs in 10% of patients and may occur during 
or several months after treatment. Cystitis may result in chronic inflammation leading 
to fibrosis, telangiectasis of the bladder epithelium and bladder cancer. Severe cases 
may be fatal. Prophylactic measures to reduce the incidence of cystitis include catheter 
bladder drainage, bladder irrigation, hyperhydration, forced diuresis and the 
administration of mesna. 
Cyclophosphamide is approved for the use in polychemotherapy and 
monochemotherapy for a variety of indications such as leukemias (ALL, AML, CLL, 
CML), lymphomas (Hodgkin's disease, Burkitt's lymphoma, multiple myeloma,  
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Non-Hodgkin's lymphoma, plasmocytoma), solid tumours (breast cancer, lung cancer, 
ovarian cancer, neuroblastoma, Ewing sarcoma), auto-immune deficiencies and 
immunosuppressive treatment after organ transplantation (Seeber and Schütte, 2003). 
Cyclophosphamide is dosed according to body weight in children and according 
to BSA in adults. The individual dosage depends on the treatment regimen. In 
combination with epirubicin in the adjuvant treatment of breast cancer it is dosed at 
600 mg/m2 BSA. 
1.1.1.3 Public awareness 
In recent years public awareness of breast cancer has clearly increased. The German 
government introduced disease management programmes for patients with breast 
cancer, new patient initiatives were founded (e.g. Mamazone e.V.) and a number of 
studies have been conducted which surveyed the perception of the care process by 
the affected women (Veronesi et al., 1999; Jänel et al., 2000; Deutsche Krebshilfe, 
2003). Thirteen European countries participated in the ‘Caring about women and 
Cancer – CAWAC’ study. More than 13,000 patients completed questionnaires of 
which 77% had breast cancer and 10% had ovarian cancer. The study identified 
aspects of care which seem to offer a potential for improvement. Among others the 
information on side effects was judged unsatisfactory by a considerable number of 
patients depending on the received treatment (15-25%) (Veronesi et al., 1999). The 
study group concludes that although there is a raised awareness of the importance of 
well educated and informed patients, there are still shortcomings in the delivery of 
information. This has also been found by Jänel et al. (2000). They surveyed the care 
situation of breast cancer patients in Germany. Patients expressed their need for 
comprehensive information on their treatment to be able to participate in the decision 
process. The involved physicians criticesed the delayed information flow between the 
different treating institutions and supported the idea of a better interdisciplinary 
cooperation.  
The German ‘Krebshilfe’ recently conducted a study to illustrate the current 
situation of ‘women with breast cancer in the medicine system’ (Deutsche Krebshilfe, 
2003). Based on the results twelve goals were defined which aim at improving the 
provision of care to breast cancer patients. A number of these objectives are 
addressed by pharmaceutical care. One major proposal are guidelines for appropriate 
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patient-oriented information, which covers the complete treatment process. Different 
target groups should be considered and guidelines on how to conduct a consultation 
with the patient should be made available to the practitioner. Such guidelines should 
become a standard in the care of cancer patients just like for any other aspect of 
medical treatment. Another demand is the quality assurance in the treatment of breast 
cancer. This can be achieved by interdisciplinary cooperation, specialisation of care 
providers, implementation of clinical guidelines which cover the complete treatment 
process and certified breast centres. The information on the treatment options and the 
different therapy settings should be made accessible, comparable and transparent to 
the patient. The individual’s quality of life should be a main focus for treatment 
decisions. The information on the planned treatment should be offered to the patient 
prior to the beginning of the treatment and in a sufficient amount of time to enable the 
patients to make informed decisions. The information process should be structured 
and integrate different suitable media. The results of the study undertaken by the 
German ‘Krebshilfe’ also indicate that the ambulatory sector should be integrated 
better in the whole treatment process. 
1.1.2 Ovarian cancer 
1.1.2.1 Epidemiology 
In Germany approximately 7,400 new cases of ovarian cancer are diagnosed per 
annum. With this incidence ovarian cancer represents about 4% of malignancies in 
women. Ovarian cancer is the sixth most common neoplasm among women (Trope 
and Kristensen, 1997). The aetiology of this type of cancer has not yet been 
elucidated, however there are several known potential risk factors. Age, as in many 
other malignancies, is a discussed risk factor. The prevalence among women older 
than 60 years is noticeably higher than among younger women. Other risk factors 
include: total number of ovulations, where risk increases with increased number of 
ovulations, previous gynaecological malignancies and nutritional factors (Batzler et al., 
2002a). A genetic predisposition underlies approximately 5-10% of the cases (Engel et 
al., 2001). The prevalence of ovarian cancer in Germany has been almost constant 
over the past 20 years. Compared to other gynaecological malignancies the prognosis 
is considered unfavourable. The 5-year survival rate is about 35%. Over the last 
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decade the mortality in Germany declined marginally (Batzler et al., 2002a). This is 
concordant with observations in the US. McKean-Cowdin et al. attribute this 
development to the increased use of oral contraceptives in the female population 
which has a protective effect by reducing the total number of ovulations (2000).  
Ovarian cancer is referred to as a heterogeneous group of neoplasms evolved 
from the ovary. In the ICD 10, ovarian cancer is categorised C56 among gynaecologic 
malignancies. Approximately 90% of malignant ovarian neoplasms originate from the 
ovarian surface celomic epithelium. This type is characterised as epithelial ovarian 
cancer (EOC). The remaining cases are represented by germ cell tumours and stromal 
tumours. EOCs are differentiated according to their histological appearance. The 
different types are classified according to the WHO classification system (Dettmar et 
al., 2001; Morin and Pizer, 2001). 
In addition, a histopathological grading is performed to determine the 
differentiation of the tumour cells. Silverberg proposed criteria in 1998 which are now 
commonly used (Shimizu et al., 1998). A sum score integrating histological parameters 
such as architectural pattern of the cell, nuclear polymorphism and mitotic count leads 
to one of three categories as described for breast cancer (see chapter 1.1.1.1). With 
complete and sound histological findings the disease staging can be performed. 
Usually the stage of ovarian cancer is specified according to the TNM classification 
and the FIGO classification (appendix B, Tab B-2). 
1.1.2.2 Treatment concepts 
The treatment of ovarian cancer depends foremost on its stage at diagnosis. The main 
treatment options applied are surgery and chemotherapy. As with most cancers the 
therapeutic options should be tailored to the patient’s individual situation. Surgery is 
indicated in all malignant cases and can, depending on the stage of the disease, either 
be applied independently or in combination with other therapeutic options such as 
chemotherapy. Studies indicate a benefit of combination therapy in many situations. 
Radiation therapy is only performed for particular indications such as for palliative 
symptom relief and for inoperable tumours. In the adjuvant situation the benefit of 
radiation therapy is controversial (Lindner and Würschmidt, 2001). 
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The choice of the eligible chemotherapy depends mostly on disease stage and 
the type of previously administered chemotherapy regimens. To achieve an optimal 
treatment outcome a combination regimen using more than one chemotherapeutic 
agent has proved to be the most effective strategy (Advanced Ovarian Cancer Trialist 
Group, 1991; Trope and Kristensen, 1997; Lutz et al., 2001). The question of which 
antineoplastic agents are the most effective combination has been addressed in 
several clinical investigations. Before the introduction of the taxanes as a treatment 
option, the various available combination regimens did not produce convincing results 
in terms of survival differences or complete response rates (Advanced Ovarian Cancer 
Trialist Group, 1991; Trope and Kristensen, 1997). For many years a combination of 
cisplatin and cyclophosphamide was standard in the treatment of advanced ovarian 
cancer. When paclitaxel was introduced as an antineoplastic agent with a novel 
mechanism of action survival and response rates were improved (Ozols, 1995). 
Paclitaxel is now the principal component of chemotherapy regimens for advanced 
epithelial ovarian cancer together with either cisplatin or carboplatin (Trope and 
Kristensen, 1997; du Bois et al., 1999).  
Combination of carboplatin with paclitaxel 
Since its registration in 1992 paclitaxel has been investigated in the treatment of 
ovarian cancer in various combinations and doses (Calvert et al., 1995; McGuire et al., 
1996; du Bois et al., 1997). At present the combination of paclitaxel (175 mg/m2) and 
carboplatin (AUC 5 mg⋅min/mL) is the established standard regimen (du Bois et al., 
1999). 
When drugs are used in combination, potential drug interactions need to be 
considered. For the combination of paclitaxel and carboplatin neither a 
pharmacokinetic interaction nor a sequence-dependence of pharmacokinetic 
disposition could be found. Additionally a remarkable reduction of thrombocytopenia 
was observed when patients received carboplatin in combination with paclitaxel 
(Calvert et al., 1995; Obasaju et al., 1996; Calvert, 1997; Kearns and Egorin, 1997; 
Siddiqui et al., 1997; van Warmerdam et al., 1997). The mechanism of this protective 
effect still remains to be elucidated. The major dose-limiting toxicity of this 
combination seems to be neutropenia (Langer et al., 1995; Kearns et al., 1995). Other 
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non-haematologic adverse effects described are nausea and emesis, fatigue and 
peripheral neuropathy. 
Paclitaxel 
In 1992, paclitaxel, a diterpene (Fig. 1-3) isolated from the cortex of the pacific yew 
tree (taxus brevifolia), was registered in the United States as a new antineoplastic agent 
(Bartsch, 2000). Paclitaxel is obtained semi-synthetically from the natural baccatin III. 
Baccatin III can be found in renewable sources such as needles and saplings which 
guarantee sufficient amounts for industrial production. Total synthesis has proved to be 
a difficult task. In 1994 Nicolaou et al. were the first who succeeded in synthesising 
paclitaxel, however, the total synthesis does not play a role in the industrial production. 
To date the semi-synthetically obtained paclitaxel is being used. 
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Fig. 1-3  Chemical structure of paclitaxel 
Although the exact mechanism of action of paclitaxel has not been fully explained, it 
appears to involve the promotion and excessive stabilisation of microtubule polymer 
or bundle formation during the cell cycle (Bartsch, 2000).  
In 1989 McGuire et al. described the effectiveness of paclitaxel against ovarian 
cancer even in platinum refractory types. It is now registered for the indications 
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NSCLC, ovarian cancer and breast cancer. Furthermore it showed in-vitro cytotoxicity 
against a variety of solid tumours and haematologic neoplasms such as cervical, 
pancreas, prostate, head and neck, colon, gastric, bladder, lung and CNS cancers, 
melanoma, hepatoma and leukaemia cell lines (Spencer and Faulds, 1994). 
The dose-limiting toxicity of paclitaxel is myelosuppression with leukocytes 
affected more severely and commonly than thrombocytes or reticulocytes. 
Myelosuppression is related to the duration that plasma paclitaxel concentrations are 
greater than or equal to 0.05 µmol/L (Gianni et al., 1995; Kearns et al., 1995). Other 
adverse effects include myalgias, arthralgias, alopecia, diarrhea, nausea, vomiting, 
mucositis, and in particular peripheral neuropathy. Other undesirable effects 
associated with the use of the drug are hypersensitivity reactions. These reactions 
manifest as dyspnoea, bronchospasms, hypotension, angioedema, urticaria, flushing 
and/or erythematous rash and seem to be associated with the vehicle in which 
paclitaxel is formulated in order to increase the solubility – polyoxyethylated castor oil 
(Cremophor EL). Premedication with dexamethasone and H1- and H2-receptor 
antagonists reduces the incidence of severe reactions to less than 5% (Spencer and 
Faulds, 1994).  
The pharmacokinetic of paclitaxel is nonlinear. Peak plasma paclitaxel 
concentrations and AUCs both change disproportionately to changes in dose. The 
nonlinear pharmacokinetic might be attributed to saturable processes in distribution 
and elimination which can be described using Michaelis-Menten kinetics (Kearns et al., 
1995). Van Tellingen et al. investigated the role of Cremophor EL in the nonlinear 
pharmacokinetics of paclitaxel. They found that Cremophor EL is responsible for the 
nonlinearity which they denominate as pseudo nonlinearity as higher plasma levels do 
not correlate with higher tissue levels (van Tellingen et al., 1999). The drug is mainly 
eliminated via the biliary tract (>90%) and is highly bound to plasma proteins (88-98%) 
(Sonnichsen and Relling, 1994; Spencer and Faulds, 1994; Bartsch, 2000). The 
metabolisation is dependent on the enzymesystem CYP3A and CYP2C. The 
elimination half-life is between 3.8 and 16.5 hours. For paclitaxel a high interindividual 
variability of the pharmacokinetic parameters has been described. It would therefore 
be reasonable to consider TDM for this drug in order to minimise toxicity and 
maximise efficacy. In order to find the optimal dosage for patients it is necessary to 
know pharmacokinetic–pharmacodynamic relationships that relate plasma levels to 
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toxic effects such as neutropenia and peripheral neurotoxicity as well as tumour 
response. Investigations undertaken to elucidate these relationships found that infusion 
times as well as the duration of plasma levels above a certain ‘threshold’ are 
parameters that are related to neutropenia. AUCs, on the other hand, do not seem to 
be reasonable parameters to predict toxicity as they are similar for 3-h and 24-h 
infusions (Kearns et al., 1995). To date a relationship between pharmacokinetic 
parameters and tumour response has not been shown. 
Carboplatin  
Carboplatin or Cis-diamin (1.1-cyclobutandicarboxylato) platinum II is a second 
generation analogue of cisplatin that is characterised by a different toxicity profile. 
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Fig. 1-4 Chemical structure of cisplatin and carboplatin 
Carboplatin differs from cisplatin by the leaving groups as illustrated in Fig. 1-4. The 
two chlorine ligands are exchanged for a cyclobutandicarboxylato ligand. Carboplatin 
is less toxic than cisplatin. Oto-, nephro- and neurotoxicity occur rarely. The dose-
limiting toxicity of carboplatin appears to be myelosuppression, especially 
thrombocytopenia (Van Echo et al., 1989; Highley and Calvert, 2000). 
The antitumour effect of platinum compounds is thought to be due to interaction 
with DNA. Carboplatin and cisplatin appear to share a similar mechanism of action. As 
a first step aqua complexes are formed. The aquated compounds form bifunctional 
adducts with DNA (see Fig. 1-5). Intrastrand cross-links have been observed between 
two adjacent guanines (Pt-GG) or adjacent guanine and adenine (Pt-AG). For 
carboplatin the main adduct seems to be the intrastrand cross-link G-Pt-G in which 
carboplatin is bound to two guanines separated by another base. Monofunctional 
adducts (Pt-G) and interstrand bifunctional adducts were found as well (Vermorken et 
al., 1993; Blommaert et al., 1995; Fink and Howell, 2000). Due to the lesser reactivity 
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of carboplatin, a larger dose is required compared to cisplatin to obtain an equal effect 
(van der Vijgh, 1991). 
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Fig. 1-5 Intra- and interstrand reactions of cisplatin with DNA 
Carboplatin shows an antineoplastic effect in ovarian cancer, germ cell tumours, 
bladder cancer, small cell lung cancer and head and neck cancer (van der Vijgh, 1991; 
Highley and Calvert, 2000). It is administered intravenously. 
Carboplatin exhibits linear pharmacokinetics according to an open two-
compartment-model (van der Vijgh, 1991; Vermorken et al., 1993). It is mainly 
eliminated by renal excretion, entirely through glomerular filtration. Carboplatin is less 
protein-bound than cisplatin. This can be attributed to the lower reactivity of the 
substance. Within the first two hours post infusion the ultrafilterable concentration 
accounts for 60-80% which then slowly declines to 50% (Van Echo et al., 1989; 
Highley and Calvert, 2000). The elimination half-life is 6 h for ultrafilterable platinum. A 
correlation between the AUC of ultrafilterable plasma carboplatin and the extent of 
thrombocytopenia has been shown in clinical studies. Depending on whether the 
patient has previously been treated with chemotherapy or not, linear relationships 
were described which facilitate the prediction the extent of thrombocytopenia for 
certain carboplatin AUCs (Egorin et al., 1985; Van Echo et al., 1989; Jodrell et al., 
1992; Egorin et al., 1994). Patients with carboplatin AUC 4 to 5 seem to have the 
lowest risk of developing thrombocytopenia (Jodrell et al., 1992). Additional studies 
suggest that no significant improvement in tumour response can be achieved by 
increasing the carboplatin AUC over 5 or 7 mg⋅min/mL in conventional chemotherapy 
for previously treated or untreated patients respectively (Jodrell et al., 1992; Jakobsen 
et al., 1997; du Bois et al., 1999). 
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1.2 Specific aspects of antineoplastic drug treatment 
1.2.1 Safety of cytotoxic drugs 
Antineoplastic therapy is associated with various desirable and undesirable outcomes. 
It is the main focus of the oncology care team to improve the desirable outcomes such 
as cure of the disease, slowing the disease progression, decreased symptoms, and to 
reduce the incidence of the undesirable outcomes such as mortality, disease 
progression, adverse effects, severe organ toxicity and drug resistance. Some toxicity 
may be dose-limiting and even lead to an interruption of the therapy. Thus, the success 
of the therapy is strongly connected to the severity of therapy-associated toxic effects. 
An efficient supportive care in order to control these adverse drug reactions (ADRs) is 
crucial for optimal treatment outcomes. The more complex drug regimens get the 
higher is the risk of experiencing drug-related problems (DRP). Drug-related problems 
in cancer chemotherapy can have severe consequences originating from the high 
toxicity of anticancer drugs. They may arise from lack of adherence to the protocols, 
may be associated with the chemotherapy itself or with inadequately applied 
supportive medication. Numerous attempts have been made to improve the 
prevention of medication errors in chemotherapy. Additional to systematic changes 
prevention strategies should also be applied on the individual basis. 
1.2.2 Drug-related problems in systemic drug therapy 
Whenever a patient receives a systemic drug therapy it is associated with a variety of 
potential risks. Strand et al. (1990) define drug-related problems (DRP) as problems 
which exist when a patient experiences either a disease or symptom having an actual or 
suspected relationship with drug therapy. They introduced eight categories of drug-
related problems which physicians and pharmacists should be aware of. DRPs arise 
when (1) a patient does not receive a drug for an existing indication, (2) a wrong drug 
has been chosen for the indication, (3) under-dosage of the correct drug, (4) over-
dosage of the correct drug, (5) a medical condition resulting from an ADR occurred, 
(6) a drug-drug, drug-food or drug-laboratory interaction is observed, (7) a medical 
condition occurs due to taking a prescribed drug or (8) a medical condition occurrs 
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because no valid drug has been prescribed. 
Adverse drug reactions (ADR) represent a particular group among the DRPs. 
According to the World Health Organization ADRs are any noxious, unintended, and 
undesired effects of a drug, which occur at doses used in humans for prophylaxis, 
diagnosis, or therapy. This definition excludes therapeutic failures, medication errors 
and abuse. Lazarou et al. found that fatal adverse drug reactions (ADRs) ranked 
between fourth and sixth leading cause of death in the United States in 1994 (Lazarou 
et al., 1998). Serious ADRs presented with an incidence of 6.7% (95% CI 5.2-8.2%) 
and fatal ADRs with an incidence of 0.32% (95% CI 0.23-0.41%). The authors 
explicitly checked ADRs which only account for a part of all potential drug-related 
problems. This impressively illustrates how crucial the prevention of ADRs and thus 
DRPs is. 
Compared to the two terms discussed above another term has to be 
differentiated. Adverse drug events (ADE) are injuries which result from a medical 
intervention related to a drug, but compared to an ADR it also covers events if the 
drug has been used inappropriately and it also applies if it is not clarified whether the 
event is actually caused by the drug involved. Bates et al. published data of the 
incidence of ADEs in hospitalised patients (Bates et al., 1995). They detected 6.5% 
ADEs (related to hospital admissions) of which 30% were serious ADEs and 28% of all 
observed ADEs were judged as preventable. Only looking at the serious and life-
threatening ADEs 42% were preventable. These results reflect that ADEs can be rated 
as common problems which have a good potential for optimisation. This conclusion 
can also be drawn from data of Gandhi et al. (2003). They surveyed the incidence of 
ADEs in ambulatory care. In total 25% ADEs (related to the number of patients) were 
detected of which 13% were rated serious and 11% preventable. The frequency of 
ADEs observed in ambulatory care is four times as high as in the comparable study for 
hospitalised patients. This is partly due to the fact that not only patient charts were 
reviewed but also patients reported ADEs. Another remarkable fact is that the main 
factor associated with the risk of an ADE was the number of drugs taken. The 
complexity of the treatment as a risk factor for adverse events has also been described 
by Leape et al. (1991). Applying these findings to the pharmaceutical care of 
ambulatory cancer patients offers many starting points. These patients receive a 
complex treatment and have an additional risk of experiencing ADEs in the ambulatory 
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setting. 
Not only for safety reasons it seems important to reduce the incidence of ADRs, 
DRPs and ADEs. Studies conducted in American nursing homes have shown that with 
every dollar spent on drugs 1.33 US$ have to be afforded for treating adverse drug 
events (Alliance for Aging Research, 1998). Therefore, the prevention or the detection 
of drug-related problems at an early stage has also a large saving potential. 
1.2.3 From compliance to concordance 
Another factor which influences the optimal treatment outcome is the way in which a 
patient translates the recommendations of the healthcare provider into action. The 
patients’ ‘compliance’ has been an issue for many years. Along with the development 
of a new patient role goes the development of a new term as a replacement for 
“compliance”. The Royal Pharmaceutical Society of Great Britain published a report 
which addresses this topic (1997). The report is based on the assumption that about 
50% of patients who suffer from chronic diseases do not take their medication in 
therapeutic doses and so do not derive the optimum benefits from their treatment. 
This being the cause for increased health services expenditure as well as a dissatisfying 
quality of health care should be surveyed and improved. One of the several reasons 
researchers have identified for the failure to achieve the potential benefit from 
medication is the failure in communication with patients. They suggest, that the most 
salient and prevalent influences on medicine taking are the beliefs that people hold 
about their medication and medicines in general. These beliefs often differ from the 
best evidence from medical science. Yet they are firmly rooted in the personal, familial 
and cultural experiences of our society. The concept of compliance does not take this 
cognition into account and more or less asks of the patient for absolute obedience to 
the recommendations of the healthcare provider. Concordance in the opposite is 
based on the notion that the working relationship between the healthcare provider 
and patient is a negotiation among equals and that therefore the aim is a therapeutic 
alliance between them. Its strength is the relationship between the doctor and the 
patient. Together they can proceed on the basis of reality and not of misunderstanding, 
distrust or concealment. This new perspective goes along well with the goals of 
pharmaceutical care which aims at meeting the patients’ needs and at developing the 
treatment plan in cooperation with healthcare providers and patients.  
 18
[1] Introduction 
1.2.4 Evidence-based drug therapy 
The most common definition of evidence-based medicine (EBM) is taken from David L. 
Sackett. He describes EBM as the conscientious, explicit and judicious use of current 
best evidence in making decisions about the care of the individual patient. It means 
integrating individual clinical expertise with the best available external clinical evidence 
from systematic research (Sackett, 1997). Clinical expertise calls for life-long learning 
and the willingness to communicate with others involved in the care of the patient in 
order to gain as much information as possible to be able to make the right decision. 
The patient brings to the encounter his or her own personal and unique concerns, 
expectations, and values which should also be considered in the treatment decision in 
order to improve the compliance and to meet the patient’s needs. 
The best evidence is usually found in clinically relevant research that has been 
conducted using sound methodology. For the practitioner it is rather time-consuming 
to do profound searches in every day practice. This problem is addressed by societies 
for the medical specialities which compile evidence-based therapeutic guidelines and 
treatment algorithms. The Cochrane collaboration has developed this approach since 
1993. They produce and maintain systematic reviews in many areas of health care (The 
Cochrane collaboration, 2003) which are available to the practitioner in the Cochrane 
library. The Oxford Centre of Evidence-based Medicine published the so called ’Levels 
of Evidence’ and according ‘Grades of Recommendation’ (2001). These serve as tools 
to classify the results of meta-analyses in a standardised way.  
The elaboration of therapeutic guidelines in a multidisciplinary team approach 
with physicians, pharmacists and other healthcare professionals and their consequent 
implementation should contribute to improve the patients’ quality of life and help 
reduce unnecessary drug costs. Among others Dranitsaris et al. (2001) showed in a 
prospective intervention study that the implementation of evidence-based antiemetic 
guidelines with the support of pharmacists could promote the clinically appropriate 
use of 5HT3 receptor antagonists. The therapeutic outcome for the patient was 
improved and drug costs were reduced. 
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1.2.5 Individualised chemotherapy 
The generally narrow therapeutic range of antineoplastic agents holds a particular risk 
for the patient in terms of drug safety. The relationship between the systemic exposure 
of antineoplastic drugs and their toxic and therapeutic effects is widely recognised. For 
drugs such as fluorouracil, mercaptopurine and methotrexate a relationship between 
pharmacokinetics and treatment outcome has been shown. For other anticancer drugs 
such as platinum complexes, anthracyclines and some antimetabolites a relationship 
between the serum concentrations and the respective dose-limiting toxicity is 
described (Hon and Evans, 1998). In general all antineoplastic drugs should be dosed 
as high as tolerable for the patient in order to achieve a maximum antitumour effect. 
Optimally, the adverse effects should be limited to a minimum. 
Three basic dosage strategies can be distinguished which are illustrated in Fig. 
1-6. The empirical dosage strategy applies a definite dose to each patient which results 
in variable plasma concentrations and consequently even greater variability in the 
achieved effect. The common dosage strategy for adults in oncology is based on body 
surface area (BSA) according to Du Bois and Du Bois (1916). The observed variability 
using this method is often not much less than by using the empiric dosage strategy 
which leads to either over- or under-dosage with the according consequences 
(Gurney, 2002; Jaehde, 2003). In order to provide optimal treatment to cancer 
patients there is a strong need to find more precise dosage strategies. Conceivable 
approaches are pharmacokinetically or pharmacodynamically guided dose 
individualisation. Using the latter, the dose is adjusted based on the measurement of 
the desired effect. In oncology however, this approach is not applicable. Thus, 
pharmacokinetic dose individualisation seems to be a reasonable approach. 
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Fig. 1-6  Dose, concentration and effect variability using different dosage strategies 
(from Jaehde, 2003) 
The measure which allows a prediction of drug exposure of an individual patient is the 
concentration of free drug in the plasma over a period of time (Area under the 
concentration time curve – AUC). The dose can be adapted accordingly. With this 
method the dose varies from patient to patient and even for an individual patient 
depending on the physiological conditions. The variability of the effects (desired and 
undesired) can be limited. In oncology, therapeutic drug monitoring (TDM) is being 
used on a regular basis already to control high-dose methotrexate therapy. Except this 
example, however, TDM does not yet have a broad application in antineoplastic 
chemotherapy treatment. Another example of a dosage method based on 
pharmacokinetic considerations is the target AUC approach. This will be described in 
detail in the following section. 
1.2.5.1 Dose individualisation of carboplatin 
Investigations on the pharmacokinetics and pharmacodynamics of carboplatin as 
mentioned above have led to the proposal for new methods of individualising dose. 
The reason for seeking an alternative dosage strategy was the observation of extreme 
variability in the AUC of the drug depending on the pre-treatment GFR of the 
individual patient (Calvert et al., 1989; van Warmerdam et al., 1996). Renal excretion is 
accomplished exclusively by glomerular filtration (measurable as GFR). Thus, the AUC 
of carboplatin is dictated primarily by the pre-treatment GFR. Several authors have 
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proposed dosage strategies based on the renal clearance of the drug (Egorin et al., 
1985; Calvert et al., 1989; Chatelut et al., 1995; Huitema et al., 2000). The AUC 
correlates highly with drug-related toxicity especially thrombocytopenia and also with 
tumour response (Egorin et al., 1984; Jodrell et al., 1992; Calvert and Egorin, 2002). 
Currently there are two principle methods being used to calculate the 
carboplatin dose. Calvert et al. derived a dosing formula based on the individual GFR: 
)25[mL/min] (GFRmin/mL][mg AUC[mg] Dose +⋅⋅=   (Eq. 1-1) 
 
The absolute dose is determined from the target AUC and the GFR. The constant of 25 
represents the average non-renal clearance for adults. Calvert used the 51Cr-EDTA 
method to estimate the GFR. As this method is rather inconvenient it did not establish 
in clinical practice. Another method to determine the creatinine clearance is to collect 
24-h urine and analyse the contained creatinine. Similar to carboplatin, creatinine is 
primarily excreted by glomerular filtration. This method is not widely used either as it 
requires a 100% patient compliance in order to collect the urine completely. 
Alternatively there are two other methods being used to estimate the GFR. Cockcroft 
and Gault (Eq.1-2) as well as Jelliffe (Eq. 1-3) derived equations to estimate creatinine 
clearance (CLcr) taking into account the serum creatinine concentrations and other 
patient-specific factors such as body weight, sex and age (Jelliffe, 1973; Cockcroft and 
Gault, 1976). Subsequently, the estimated creatinine clearance is equated with the 
GFR in Eq. 1-1. This assumption is not permitted if patients have been pre-treated with 
cisplatin, as renal function is most likely to be affected by cisplatin-exposure. 
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The Cockcroft-Gault equation is currently the most commonly used method to 
estimate the GFR for use in the dosage method established by Calvert et al.. 
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Chatelut et al. developed a method for the prediction of the carboplatin 
clearance in order to calculate the optimal dose for a patient to achieve a definite AUC 
based on population pharmacokinetic data.  
They start with the basic pharmacokinetic equation AUC = dose/CL: 
[mL/min]CLmin/mL][mg AUCTarget [mg] dose nCarboplati nCarboplati⋅⋅=   (Eq. 1-4) 
 
Based on this equation, carboplatin clearance is estimated to obtain the optimal 
carboplatin dose.  
For the development of the method the data were analysed using a non-linear 
mixed-effect model (NONMEM). A two-compartment linear model was used which 
integrated potential co-variates such as gender, age, height, weight, BSA, serum 
protein levels, cisplatin pre-treatment and serum creatinine concentration. The 
resulting equation is (w = weight, a = age): 
mol/L][ creatinine Serum
sex)]0.314(1[years])0.00457(1w[kg] [218
w[kg] 0.134  [mL/min]CL nCarboplati µ
⋅−⋅⋅−⋅⋅+⋅= a
   (Eq. 1-5) 
Depending on the gender of the patient a factor of 0 for male and 1 for female patients 
is inserted in the equation. This equation has been approved by Cahtelut et al. for the 
use in adult patients. In contrast to the Calvert formula this method is applicable to 
patients with impaired renal function and patients that are pre-treated with cisplatin. 
1.2.6 Therapeutic drug monitoring 
As mentioned above the dose calculation based on body surface area goes along with 
an unpredictable inter-patient variability in drug exposure. The consequences can 
either be over-dosing and increased toxicity which is usually quite easy to detect or 
unexpected under-dosing which leads to reduced efficacy of the chemotherapy. 
Estimations suggest an approximate under-dosing rate of 30% when BSA is used 
(Gurney, 2002). On the other hand, an unnecessary over-dosing does not necessarily 
improve the antitumour effect as many cytotoxic drugs show a plateau in the dose-
response curve. This has been described for carboplatin in the treatment of ovarian 
cancer. An AUC between 5 and 7 mg⋅min/mL might be associated with maximal 
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response rates (Duffull and Robinson, 1997).  
Therapeutic drug monitoring (TDM) aims at optimising individual dosage 
strategies by including plasma concentration measures. However, the strategy has its 
limitations for a number of reasons. For one thing the drugs are usually given in 
combination and it is difficult to assess the pharmacodynamic effects of single agents. 
Furthermore, the target tissues are often remote from the plasma used for analysis, 
which may confound the interpretation. 
TDM for carboplatin is not yet part of the clinical routine. In some clinical studies 
the AUC of carboplatin has been determined, but generally dose is calculated using 
the introduced methods described in 1.2.5. Since the introduction of the target AUC, 
inaccuracies in dosage have been observed. Studies addressing this question have 
shown that under-dosage resulted from using the modified Calvert method predicting 
the GFR with either the Cockcroft and Gault or Jelliffe equation. The equation 
developed by Chatelut et al. might also result in inaccuracies, but to a lesser extent 
(van Warmerdam et al., 1996; Panday et al., 1998; Donahue et al., 2001). This 
knowledge suggests reconsideration of the common practice. 
1.2.7 Supportive therapy 
The goal of supportive care is to prevent, control, or relieve complications and adverse 
effects and psychological, social, and spiritual problems associated with the treatment 
or disease in order to improve the comfort and quality of life of people who receive 
antineoplastic therapy. Adverse effects or complications of treatment cause 
inconvenience, discomfort, and occasionally even fatality to patients. Furthermore, 
they may also cause a delay in the delivery of the prescribed dose of therapy at the 
specific time and in the treatment-schedule. 
The debate about ‘cure’ and ‘care’ entailed in 1987 the development of the 
concept of supportive care. Realising that cure is not always possible the concept of 
care gained more significance. Supportive care concepts aim at ameliorating the 
patient’s situation by trying to alleviate the treatment- and disease-associated 
symptoms (Senn and Glaus, 2002). 
 
 24
[1] Introduction 
1.2.7.1 ADRs associated with chemotherapy in gynaecological malignancies 
The ADRs associated with chemotherapy vary depending on the combination of drugs 
administered. Thus, the supportive therapy offered to the patient much depends on 
the toxicity profile of the administered regimen. Tab. 1-4 outlines the common ADRs 
associated with the two selected chemotherapy regimens. 
Tab. 1-4 Toxicity associated with the two selected standard chemotherapy 
regimens 
(du Bois et al., 1997; Neijt et al., 2000; Piccart et al., 2001; Partridge et al., 
2001; Ozols et al., 2003) 
 Breast cancer Ovarian cancer 
 Epirubicin/ 
Cyclophosphamide 
Paclitaxel/ 
Carboplatin 
Leukopenia 
(Increased risk of infections) 
+++ +++ 
Thrombocytopenia 
(Increased risk of bleeding) 
+++ +++ 
Anaemia n.s. +++ 
Fatigue +++ +++ 
Nausea and Emesis +++ +++ 
Diarrhea ++ ++ 
Constipation +++ ++ 
Mucositis +++ ++ 
Damage on skin, nails,  
mucous membranes ++ ++ 
Alopecia +++ ++ 
Cystitis ++ - 
Peripheral neuropathy - +++ 
Myalgia/arthralgia n.s. +++ 
Allergic reactions + +++ 
+++  very common (> 10%)  
++  common (1-10%) 
+  occasional (0.1-1%) 
-  rare (0.01-0.1%) 
n.s. not specified 
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1.2.7.2 Prophylaxis of nausea and emesis 
Of all ADRs associated to chemotherapy patients rate nausea and emesis as one of the 
most distressing events (Senn and Glaus, 2002). This is the reason for focusing on 
these adverse effects in the present context. Every patient receiving chemotherapy 
should therefore receive appropriate antiemetic prophylaxis. A considerably large 
number of drugs is available to the prescriber in order to achieve this. Depending on 
the emetogenic potential of the administered chemotherapy these drugs can be 
combined. The main classification system for the emetogenicity of antineoplastic drugs 
has been set up by Hesketh (Hesketh, 1999). It is based on empirical data and also 
includes an algorithm to estimate the emetogenicity of combination regimens. The 
guidelines for antiemetic treatment differentiate between high, moderate and low 
emetogenicity. 
The selection of a drug combination also depends on the kind of nausea and 
emesis. Three types are differentiated. Acute nausea and emesis occur within the first 
24h post chemotherapy. Delayed nausea and emesis emerge per definition from day 
two to five after chemotherapy. A third type is denominated anticipatory nausea and 
emesis, developing after previous undesirable experiences with therapy-associated 
nausea and emesis. All three types of nausea and emesis are based on different 
pathomechanisms and thus are treated differently. 
To be precise it must be mentioned that nausea and emesis are different 
symptoms which are strongly connected. In this context both symptoms are 
considered in combination. Still, nausea is not so well investigated and therefore not as 
well controlled as emesis. The pathomechanism of acute emesis is fairly well 
understood. Cytotoxic agents as well as radiation therapy cause the release of 
serotonin from enterochromaffine cells of the small intestine. Serotonin binds to 
5HT3 receptors on vagal afferent neurons thereby initiating the emetic reflex arch 
(Herrstedt, 2002). The pathomechanism of delayed emesis is not fully understood yet. 
Serotonin seems to play a minor role in this phase. However, more and more evidence 
is gained which suggests that neuropeptides are involved in the pathomechanism of 
delayed emesis. The neuropeptide substance P has been discussed for a while and the 
recently approved first NK1-receptor antagonist aprepitant has shown efficacy in the 
control of delayed emesis. Also high levels of endogenous noradrenaline cause 
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delayed emesis. A study showed that reserpine can also prevent delayed emesis 
(Tanihata et al., 2000). 
5HT3 receptor antagonists 
Since the early 1990s this new group of drugs has changed the antiemetic prophylaxis 
and therapy immensely. Fig. 1-7 shows the currently most commonly used substances 
ondansetron, granisetron and tropisetron. These drugs have proved to be effective 
particularly in acute emesis. Their significance in the prevention of delayed nausea and 
emesis is discussed controversially. Studies suggest that in delayed nausea and emesis 
they are equipotent to corticosteroids and dopamine antagonists (Ioannidis et al., 
2000).  
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Fig. 1-7 Chemical structures of 5HT3 receptor antagonists 
Serotonin receptors of the 5HT3 type are present both peripherally on vagal nerve 
terminals and centrally in the chemoreceptor trigger zone of the area postrema. It is 
uncertain whether the 5HT3 receptor antagonists’ antiemetic action is mediated 
centrally, peripherally, or at both sites. 
The 5HT3 receptor antagonists themselves may cause ADRs. Commonly 
observed are headache, malaise, somnolence, constipation or diarrhea and dizziness. 
In rare cases hypersensitivity reactions, effects on the central nervous system or 
cardiac effects have been reported. 
 27
[1] Introduction 
Corticosteroids 
Of the corticosteroids especially dexamethasone plays a significant role in the 
antiemetic treatment. Ioannidis et al. undertook a metaanalysis in order to identify the 
potential of this corticosteroid (Ioannidis et al., 2000). Their result convincingly showed 
that dexamethasone in combination with a 5HT3 receptor antagonist prevents acute 
emesis more effectively than the respective 5HT3 receptor antagonist alone. For the 
control of delayed emesis the findings even suggest superiority over 5HT3 receptor 
antagonists. Roila et al. recommend to base prophylaxis and therapy of delayed emesis 
on dexamethasone which can be combined with either 5HT3 receptor antagonists or 
dopamine antagonists such as metoclopramide in high emetogenic chemotherapy 
regimens (Roila et al., 2002). 
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Fig. 1-8 Chemical structure of dexamethasone 
The mode of action of dexamethasone is not yet elucidated. Dexamethasone causes 
the adverse reactions typical for corticosteroids. Ioannidis et al. found that the 
administered doses of dexamethasone vary within a wide range. The differing doses 
were not related to a variability in treatment effects which suggests that low doses 
might already achieve a protective effect (Ioannidis et al., 2000). 
Dopamine antagonists 
Among this group of drugs metoclopramide is a commonly used drug in antiemetic 
treatment and prophylaxis.  
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Fig. 1-9 Chemical structure of metoclopramide 
Dopamine antagonists minimise the effect of dopamine at the D2 receptor in the 
chemoreceptor trigger zone, thereby limiting emetic input to the medullary vomiting 
center. Although dopamine antagonists are inexpensive and have broad efficacy, they 
have an extensive adverse effect profile that includes sedation, orthostatic 
hypotension, and extrapyramidal symptoms such as tardive dyskinesia. In the 
treatment of nausea and emesis doses of 10 to 20 mg are recommended in order to 
make use of the additional antiserotonergic effect which occurs at higher dose levels. 
Other drugs 
Antihistamines have shown only limited effects in the control of nausea and emesis. 
None of the guidelines includes them in their primary recommendations. 
Benzodiazepines (e.g. lorazepam) have an effect in anticipatory emesis. Propofol and 
metopimazine are drugs discussed for the control of breakthrough and therapy-
refractory emesis whereas the evidence is still sparse (Herrstedt, 2002). 
Therapy guidelines
In times of increased awareness of the importance of evidence-based drug therapy a 
number of expert panels and scientific societies devised therapeutic guidelines for the 
prophylaxis and treatment of chemotherapy-induced nausea and emesis (Antiemetic 
Subcommittee of the MASCC, 1998; ASHP Commission on Therapeutics, 1999; Gralla 
et al., 1999; ESMO guidelines task force, 2001). Some problems emerge with the so 
far existing guidelines. Data of high quality, requested for the establishing of EBM 
guidelines, is often lacking. Instead the guidelines often have to rely on ‘expert 
opinions’. Additionally the existing guidelines are not congruent. This causes irritation 
among the prescribing physicians which leads to ‘non-compliance’ to the best 
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available evidence (Roila, 2002). The MASCC initiated the formulation of mutual 
therapeutic guidelines of the main scientific associations. In March 2004 a consensus 
conference was held in Perugia, Italy addressing this task (Gralla, 2004).  
1.2.8 Complementary medicine 
Complementary medicine summarises a variety of treatment options which are based 
on different medical philosophies. They have in common that they are not part of the 
conventional medicine as they often still lack sound scientific evidence regarding 
efficacy and safety. In contrast to the causal approaches of the conventional medicine 
most complementary treatment options pursue holistic approaches. Over the past 
years complementary medicine has reached an increased consciousness among health 
care providers in oncology. This can have several reasons. As described above the 
requirements of the modern health care system increased and consequently the 
demands on health care providers to offer a high quality and needs-based service. As 
studies demonstrate cancer patients’ needs for complementary medicine is especially 
in Germany fairly high. In a patient-oriented view where a patient is addressed as a 
competent partner it is mandatory to accept and integrate patients’ needs also in terms 
of unconventional methods. Weis et al. showed that 58.4% of the asked patients had 
experience with complementary medicine after they had been diagnosed with cancer. 
The highest rate of users of complementary medicine was found among the breast 
cancer patients (72%). Of the different methods mistletoe (61.1%), vitamins (45.2%) 
and trace elements, such as selenium, zinc or others (40.4%) ranked on the first places 
(Weis et al., 1998).  
In their study Weis et al. addressed the question why complementary medicine is 
significant to the cancer patient (1998). They found that the two main reasons for 
seeking support in complementary medicine are to strengthen the immune system and 
to contribute self-commitment to the therapy process.  
All patient-oriented services offered to cancer patients should keep these aspects 
in mind. Nevertheless it has to be kept in mind that sufficient and reliable data for most 
complementary treatments is sparse and that a critical appraisal in an individual case is 
mandatory. 
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1.3 Changes in health systems 
1.3.1 Patient-focused approaches 
In recent years a paradigm shift towards a patient-focused rather than a disease-
focused approach occurred in many health care systems. Patient-focused approaches 
are designed to meet the needs and wishes of the individual receiving care and 
treatment. Currently discussed care concepts such as case- and disease-management 
programmes or pharmaceutical care strategies aim at improving patients’ outcomes by 
following evidence-based therapeutic guidelines, by trying to meet patients’ needs and 
by taking into account economic aspects (Hepler and Strand, 1990). All models 
advocate patients’ active participation in the therapeutic process and try to integrate 
quality assurance measures. Jackson and Kroenke describe the classic triad of quality 
care based on structure, process and outcome (Jackson and Kroenke, 1997). The 
former focus was on the structure and process of care, but it is changing towards the 
evaluation of the achieved outcome due to increasing patient enrollment and more 
sophisticated consumers. The competent patient should be well-informed and thus be 
able to make informed decisions regarding treatment. The Ottawa Charter for health 
promotion initiated this new way of thinking (International Conference on Health 
Promotion, 1986). It claims equal conditions for people to improve their health and 
well-being. In addition, it emphasises the importance of access to information for 
patients to increase control over their health and to be able to take on responsibility 
for their personal well-being. 
1.3.2 Patients’ needs 
The WHO defined ‘health’ to be a state of complete physical, mental and social well-
being, and not merely the absence of disease or infirmity (World Health Organization, 
1948). Any disorder of health might be associated with reduced quality of life (QoL). It 
is desirable to not only pay attention to the symptom control when treating a person, 
but also consider the tolerability of the chosen treatment for the patient. Recently QoL 
evolved to be a popular outcome parameter in clinical trials. Still, a universally 
accepted definition is lacking. Investigators argue that in the Western world most 
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people are familiar with this expression and have an intuitive understanding of what it 
stands for. One associates with QoL predicates such as well-being, happiness and 
satisfaction with life. It has to be kept in mind, that it means different things to different 
people depending on the context and situation. Hence in health care science it is 
referred to as health-related quality of life. When mentioning QoL in the context of this 
project health-related QoL is meant. Health-related QoL includes a variety of aspects 
such as general health, physical functioning, physical symptoms and toxicity, emotional 
functioning, cognitive functioning, role functioning, social well-being, sexual 
functioning and also existential issues. Depending on the type and objectives of the 
conducted trial individual aspects are selected (Fayers and Machin, 2000). 
The special situation of cancer patients has been taken into account with the 
development of specific instruments. Already in 1947 the Karnofsky Performance 
Scale was introduced to assess patients beyond physiological and clinical 
examinations. The European Organisation for Research and Treatment of Cancer 
(EORTC) developed and validated a basic module – the QLQ C30 questionnaire – and 
cancer type specific modules to assess cancer patients’ quality of life (Aaronson et al., 
1993).  
Especially for cancer patients information on their disease and treatment plays an 
important role. Cassileth et al. found that the majority of cancer patients wants as 
much information as possible (Cassileth et al., 1980). The information appears to be 
relevant for developing coping strategies (van der Molen, 1999) and to initiate self 
care behaviour (Dodd, 1983). Moreover, satisfaction with the available information 
appears to be associated with an improved QoL (Annunziata et al., 1998). 
The WHO indicates in its report on ‘Quality of care: Patient safety’ that health 
care interventions in general are intended to benefit the patients (World Health 
Organization, 2001). They remark that the modern health care delivery systems with 
their complex combination of processes, technologies and human interactions can 
bring significant benefits for the patients. Nevertheless, it involves inevitable risks of 
adverse events of different kinds and origins. The WHO summarises the core goals of 
most of the current health policy trends which will be introduced in the following.  
 32
[1] Introduction 
1.3.3 Current health policy trends 
With increased expectations regarding quality of care and an increasing pressure on 
public health care institutions to compete with private institutions, the evaluation of 
offered services has become a necessity. Therefore, applicative outcome parameters 
capable of assessing the quality of care have been developed. The use of outcome 
parameters such as patient satisfaction and quality of life are mainly driven by two 
rationales: cost containment and competition. In Germany the enactment of the 
‘Gesetz zur Reform der gesetzlichen Krankenversicherung ab dem Jahr 2000’, a law 
which gives the health system a new structure, introduced the legal obligation to 
assure and further develop a high quality standard for health care services by 
implementing §135a in the code of social law V (Bundesministerium für Gesundheit, 
1999). 
A variety of models have been introduced to achieve this goal. Donabedian 
discussed the different prospects of the quality of health care (Donabedian, 1990). The 
efficacy and effectiveness of care should be preferably high, which means that the 
requirements for an optimum of care need to be established and the conditions need 
to facilitate the best possible realisation. Due to the financial pressure the efficiency 
has to be considered as well. It is a measure of the cost at which any given 
improvement in health care is achieved. Still, the optimum should be aimed at. This 
means that costs and benefits ought to be in a reasonable relation. Additionally, 
Donabedian refers to the quality of care from the patient’s perspective. Accessibility to 
care, the patient-carer relationship, the amenities of care, the patient’s preferences of 
the effectiveness and the costs of care should be taken into consideration when quality 
of care is addressed. All these factors need to be amalgamated to assure a high quality 
and affordable health care system. The following models integrate many of these 
factors. 
1.3.3.1 Quality management 
To enhance the quality of care, quality management systems which are known from 
industrial production sites have been adapted in several ways to health care 
(Süverkrüp, 2003). The idea of the total quality management builds the fundament of 
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most of the currently discussed concepts. As illustrated in Fig. 1-10 the delivery of any 
health care service, described as a ‘product’ from a ‘supplier’ (hospital, general 
practitioner, pharmacist etc.) to the ‘customer’, in case of health care usually the 
patient, is embedded in a continuous process of quality improvement. The supplier 
defines goals to achieve a high quality of the delivered product. The customer receives 
the product which is associated with a number of requirements. These can be 
objective requirements as well as subjective requirements. The described coherences 
are basic considerations. In reality additional influences such as monopolisation add to 
the complexity of the system. 
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Fig. 1-10  Total quality management 
The customer gives feedback to the supplier who redefines the goals accordingly in 
order to systematically improve the product. Both, the supplier and the customer, are 
influenced by several parameters, which direct their actions. Usually, especially in 
health care, they are also interchanging with other players. These might not necessarily 
be interacting, which complicates the described process. To assure a functioning 
quality management an effective information flow plays an important role. This is taken 
into account by implementing documentation systems and integrating networks which 
enclose all involved parties (Schmidt, 1998; DIN Deutsches Institut für Normung e.V., 
2000; Süverkrüp, 2003; Engel et al., 2003). 
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The idea is to standardise the processes and to guarantee a continuous quality 
improvement to the customer. Standardisations like the DIN EN ISO 9001 have been 
set up to implement this philosophy into practice. Also legal obligations bind to quality 
management. As mentioned above the code of social law V in its current version calls 
for quality assurance and improvement of quality of the provided services. The services 
need to be based on actual scientific evidence and be presented in a professional 
manner. Cross-institutional measures to assure the quality, especially those which aim 
at improving the quality of outcomes should be taken and quality management 
systems should be implemented. According to §137b the quality assurance should be 
achieved in a cross-professional approach. 
1.3.3.2 Integrated care 
Disease management programmes (DMP) are based on the same considerations as 
described above. Todd et al. suggest that a common vision on what should be 
achieved is necessary to implement DMPs (Todd et al., 1997). The idea is based on 
continuous quality improvement. With the use of selected components, such as 
databases, evidence-based guidelines, outcome assessment, communication tools etc. 
this aim is to be reached. Again, in this context a consensus among all healthcare 
providers is seen inevitable. In Germany the code of social law V serves as a basis for 
the implementation of DMPs for various chronic indications, breast cancer being one 
of them. The government published consensus recommendations from a group of 
experts on the DMPs for breast cancer in 2002 (Koordinierungsausschuss, 2002). The 
DMPs should cover the whole care process which begins with the early diagnosis of 
the disease and aims at providing the optimal medical care by the implementation of 
evidence-based guidelines (Engel et al., 2003). In addition, preventive measures should 
be part of DMPs as well as the rehabilitation. In terms of breast cancer many 
disciplines contribute to the care process. Thus the consensus statement calls for cross-
profession and cross-sector cooperation in order to improve the information flow. This 
seems to be especially important when looking at the intersection between hospital 
and ambulatory patient care. Breast cancer patients often switch from one to the other 
setting. Seamless care concepts which aim at optimising the handing over of the 
patient with the important information from one setting to another by implementing 
coordinating professionals such as nurses, social workers or pharmacists are 
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conceivable and are currently being surveyed. The code of social law V in its current 
version deals with the quality assurance in the ambulatory and hospital care and in 
during rehabilitation. 
1.4 Oncology pharmacy 
As other professions, the pharmacy profession experienced a change from traditional 
drug-oriented services such as drug distribution and preparation towards patient-
oriented services. Within the last decade the speciality of oncology pharmacy 
developed and gained experience and knowledge to serve the expanding demands of 
the health system regarding cancer care. The setting-up of central cytotoxic services 
and standardisation of the chemotherapy order forms have been one of the first 
pharmaceutical contributions to decrease prescribing and dosing errors, and to 
increase the safety in handling cytotoxic drugs. Meanwhile the list of oncology 
pharmacy services expanded considerably as shown in Tab. 1-8. 
Tab. 1-5  Pharmacy services in oncology 
Central cytotoxic service 
Drug information service 
Therapeutic drug monitoring 
Nutritional support 
Parenteral medication (e.g. antibiotics, analgesia) 
Unit dose system 
Compiling medication histories 
Pharmaceutical care 
1.5 Pharmaceutical care 
1.5.1 Definition 
The recognition of the numerous risks to the individual patient associated with 
complex drug therapies has led to the development of a conceptual framework for an 
advanced pharmacy practice philosophy. In 1990 Hepler and Strand introduced the 
concept of pharmaceutical care as a further development of the pharmaceutical 
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profession (Hepler and Strand, 1990). They understand pharmaceutical care as the 
responsible provision of drug therapy for the purpose of achieving definite outcomes 
that improve patients’ quality of life.  
The Fédération International Pharmaceutique (FIP) extended this definition in 1998, 
describing it as a collaborative process that aims to prevent or identify and solve 
medicinal product and health-related problems which can be regarded as a continuous 
quality improvement process for the use of medicinal products. Pharmaceutical care is 
a comprehensive practice model. It should be offered to the patient as a whole 
(Fédération International Pharmaceutique, 1998).  
The American Society of Health System Pharmacists set up guidelines on a 
standardised method for pharmaceutical care to assure that pharmacists practicing 
pharmaceutical care work on the same quality level (1996). These guidelines 
amalgamate the aspects introduced above. The London oncology pharmacy group 
also introduced guidelines for the pharmaceutical care of the cancer patient which not 
only include the actual ‘pharmaceutical care’ as such, but also standardise the clinical 
pharmacy activities, dispensing, updating therapeutic policies, cytotoxic reconstitution, 
drug information, clinical trials and the oncology training of the pharmacists (Hoare 
and Beer, 1995). In Germany the Federal Chamber of Pharmacists 
(Bundesapothekerkammer) set up guidelines for the standardised application of 
pharmaceutical care (Bundesapothekerkammer, 2003a; Bundesapothekerkammer, 
2003b). These are general recommendations and introduce the systematic approach. 
To support the pharmaceutical care of patient groups with special characteristics and 
needs such as asthma, diabetes or cancer patients, the Federal Union of the German 
Associations of Pharmacists (ABDA) initiated the publication of practice manuals 
which address the specific needs of such patient groups.  
A fundamental development of pharmaceutical care compared to other 
pharmaceutical services is that pharmacists accept responsibility for the patient’s 
pharmacotherapeutic outcome alongside the physicians. Consequently this concept 
only works in close collaboration with the other involved professionals as shown in Fig. 
1-11.
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Fig. 1-11 Pharmaceutical care as a collaborative concept 
Pharmaceutical care is a needs-based approach. For pharmaceutical care providers the 
main focus are the drug-related needs of the individual patient. The individual drug 
therapy should be appropriately indicated, effective, safe and convenient to the patient 
to assure good compliance and thus an optimal treatment outcome (Cipolle et al., 
1998). These drug-related needs are not necessarily met, which can result in a variety 
of drug-related problems (see Tab. 1-9).  
Tab. 1-6 From drug-related needs to drug-related problems  
(modified from Cipolle et al. (1998)) 
Drug-related needs Drug-related problems 
Indication Additional drug therapy 
 Unnecessary drug therapy 
Effectiveness Wrong drug for the indication 
 Dose too low 
Safety Adverse Drug Reaction 
 Dose too high 
Compliance Non-compliance 
 
To detect potential DRPs and prevent or solve them, the therapeutic outcome 
monitoring serves as a helpful tool (Hepler, 1997). The medication record listing all 
drugs a patient is taking at a time gives an overview and helps interprete the patient’s 
situation. A number of problems can be detected just from analysing the record.  
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In collaboration with the prescribing physician and the patient the goals of the 
drug therapy are to be defined and added to a therapeutic plan as shown in Fig. 1-12. 
Desired outcomes, such as reduction of emetic episodes and degree of nausea, 
patient knowledge about a certain drug, compliance etc. are selected to monitor this 
plan. The monitoring plan is structured following the SOAP method. Subjective 
information and objective parameters which characterise the patient are analysed and 
integrated in the plan.  
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Fig. 1-12 Therapeutic outcome monitoring based on the SOAP method 
The care concept is designed as a continuous process. Regular appointments with the 
pharmacist throughout the therapy are integrated to follow up the therapeutic plan. 
The primary plan needs to be re-evaluated and if necessary adjusted according to the 
patient’s needs. It can be described as a comprehensive drug therapy management. 
The continuity can only be achieved with a thorough documentation of the 
patient-specific data. Not only the medication-related information should be collected, 
but also demographic data, information on the life style (e.g. diet, exercise, social drug 
use), religious affiliations and the social background should be recorded. This 
information allows to get a realistic picture of the patient and to assess the situation.  
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It seems that in particular patients with complex drug regimens and/or chronic 
diseases and those who frequently need to be hospitalised benefit from 
pharmaceutical care. These characteristics apply to many oncology patients. 
1.5.2 Integration in current health policy trends  
Currently discussed care concepts such as case and disease management programmes 
(DMP) aim at improving patients’ outcomes by following evidence-based therapeutic 
guidelines, by trying to meet patients’ needs and by taking into account economic 
aspects. All models advocate patients’ active participation in the therapeutic process 
and try to integrate quality assurance measures (see 1.3). 
In terms of drug therapy, disease management aims to integrate the upper 
mentioned therapeutic goals in a much standardised manner to obtain transparency 
for the patient and the third-party payers. It fosters interdisciplinary approaches in 
order to achieve these goals.  
Pharmaceutical care concepts seem to have a good potential of supporting the 
idea of DMPs. To be integrated in these programmes it is mandatory to document the 
impact of pharmaceutical care on patient outcomes in order to comply with the 
demand for transparency. 
1.5.3 Integration in a societal context 
Due to the above mentioned changes in the health care systems pharmacy profession 
has been endeavouring to adapt its profile accordingly over the past decades. In1987 
the German Pharmacy Practice Ordinance (Apothekenbetriebsordnung) was amended 
by §20 which introduced the duty of pharmacists for consultation on medicines. A 
long debate preceded the enactment of the changed ordinance on the topic which in 
one way or the other still continues (Schubert, 1995). In this process, pharmaceutical 
care is a consistent practice concept which has the potential of amalgamating the legal 
obligations of the pharmacist and the described requirements of a modern health 
system. In addition, it supports the professional legitimation of the pharmacy 
profession which has been discussed controversially in recent times.  
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1.5.4 Pharmaceutical care for the cancer patient 
Within the anticancer therapy concepts the drug regimens are administered following 
established protocols which have been generated in clinical trials and proved to be 
efficient for the respective indication. The administration of supportive therapies is not 
as controlled as the antineoplastic therapy itself. Various settings emphasise supportive 
care in a different manner. Furthermore, in supportive care evidence-based therapy is 
not usual practice, yet. Additionally main parts of the supportive therapy are not 
carried out by the oncology clinic, but from the general practitioners or the patients 
themselves. Many things have to be taken into consideration which often leads to less 
effective protection from adverse effects and thus to a decreased quality of life. That is 
why supportive care has been considered a field for the oncology pharmacist offering 
pharmaceutical care to the cancer patient. The two concepts work well together 
comparing the initial objectives.  
Especially in ambulatory care the continuous monitoring of the medication use 
process should be mandatory. Patients receiving care in the community often 
experience fragmented services. The prescriber often does not see the patient until the 
next visit in the clinic or outpatient department which might be after a few weeks. 
Meanwhile ADRs can occur which might not be detected in time. Furthermore, 
patients tend to see more than one physician involved in the cancer care process as 
well as alternative practitioners. Patients are also exposed to a tremendous choice of 
products which are available to the customer without prescription (over-the-counter - 
OTC).  
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Fig. 1-13 Pharmaceutical care in oncology therapy 
Fig. 1-13 illustrates the complexity of cancer patients’ drug therapy and the possibly 
resulting drug-related problems which are addressed by the therapeutic outcome 
monitoring. 
The different prescribers, nurses and relatives and the patient with self-
medication are all part of the individual drug therapy team. Thus, they all need to be 
included in the collaborative process. A group of British experts drew up a policy 
framework for commissioning cancer services. They suggest the establishment of 
structures which support the seamless care of cancer patients in the community setting 
in a network of all parties in order to make use of the respective speciality knowledge 
(Working Party Report, 1997). Accordingly the information flow at discharge from 
hospital to the ambulatory setting should be optimised utilising pharmaceutical care 
plans to make sure that the efficient distribution of the medication to the patient is not 
interrupted. 
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Tab. 1-7 Pharmaceutical aspects of supportive care 
Supportive Care 
(examplary) 
Traditional pharmaceutical 
tasks 
Patient-oriented tasks 
Nutritional support Distribution of appetite 
stimulating drugs 
Distribution of hypercaloric 
products 
Calculation of nutritional 
regimens 
Preparation of total parenteral 
and enteral nutrition 
Individual nutrition counselling 
Pain management Distribution of drugs Preparation of parenteral 
medication 
(patient controlled analgesia PCA, 
different pump systems etc.) 
Counselling on taking modalities 
Non-medical advice on  
preventive behavior 
Mucositis 
prophylaxis and 
therapy 
Preparation of mouth washes Patient education on oral hygiene 
algorithms 
Non-medical advice on  
preventive behavior 
Antiemetic 
prophylaxis 
Distribution of drugs Elaboration of therapeutic 
algorithms  
Counselling on taking modalities  
Non-medical advice on 
preventive behavior 
 
A few examples on how pharmacists’ activities in supportive care expanded from the 
traditional tasks towards the patient-oriented tasks in the framework of pharmaceutical 
care are listed in Tab. 1-7. Within the pharmaceutical care process the application of 
agreed therapeutic algorithms can be assured on the individual basis. The adherence 
of the patient can be improved by patient education before and during the treatment 
cycles combined with patient counselling regarding drug therapy, adverse effects and 
complementary treatment options. 
1.5.5 Pharmaceutical care research  
There are numerous publications on the philosophy and theoretical background of 
pharmaceutical care. Additionally there are many reports on the experience with the 
implementation into practice settings. The major gap seems to be the lack of scientific 
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evidence of the impact of pharmaceutical care on health care provision. Kennie et al. 
addressed this problem and critically analysed pharmaceutical care research literature 
in order to determine deficiencies in study design and research methods and to 
formulate recommendations to improve the situation (Kennie et al., 1998). Among 
other recommendations they emphasised the importance of using the term 
‘pharmaceutical care’ properly. In the evaluated studies they found that the term had 
been used to describe other pharmacy services such as pharmacokinetic services or 
patient counselling which on their own do not constitute pharmaceutical care. They 
also called for scientific standards such as controlled study designs, which should be 
implemented. In the literature only a few studies can be found which were conducted 
following research standards. Especially on asthma and COPD, studies were 
conducted and the results were published in renowned journals (Knoell et al., 1998; 
Schulz et al., 2001; Weinberger et al., 2002). Moreover, pharmaceutical care for 
elderly people was investigated in a multicentred, randomised controlled trial 
(Bernsten et al., 2001). A further suggestion was the development of a pharmaceutical 
care network which could coordinate the international effort to improve the research 
and to identify fields of interest. The Pharmaceutical Care Network Europe (PCNE) has 
taken up these suggestions and meets annually to address these questions. 
In oncology, there is little scientific evidence on the feasibility of pharmaceutical 
care and actual benefit to the patient so far. In Canada projects have been carried out 
which suggest to implement suitable outcome parameters to evaluate the impact of 
pharmaceutical services in oncology (Broadfield, 1995). These have stimulated a 
founded discussion in Canadian health care politics regarding the necessity of the 
offered services. 
In Germany various research projects are being carried out or have been 
completed which survey the benefit and the feasibility of pharmaceutical care for 
patients with different indications. Fig. 1-14 illustrates the distribution of the projects 
within the country. Cancer patients are the focus of a project in Hamburg which is 
working on lung cancer patients and the present study. 
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Northrhine - Westphalia: 
• Geriatric patients
• Data management
• Cancer
Baden-Wuerttemberg:
Type-II-Diabetes
Saxony: Pain
Hamburg: Asthma & Cancer
Brandenburg: 
Hypertension
Thuringia: Hypertension
Saarland / Rhineland-Palatinate:
Metabolic syndrome & Asthma 
Hesse:
Self-medication of 
patients with dyspepsia
Mecklenburg-Western Pomerania:
Cardiovascular disease
Berlin: Geriatric patients
Bavaria: 
• Pharm. Care in small pharmacies
• Asthma (Augsburg) 
• DRP
Bremen / Lower-Saxony: Migraine
Saxonia-Anhalt: Diabetes
 
Fig. 1-14 Pharmaceutical care research projects in Germany  
[Schulz, personal communication]
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2 Aim and Objectives 
The present work is the first in the research field of pharmaceutical care in oncology in 
Germany and thus could not refer to much knowledge of previous projects. It is 
composed of three parts. Part one adapted a Canadian questionnaire on patient 
satisfaction with information on cancer treatment for German settings. The second 
main part of this pilot is the survey on the feasibility and benefit of pharmaceutical care 
for patients with gynaecological malignancies. Part three is the monitoring of 
carboplatin in patients with ovarian cancer. It can be viewed separately as well as 
integrated in the model of pharmaceutical care. 
2.1 Patient satisfaction with information on cancer treatment 
The objective of the first study of this thesis was to adapt the Canadian PS-CaTE 
questionnaire for use in German-speaking countries in order to provide a suitable 
outcome measurement instrument. In addition, the adapted questionnaire was applied 
to survey different cancer care settings across Germany and thus provides an 
assessment of the present situation in Germany. The results are intended to support 
the development of pharmaceutical care strategies for cancer patients by detecting 
and compensating information deficiencies. 
2.2 Pharmaceutical care for patients with gynaecological malignancies 
Pharmaceutical care in oncology aims at reducing treatment-related toxicity and at 
improving patients’ quality of life. The aim of this work was to develop a specific 
pharmaceutical care model for breast and ovarian cancer patients including patient 
counselling on the management of treatment-associated adverse effects, optimisation 
of supportive medication and the implementation of a therapeutic algorithm for 
antiemetic prophylaxis. 
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2.3 Monitoring of carboplatin 
Carboplatin is commonly dosed to achieve a defined target AUC. The estimations 
used in clinical practice proved to be inaccurate, consequently leading to either over- 
or more likely under-exposure to carboplatin. Therapeutic drug monitoring has a great 
potential for optimising individual drug therapy. This method is capable of improving 
the dosage accuracy as well as the safety of drugs with a narrow therapeutic range. It is 
the objective of this pilot study to assess the value of therapeutic drug monitoring for 
patients treated with antineoplastic agents, in particular carboplatin, the feasibility in 
outpatient settings and its contribution to pharmaceutical care. 
2.4 Working hypotheses 
The following working hypotheses were defined: 
 The systematic optimisation of the supportive therapy by the pharmacist 
reduces incidence and severity of undesirable effects during and after 
chemotherapy. 
 The minimisation of therapy associated toxicity improves the specific 
quality of life (symptomatic). 
 Pharmaceutical care improves the communication regarding drug 
treatment and the global quality of life of patients. 
 Individual dosage strategies based on pharmacokinetic parameters, e.g. 
therapeutic drug monitoring (TDM), are applicable to outpatient settings. 
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3 Material and Methods 
3.1 Patient satisfaction with information on cancer treatment 
In order to develop patient-oriented standards for a care process, it is necessary to 
know what type of information patients want and to what extent patients need to be 
informed. In addition, quality assurance plays an increasingly important role in the care 
of cancer patients. In order to obtain a high standard in cancer care it seems to be 
reasonable to establish measures that are capable of assessing the performance of 
care. Patient satisfaction may act as an indicator of the quality of health care services. It 
reflects the ability of the care provider to meet the patients’ needs. 
3.1.1 PS-CaTE questionnaire 
In Germany, there are presently no appropriate instruments which measure patient 
satisfaction with the information given on cancer treatment. The British Columbia 
Cancer Agency, Vancouver, Canada, developed the ‘Patient Satisfaction with Cancer 
Treatment Education (PS-CaTE)’ questionnaire (Pohar and Taylor, 2000). This 
instrument was established to measure patients’ satisfaction with the information they 
received within the framework of a cancer treatment education programme.  
Intensive discussions with experts about the methodology of measurement 
scales resulted in the decision to translate an existing instrument rather than to develop 
a new one. This also facilitates comparing the status of cancer care in different 
countries as it has already been done with quality of life measures, such as the QLQ-
C30 from the European Organisation for Research and Treatment of Cancer (EORTC) 
(Aaronson et al., 1993). 
3.1.2 Translation of the PS-CaTE questionnaire 
The Canadian questionnaire was translated using a systematic approach. Literal 
translation may result in different meanings as it might introduce subtle forms of 
distortion into the scales. To address this concern the Canadian ‘Patient Satisfaction 
with Cancer Treatment Education (PS-CaTE)’ questionnaire was translated into German 
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following the forward/backward translation method as shown in Fig. 3-1 (Streiner and 
Norman, 2000). Two bilingual translators who were familiar with the textual 
background of the questionnaire were asked to translate the original version into 
German. These independent versions were compared and the translators agreed upon 
one version. In this way possible misinterpretations could be detected and eliminated. 
The agreed German version was then translated back into English by two other 
bilingual speakers. They too compared their results and compiled an agreed English 
version. The last step in the procedure was to compare the original version with the 
English version translated back from the German version. All involved translators 
discussed uncertain aspects and adapted the German translation accordingly. Selected 
socio-demographic variables, including educational status, marital status, age, 
diagnosis, time since diagnosis, were added to the original version of the questionnaire 
to facilitate subgroup analysis. 
English original agreed
German translation
agreed
English translation
D2
D1
E2
E1
Alignment of the English translation with the original version
Forward translation Backward translation
D1/D2:  independent translations into German
E1/E2 :   independent translations into English
 
Fig. 3-1 Translation process of the questionnaire 
3.1.3 Psychometric properties 
Due to the translation process, the psychometric properties of the scales such as 
reliability and validity can be affected. It is therefore mandatory to reassure these test 
quality criteria.  
The reliability of a questionnaire or a scale refers to the precision or homogeneity 
of the instrument, leaving questions of content out of consideration. It reflects the 
reproducibility of the scale measures across repeated administrations of the same test 
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or parallel test forms (Crocker and Algina, 1986). The reliability coefficient is defined as 
the ratio of the true score variance to the total variance of the test scores (Lord and 
Novick, 1968). Two commonly used reliability estimates are the Spearman Brown split-
half reliability and the internal consistency coefficient (Cronbach’s alpha). These 
coefficients were assessed both in a pre-test and in the main test. The procedures are 
described under 3.4. 
The validity is the extent to which a measurement instrument actually measures 
the underlying concept it is supposed to measure. In our study the so-called face 
validity (or content validity) was assessed. Face validity indicates that an instrument 
appears to assess the desired dimension because of the semantic content of the items. 
It represents a subjective judgement based on a review of the instrument by one or 
more experts (Streiner, 2000). The German version of the questionnaire was handed 
out to experts of pharmacy practice, medical practice and patient speakers for 
reviewing. These experts were asked to critically appraise whether each item and the 
whole questionnaire were suitable to measure patient satisfaction with information on 
cancer treatment. 
3.1.4 Patient selection 
Patients with all types of cancer were asked to participate in the survey. A main 
criterion of inclusion was the ability to complete the questionnaire without help from 
others. Thus patients needed to be able to read and write German and to be mentally 
healthy. For the pre-study, patients did not have to give written informed consent. The 
patients were assured that anonymity would be maintained and that a refusal to 
participate would not in any way affect the quality of their care. A short letter 
preceding the questionnaire informed the patients about the content of the study (see 
appendix J). 
3.1.5 Distribution among cancer centres in Germany 
The questionnaire was distributed among patients of 11 cooperating hospitals, 
oncology practices, pharmacies and self-aid groups across Germany. 
Persons entrusted with the distribution of the questionnaires encouraged patients 
to complete the questionnaire independently in order to minimise the tendency for 
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socially desired answering. Where possible, the individuals distributing the 
questionnaire were not involved in patient care. The completed questionnaires were 
either collected on the ward, in the general practitioner’s office or in the pharmacy to 
be sent back by the distributor, or they were sent back by the patients themselves in 
previously addressed and stamped envelopes. All questionnaires were sent to the 
University of Bonn for analysis. 
3.2 Pharmaceutical care for patients with gynaecological malignancies 
The present project was initiated as the first study to survey pharmaceutical care for 
cancer patients in Germany. In addition little scientific evidence was available on 
pharmaceutical care research in general. Therefore this work was planned as a pilot 
study. Infrastructural aspects had to be solved and a suitable design had to be selected 
before the actual work could be started.  
3.2.1 Study protocol 
Two universal binding regulations determine the principles for clinical research with 
humans. The World Medical Association (WMA) constitutes in their ‘Declaration of 
Helsinki’ ethical principles which safeguard patients’ rights in clinical research. They 
declare that medical research is subject to ethical standards that promote respect for 
all human beings and protect their health and rights. The WMA claims the application 
of basic principles for the medical research in order to protect patients’ rights, 
including the scientific principles, the thorough formulation of an experimental 
protocol and an approval of an independent ethics committee (World Medical 
Association, 1964). The note for guidance on good clinical practice (GCP) comprises 
these principles likewise in order to assure a standardised quality (The European 
Agency for the Evaluation of Medicinal Products, 1996). In order to meet the 
requirements of these guidelines the principles mentioned above were considered in 
the planning of the study. A study protocol was worked out prior to the start of the 
study. The planning and realisation of the present work was accomplished by a 
research pharmacist. 
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3.2.1.1 Legal obligations 
The German drugs act (Arzneimittelgesetz) regulates the protection of humans in 
clinical trials in §§ 40-42 (1976). According to this  
 the expected risks for the involved person must be in relation to the 
expected benefit and must be justifiable. 
 the patient needs to be thoroughly informed about the aim, content and 
associated risks of the study (see appendix E) 
 the patient has to agree to participate by signing an informed consent (see 
appendix F) 
 the study has to be supervised by a physician with at least two-year 
experience in clinical research 
 a study protocol based on the current scientific evidence has to be set up 
and be approved by an ethics committee. 
 an appropriate patient insurance has to be signed which covers € 500,000. 
 
These requirements were considered in the present study. In order to obtain the same 
approach in all participating centres standard operating procedures (SOP) were set up 
(see appendix D). 
Personal data of the participating patients were protected by applying §4, sect. 3 
of the data protection act of North-Rhine-Westphalia (2000). The patients had to sign 
an agreement prior to the study allowing the caring pharmacist to inspect patient 
record and to analyse the collected data (see appendix G). All patient-associated data 
were anonymised with a specific code to assure complete data protection. 
The ethics committee of the medical council of North-Rhine approved the study. 
Additionally, the ethics committees of the individual institutions, when existing, 
approved the study for their setting. 
3.2.1.2 Selection of patients and drugs 
To obtain a homogenous study population inclusion and exclusion criteria were 
defined (Tab. 3-1). 
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Tab. 3-1 Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Diagnosed breast or ovarian cancer 
First chemotherapy  
Age 18–65 years 
Diseases or mental states which impede  
that the patient completely understands 
the provided information on the study  
(e.g. Alzheimer’s disease). 
Written informed consent 
Ability to speak, read and write in the  
German language 
Impaired capability of reading and 
completing questionnaires self-
administered 
 
Moreover, only patients with predefined chemotherapy regimens were included in the 
study. Two chemotherapy regimens were selected that were regarded as standard 
regimens and presented a toxicity profile which required extensive supportive therapy. 
As described before the chosen regimens accomplish these considerations (Tab. 3-2). 
However, the prescribing oncologists were not influenced at all in their decision for an 
individual regimen. They were merely asked to inform about changes. 
Tab. 3-2 Selected chemotherapy  regimens 
Breast cancer Ovarian cancer 
Epirubicin 90 mg/m² BSA Paclitaxel 175-185 mg/m² BSA
Cyclophosphamide 600 mg/m² BSA Carboplatin Target AUC 5-7.5 
 
3.2.1.3 Study design 
The use of gold standards in clinical research, such as double-blinded, randomised 
controlled study designs, is limited when applied to pharmacy practice research. 
Nevertheless, it is important to define and establish standards for pharmaceutical care 
research in order to obtain reliable data. It was aimed at approaching as close as 
possible to the standards of clinical research. Different study designs were surveyed 
regarding their suitability to evaluate the care model:  
 pre-post comparison 
 parallel control group 
 preceding control group 
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During the developing process specialists with expertise in either pharmacy practice 
research or clinical research in oncology were consulted. Criteria for the developed 
study design were high scientific output, feasiblility of the study design in an 
ambulatory setting and ethical aspects. The pre-post comparison did not seem to be 
suitable as a disease progression would bias the results. The parallel control group 
design was decided to be unapplicable as ‘learning effects’ of the participating 
physicians could be expected regarding the therapeutic algorithm for the antiemetic 
treatment. Moreover, it appeared to be unethical to offer a comprehensive care to 
some patients while others would not receive it. This was particularly difficult as the 
patients who were treated concurrently intensively exchanged their experiences which 
could have led to major discontentment. Eventually an open prospective, multi-
centred, sequential control group design as illustrated in Fig. 3-2 was chosen. The 
control group was studied before the intervention group in order to avoid the 
mentioned learning effects and the inequity among the patients. Both the control (CG) 
and intervention group (IG) received the explanations about the aim and content of 
the study. The patients were allowed a respite of at least 24h until they were asked to 
decide upon their participation. 
Control group Intervention group
 
Fig. 3-2  Sequential control group design 
All patients were asked to complete the questionnaires at predetermined times. The 
patients of the control group were then asked to send the completed questionnaires 
back to the study office in postage-paid and addressed envelopes, whereas the 
patients of the intervention group brought the questionnaires to the care 
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appointments. In case of the breast cancer patients the whole procedure lasted over a 
period of approximately nine weeks (four cycles with a three weeks interval). The 
ovarian cancer patients (OC) were in the care process for about 15 weeks (six cycles 
with a three weeks interval). Additionally, blood samples were drawn from ovarian 
cancer patients on the first, third and sixth cycle in order to determine the platinum 
concentrations in plasma (see 3.3 Monitoring of carboplatin). 
For the intervention group, the following key interventions were defined: 
 Regular appointments of the research pharmacist with the patients to 
define patient’s needs and to detect and solve drug-related problems. 
 The optimisation of supportive care and application of the acquired 
therapeutic algorithm. 
 
The course of the study is illustrated in Fig. 3-3. 
3.2.1.4 Study centres 
Four gynaecological outpatient clinics and two oncological practices from the North-
Rhine area participated in the study. The physicians had to agree to cooperate with the 
research pharmacist in terms of providing necessary patient information and being 
available for queries. Moreover, they needed to comply with the therapeutic algorithm 
for the antiemetic prophylaxis and treatment which the project team concertedly 
decided. The project team regularly met to discuss the process of the study. Between 
the meetings the research pharmacists communicated with the physicians mainly by 
telephone or by short visits in the clinics or physicians’ offices. 
3.2.1.5 Patient information material 
Information on aim and content of the study 
Prior to the study every patient received extensive standardised information material 
about the aim and the content of the study. The course of the study was explained and 
the individual effort in terms of completing the questionnaire and the expectable 
benefits for the patient were described. A sample of the information material for 
ovarian cancer patients is displayed in appendix F. 
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Fig. 3-3 Course of the treatment and outcome measurement 
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Information on expected adverse drug reactions 
For the care process information material was prepared which explained the potential 
therapy-associated adverse drug reactions to the patient and gave recommendations 
for prophylactic measures as well as for emergency measures. An example is displayed 
in the appendix I. The content of these brochures was taken from a selection of cancer 
brochures from different cancer societies and textbooks (Margulies et al., 2002; 
Beckmann, 2003). 
All patient information material was formulated in close cooperation with patient 
initatives. In order to prevent incomprehensibilities and inappropriate wording all 
material was proof read by patients from patient organisations (either ‘Mamazone e.V.’ 
or ‘Frauenselbsthilfe nach Krebs e.V.’). In addition, the participating physicians 
approved the content of the information material. 
3.2.1.6 Outcome measurement 
In order to measure outcome in both groups, the following instruments were chosen: 
EORTC QLQ-C30 questionnaire to assess quality of life, a questionnaire to document 
nausea and vomiting for independent completion and the translated PS-CaTE patient 
satisfaction questionnaire referring to the given information (see 3.1). In addition, the 
kind of occurring DRPs and according pharmaceutical interventions were recorded. 
Quality of life 
Improvement of quality of life (QoL) is the main aim of pharmaceutical care. Different 
instruments are available to measure health-related quality of life (Fayers and Machin, 
2000). The EORTC QLQ-C30 (version 3.0) questionnaire (see appendix J) was 
developed for research in oncology and reflects the special needs of cancer patients 
(Aaronson et al., 1993). Not only the fact that it is a disease-specific instrument made it 
suitable for this study, but also that it is widely used in international cancer research. It 
was translated in different languages including German and tested regarding its test-
quality criteria. It was found to be reliable and valid. 
It was important to be able to image the development of the QoL over the treatment 
period. Still the load for the patients should be minimised. Therefore three points of 
time were defined for the measurement of the QoL: at baseline just before the 
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beginning of the chemotherapy, at half time (after the second cycle for breast cancer 
patients and after the third cycle for ovarian cancer patients, respectively) and at the 
end of the treatment (after the fourth (BC) or sixth cycle (OC)). For the second and 
third measurement the patients were asked to complete the QLQ-C30 questionnaire a 
week after the chemotherapy cycle. This seemed to be reasonable as patients suffer 
most adverse effects within the first week after chemotherapy. Therefore, earlier 
measurements would bias the global QoL too much. Still the measurements should 
not be performed too long after these experiences. As it is a subjective assessment and 
influenced by many factors it also seemed to be important to measure all patients in 
the same manner in order to obtain reliable data. 
The questionnaire consists of multi-item scales as well as single-item measures as 
listed in Tab. 3-3. Raw data were transformed into scores from 0 to 100 where a high 
scale score represents a higher response level (Fayers et al., 1999). For functional 
scales a high score represents a high degree of functioning, as well as a high score in 
global health status and QoL stand for high QoL. Compared to these a high score in a 
symptom scale or item represents a high degree of symptomatology. 
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Tab. 3-3 Scales of the QLQ-C30 version 3.0 
 Scale Number of items Item numbers (v 3.0) 
Global health status/QoL QL2 2 29, 30 
Functional scales    
Physical functioning PF2 5 1-5 
Role functioning RF2 2 6, 7 
Emotional functioning EF 4 21-24 
Cognitive functioning CF 2 20, 25 
Social functioning SF 2 26, 27 
Symptom scales/ items    
Fatigue FA 3 10, 12, 18 
Nausea and vomiting NV 2 14, 15 
Pain PA 2 9, 19 
Dyspnoea DY 1 8 
Insomnia SL 1 11 
Appetite loss AP 1 13 
Constipation CO 1 16 
Diarrhea DI 1 17 
Financial difficulties FI 1 28 
 
To obtain a score initially a raw score was calculated: 
RS = RawScore = (I1+I2+I3+…In)/n        (Eq. 3-1) 
 
The score for functional scales is then determined by: 
Score = 100
)1(
1 ⋅⎭⎬
⎫
⎩⎨
⎧ −−
range
RS
        (Eq. 3-2) 
 
Both symptom scales and the global health status / QoL were scored by: 
Score = 100
)1( ⋅⎭⎬
⎫
⎩⎨
⎧ −
range
RS
        (Eq. 3-3)
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Item range is the difference between the possible maximum and the minimum 
response to individual items.  
The results of the global health status/QoL and of the functional scales were calculated 
for the different time points (t1, t2) relative to the baseline value t0. 
100)(
0
1
1 ⋅= t
t
relt   100)(
0
2
2 ⋅= t
t
relt      (Eq. 3-4) 
 
For the symptom scales the absolute values were used. 
The changes in the different subscales over the treatment period were determined by 
subtracting the baseline value from the values at t1 and t2. The difference of the global 
health status/QoL and of the functional scales was related to baseline  
t1(change) = 100
)(
0
01 ⋅−
t
tt
  t2(change) = 100
)(
0
02 ⋅−
t
tt
   (Eq. 3-5) 
 
Nausea and emesis 
The questionnaire for reporting of nausea or emesis had two purposes in the present 
study. For one, it served as an outcome measure. Additionally, it was used as a tool in 
pharmaceutical care to monitor the antiemetic prophylaxis and treatment. Some 
considerations had to be made to accomplish both tasks.  
The assessment of nausea and emesis requires different methods (Morrow, 1992). 
Whereas emesis is an objective criterion, nausea is certainly subjective. Emesis can 
simply be measured by the enumeration of the emetic episodes. Strictly speaking it 
must be defined whether retching accounts for an emetic episode or not. The stringent 
criterion ‘complete control emesis’ (no event of retching nor emesis) avoids these 
definition problems. This parameter can be better recalled by patients and is also 
better comparable among different studies. Morrow describes in his meta-analysis 
different ways of measuring nausea. Frequency, severity and duration of nausea can be 
assessed. 
Moreover, the way on how to get the information on the experienced nausea 
and emesis has to be considered. A very common way is to ask patients at the 
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following appointment. This, however, is biased by incomplete recalling. Another way 
is by self-reporting on patient diary cards. This seems to reflect the real situation much 
better. 
Freidank established a patient diary for the self-recording of both nausea and 
emesis. It has successfully been used in the clinical setting and seemed applicable for 
the present study (Freidank, 1999). Patients were asked to report the emetic episodes 
and classifiy the experienced nausea from degree 0 to 4 (‘no nausea’ to ‘severe 
nausea, which makes everyday life impossible’). 
In the present study a modified version of Freidank’s patient diary was used (see 
appendix J). For nausea the sum scores of the reported degrees of nausea were 
compared whereas for emesis the achieved complete response rates were compared 
between the two groups. Still patients were asked to report all emetic episodes in 
order to evaluate the success of the antiemetic prophylxis and therapy. Patients were 
instructed to count episodes which were one minute apart as two, retching and/or 
vomiting accounted for one episode if lasting less than five minutes and for two if 
longer than five minutes. Complete response was defined as no event of retching and 
emesis over a defined period. 
Nausea and emesis were documented after every cycle. This allowed monitoring 
as well as the longitudinal evaluation of the collected data. In order to record both 
acute and delayed nausea and emesis patients were asked to fill in the patient diary 
over a period of 5 days starting at the day they received chemotherapy. 
Patient satisfaction with information on cancer treatment 
The questionnaire measuring the patients’ satisfaction with information on cancer 
treatment was completed once at the end of each chemotherapy cycle. The scoring of 
the questionnaire followed the system described inTab. 3-4. 
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Tab. 3-4 Scoring of the patient satisfaction questionnaire 
Scale Scoring 
Global satisfaction Sum score of all 14 items divided by the 
number of items 
Scale 1 Satisfaction with information 
regarding cancer treatment 
 Sum score of items 1, 5, 6, 7, 12 divided by 
5 
Scale 2 Satisfaction with information 
regarding side effects 
 Sum score of items 2, 3, 8, 13 divided by 4 
Scale 3 Satisfaction with information 
regarding vitamins, herbs 
and complementary therapy 
 
Sum score of items 4, 9, 14 divided by 3 
Scale 4 Satisfaction with information 
sources and the way 
information is provided 
 
Sum score of items 10, 11 divided by 2 
 
Pharmacists’ interventions 
An important aspect in pharmaceutical care is the detection and solution of drug-
related problems (DRPs). Schaefer developed, comparable to Strand (Strand et al., 
1990) and van Mil (van Mil and Tromp, 1997) a coding system for drug-related 
problems – PI-Doc® (Schaefer, 2002). This coding system is used in all German 
pharmacy software packages with a pharmaceutical care module. In the present study 
the detected DRPs and associated interventions were coded according to PI-Doc®. 
This system is based on a set of codes (see appendix H) which can be extended 
by the operator for extra codes for specific care issues and DRPs. In case of the 
pharmaceutical care for cancer patients a supplementation of the existing codes was 
necessary. The additional codes are listed in Tab. 3-5. 
Tab. 3-5 Supplementation of additional codes for PI-Doc®
G Other Problems (patient-related) 
GP7 Patient vomited the taken drugs 
I General intervention 
I5 Recommendation of a drug 
I5a Recommendation to change a drug 
I6 Recommendation of a preventive measure 
I7 Information regarding complementary measures 
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I8 Drug information search 
I9 Recommendation of a non-medical measure 
IG Intervention: other problems 
 Patient-related problems 
IGP4a Information about nutrition 
IGP4b Information about physical training 
IGP7 Recommendation regarding adaequate subsequent dosage 
 Technical and logistical problems 
IGT6 Clarification of a seamless therapy continuation 
 
3.2.2 Therapeutic algorithm for the antiemetic prophylaxis and treatment 
In order to optimise the antiemetic prophylaxis and treatment the currently available 
and evidence-based therapeutic guidelines of the scientific societies were applied (Tab. 
3-6). 
Tab. 3-6 Therapeutic guidelines for the antiemetic prophylaxis and treatment 
American Society of 
Clinical Oncology 
ASCO Recommendations for the use of 
antiemetics: Evidence-based, 
clinical practice guidelines  
Gralla et al., 1999  
European Society of 
Medical Oncology  
ESMO ESMO recommendations for 
prophylaxis of chemotherapy-
induced nausea and vomiting 
ESMO guidelines 
task force, 2001  
Multinational 
Association of 
Supportive Care  
in Cancer 
MASC Prevention of chemotherapy- 
and radiotherapy-induced 
emesis: Results of the Perugia 
consensus conference 
Antiemetic 
Subcommittee of 
the MASCC, 1998  
American Society of 
Health System 
Pharmacists 
ASHP ASHP Therapeutic Guidelines on 
the pharmacologic management 
of nausea and vomiting in adult 
and pediatric patients receiving 
chemotherapy or radiation 
therapy or undergoing surgery 
ASHP Commission 
on Therapeutics, 
1999 
The research pharmacist studied the available guidelines and worked out a proposal 
which served as a basis for discussion within the project team. 
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Three questions had to be answered: 
 How is the emetogenicity of the two selected chemotherapy regimens 
classified? 
 What are the concordant recommendations of the scientific societies for 
the treatment of acute and delayed nausea and emesis? 
 Do individual risk factors play a role in the treatment decision? 
According to the consulted literature and taking the experience of the participating 
physicians into account the chosen regimens were classified (Hesketh et al., 1997; 
Antiemetic Subcommittee of the MASCC, 1998; ASHP Commission on Therapeutics, 
1999; Gralla et al., 1999; ESMO guidelines task force, 2001). Epirubicin (90 mg/m2) in 
combination with cyclophosphamide (600 mg/m2) has a moderate to high emetogenic 
potential whereas paclitaxel (175 (185) mg/m2) in combination with carboplatin 
(target AUC 5 – 7.5 mg⋅min/mL) is classified highly emetogenic. 
The prophylactic treatment options for nausea and emesis recommended by 
expert groups of the different scientific societies were intensively discussed with the 
participating physicians until a consensus was reached in the project team. The 
consensus of the project team mainly applied these recommendations, which do not 
vary a lot. Regarding the significance of dexamethasone a deliberate modification was 
applied. Instead of dexamethasone metoclopramide was selected basic component of 
the antiemetic prophylaxis. The agreed therapeutic algorithm is illustrated in Fig. 3-4.  
Regarding the individual risk factors only ASCO and ASHP mention the impact of 
young age, female sex, little alcohol intake and previous bad experiences which 
influence the symptomatology of nausea and emesis. Still, in neither of the studied 
guidelines these factors have an impact on the therapeutic recommendation. The 
project team therefore decided to act accordingly. In terms of the prophylaxis of 
anticipatory nausea and emesis the project team agreed that the mental condition of 
the patient prior chemotherapy should be considered. It was differentiated whether 
the patient was anxious or confident. Anxious patients received additional lorazepam. 
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Day 
2
Day 
3
Day 
4
Day 
5
2x   8 mg Dexa p.o.
+ 3x 20 mg MCP p.o.
+ 5HT3-RA as Rescue p.o.
2x    8 mg Dexa p.o.
+ 3x 20 mg MCP p.o.
+ 5HT3-RA as Rescue p.o.
2x  4 mg Dexa p.o.
+ 3x 20 mg MCP p.o.
+ 5HT3-RA as Rescue p.o.
2x  4 mg Dexa p.o.
+ 3x 20 mg MCP p.o.
+ 5HT3-RA as Rescue p.o.
3x 20 mg MCP p.o.
+ 5HT3-RA as Rescue p.o.
3x 20 mg MCP p.o.
+ 5HT3-RA as Rescue p.o.
3x 20 mg MCP p.o.
+ 5HT3-RA as Rescue p.o.
3x 20 mg MCP p.o.
+ 5HT3-RA as Rescue p.o.
2x   4 mg Dexa p.o.
+ 3x 20 mg MCP p.o.
+ 5HT3-RA as Rescue p.o.
2x   4 mg Dexa p.o.
+ 3x 20 mg MCP p.o.
+ 5HT3-RA as Rescue p.o.
3x 20 mg MCP p.o.
+ 5HT3-RA as Rescue p.o.
3x 20 mg MCP p.o.
+ 5HT3-RA as Rescue p.o.
3x 20 mg MCP p.o.
+ 5HT3-RA as Rescue p.o.
3x 20 mg MCP p.o.
+ 5HT3-RA as Rescue p.o.
3x 20 mg MCP p.o.
+ 5HT3-RA as Rescue p.o.
3x 20 mg MCP p.o.
+ 5HT3-RA as Rescue p.o.
Acute
Nausea and Emesis
No acute
Nausea and Emesis
Chemotherapy
24 h post   Chemotherapy
Highly emetogenic
chemotherapy
(Paclitaxel/Carboplatin)
Moderately emetogenic
chemotherapy
(Epirubicin/Cyclophosphamide)
Confident patient Anxious patient Confident patient Anxious patient
5HT3-RA (alternatively)
Ondansetron 8 mg i.v.
Granisetron 1-2 mg i.v.
Dolasetron 1.8 mg/kg i.v.
Tropisetron 5 mg i.v.
Corticosteroide
Dexamethasone 12 mg i.v.
Chemotherapy
24 h post   Chemotherapy
Acute
Nausea and Emesis
5HT3-RA (alternatively)
Ondansetron 8 mg i.v.
Granisetron 1-2 mg i.v.
Dolasetron 1.8 mg/kg i.v.
Tropisetron 5 mg i.v.
Corticosteroide
Dexamethasone 12 mg i.v.
No acute
Nausea and Emesis
No additive required No additive required
Requires therapy for
highly emetogenic
chemotherapy
Benzodiazepine
Lorazepam 1-2mg p.o.
 
Fig. 3-4 Therapeutic algorithm for the antiemetic prophylaxis and treatment 
(RA = receptor antagonist, Dexa = dexamethasone, MCP = metoclopramide) 
3.2.3 Evaluation of the collected data 
The aim of this work was to study the feasibility and benefit of pharmaceutical care for 
patients with gynaecological malignancies. Little was known about the impact of 
pharmaceutical care on the selected outcome parameters. In the pilot phase 
pharmaceutical care was established and first knowledge on primary and secondary 
endpoints was obtained. 
Due to the fact that information, necessary for a reasonable statistical planning, 
was lacking, a dual-stage adaptive design was chosen (Wassmer, 1999). In this 
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precursory pilot phase the important information was collected which than was used 
to thoroughly plan the subsequent main study. The advantage of this design is the 
opportunity to evaluate both patient groups together. This reduces the number of 
patients needed to show the difference between two groups regarding a selected 
effect. 
As the improvement of the health related quality of life is per definition the aim of 
pharmaceutical care it was chosen to be the primary endpoint in the precursory phase 
of the study. Apart from the primary endpoint other parameters were regarded as 
secondary endpoints. Acute and delayed nausea, acute and delayed emesis, complete 
control of emesis and patient satisfaction were evaluated. To decide whether there is a 
difference in quality of life between control and intervention group the nullhypothesis 
H0: QoLControl = QoLIntervention, 
that is, QoL in both groups is equal, has to be disproved in order to accept the 
alternative hypothesis  
H1 (two-sided): QoL Control ≠ QoLIntervention,  
that is, QoL in both groups is unequal. 
Determination of α0, α1 and cα and the decision-algorithm 
The dual-stage adaptive design required the predefinition of threshold values α0, α1 
and cα which were part of the decision algorithm which was applied at the end of the 
pilot phase in order to decide how to proceed. It will also be used at the end of the 
main study. These threshold values resulted from the assumption that the total error 
should be less than 5%. According to Bauer and Köhne (1994) α = 0.05 and α0 = 0.50 
a critical value α1 = 0.0233 and cα = 0.0087 resulted. 
This consequently led to the following decision algorithm: 
If the p-value p1 of the internal pilot study p1 ≥ α0 = 0.50, the study will be terminated 
accepting H0. 
If p1 ≤ α1 = 0.0233, the study will be terminated with the disaffirmation of H0. 
 71
[3] Material & Methods 
If α1 < p1 < α0, the second phase of the study will be carried out. In the second phase 
H0 will be rejected, if p1p2 ≤ cα = 0.0087. 
3.2.4 Pharmaceutical care process 
3.2.4.1 Patient recruitment 
The treating physician drew the patients’ attention to the study and asked their 
permission to be contacted by the research pharmacist. The pharmacist then 
contacted the patient either in the clinic, practice or by telephone and made an 
appointment for an informative talk. Patients had 24h time to consider their 
participation until they were asked for their decision. They were informed that they 
would always have the chance to withdraw their consent without the need to explain 
the reasons or having to fear consequences for their treatment. 
When patients agreed to participate in the study they were handed out a patient-folder 
which contained the 
 Patient information 
 Contact addresses of physicians and pharmacists 
 Certificate of patient insurance 
 Plan of the course of the study 
 Copy of the written informed consent and the privacy statement 
 Pre-printed form of a patient diary 
 Questionnaires which had to be completed during the study period sorted 
by chemotherapy cycle 
 Postage-paid and addressed envelopes to assure a complete return flow of 
the questionnaires 
Some time was spent with each patient in order to explain the process and the 
questionnaires in detail. The questionnaires were filed cycle-wise in the same order in 
which they were meant to be completed by the patient. This measure was meant to 
improve the compliance of the participating patients to the study. Furthermore 
patients were offered the option to be reminded by the research pharmacist to 
complete the questionnaires either by phone or with a postcard. 
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3.2.4.2 Care appointments 
The pharmaceutical care was conducted by two pharmacists in the following referred 
to as caring pharmacists. The care appointments took place on a regular basis 
according to the previously described study course. The first appointment was prior to 
the first chemotherapy whereas the following appointments usually took place about 
one week after the chemotherapy. This schedule was chosen to bridge the time 
between the patients’ appointments with the oncologist in order to give the patient an 
immediate chance to discuss DRPs which might have occurred. 
At the first appointment the focus was put on general information about the 
chemotherapy, the expectable adverse effects and the possibilities to avoid these. 
Patients were handed out written information (see appendix I) and patient brochures 
of the German “Krebshilfe”. For the prophylaxis of nausea and emesis additional 
individualised information was given to the patient on when and how to take the 
prescribed medication. Time was taken to allow and answer patients’ questions and 
concerns. This first appointment also proved to be important to establish a confiding 
relationship. 
The following appointments were used to update on the well being of the 
patient. According to the concept of pharmaceutical care the past weeks were 
reviewed, drug related problems were discussed and mutual solutions were refined. In 
between the appointments patients always had the chance to get in contact with the 
caring pharmacist. Usually these contacts were by telephone and if necessary 
additional appointments were made.  
3.2.4.3 Documentation 
At the beginning of the care process the specific patient data were collected in a 
patient master file (see appendix K). The medical findings and laboratory data were 
documented as background information for an appropriate care process. All 
medication used by the patient was documented in a medication file and medication 
profile including prescribed and OTC medication(see appendix K). A care plan was 
developed according to the SOAP scheme. 
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The content and the time needed for each care appointment were documented 
in a protocol. Besides, the drug-related problems were documented and categorised 
using the PI-Doc®-System (Schaefer, 2002). 
3.3 Monitoring of carboplatin 
3.3.1 Patient selection 
Patients with diagnosed epithelial ovarian cancer and a prescribed chemotherapy 
regimen of paclitaxel (175-185 mg/m²) in combination with carboplatin (target AUC 5-
7.5 mg⋅min/mL) were included in the study. Study patients had to meet the inclusion 
criteria according to the study protocol. The patients were informed about the content 
of the study and the associated risks at least 24h prior to the study. Patients provided 
written informed consent. This part of the study was also approved by the ethics 
committee. 
During the study period four patients agreed to participate in this part of the 
study and received all six cycles of the mentioned combination chemotherapy. The 
drug monitoring did not differ between the study groups. The statistical evaluation was 
descriptive, depicting the actual achieved AUC and the degree of thrombocytopenia. 
3.3.2 Limited blood sampling 
Blood sampling was planned in a way that was meant to integrate well with everyday 
clinical practice. Therefore, a limited sampling method was applied in order to reduce 
the number of necessary blood samples. Sørensen et al. developed a method to 
estimate the area under the concentration versus time curve of carboplatin requiring 
only two samples drawn at fixed time points, 15 minutes and 2 h and 45 minutes after 
the end of the infusion (Sørensen et al., 1993). AUC can be calculated from the 
respective ultrafilterable plasma concentration as follows: 
628.0401.0053.0 75.225.0 +⋅+⋅= hh CCAUC      (Eq. 3-6) 
The two-sample method is unbiased (MPE% ± SD: -2.2% ± 2.1%) and precise 
(RMSE%: 9.4%). 
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3.3.3 Drug analysis 
3.3.3.1 Laboratory data 
The routinely performed laboratory analysis of patients’ blood was documented. In 
particular, the white blood cell count (WBC) and platelet count were documented. 
3.3.3.2 Sample collection and preparation 
Blood samples were drawn in line with the study protocol when cycle I, cycle III and 
cycle VI were administered. As the results did not have immediate consequences for 
the patients’ individual dosage it seemed to be sufficient to obtain AUCs of three out 
of six cycles. 
All blood samples were drawn from the opposite arm of the carboplatin infusion 
at 0.25 h and 2.75 h after the end of the carboplatin infusion in EDTA tubes (S-
Monovettes®). Within 15 minutes after blood withdrawal, plasma was obtained by 
centrifugating the full blood at 3200 g for 10 minutes (at 20°C). Aliquots were taken 
from the plasma and 1 mL was used to obtain ultrafiltrate. Ultrafiltrate was used in 
order to measure the unbound platinum fraction. In an Amicon Centrifree® Millipore 
tube, plasma was centrifugated for another 20 minutes at 2000 g (at 20°C). The 
aliquots were stored at -20°C for transportation and afterwards at –80°C until analysis. 
3.3.3.3 Atomic absorption spectrometry 
Flameless atomic absorption spectrometry (FAAS) is a common method to detect 
traces of metals in different biological matrices. It has been used to quantify 
carboplatin in several pharmacokinetic studies (Kloft et al., 2002; Calvert et al., 1995; 
Obasaju et al., 1996; van Warmerdam et al., 1997; Boddy et al., 2001). 
The quantification of metals in different matrices is based on their ability to 
absorb light of definite wavelengths after atomisation. This method uses light with the 
same wavelength that would be emitted by the element to be determined. 
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The correlation between the amount of light absorbed by the sample and the 
concentration of the respective metal is described by the law of Lambert-Beer:  
cdk
I
I
 log A 0 ⋅⋅==          (Eq. 3-7) 
 
A Absorption 
I0 Light intensity 
I Light intensity after passing the sample 
k Absorption coefficient 
d Layer thickness 
c Concentration of the analyte 
 
This proportionality is only valid for low concentrations and a constant layer thickness.  
Analytical conditions  
In this study platinum was quantified in human plasma and ultrafiltrate using the 
flameless atomic absorption spectrometer SpectrAA® with a graphite furnace 
technique. The instrumentation and operating conditions are listed in the appendix L. 
The graphite tube was heated up by electric current. Argon served as an inert gas to 
prevent the self-inflammation of the graphite tube. The argon stream was interrupted 
during atomisation in order to avoid disturbance of the signal detection. A defined 
temperature programme was applied to eliminate potentially interfering substances 
such as proteins from the sample. The temperature programme was operated in five 
phases as described in Tab. 3-7. 
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Tab. 3-7 Temperature programme of the GF-AAS 
Step Phase Temperature [°C] Time [sec] Gas flow [L/min] Absorption 
recording 
1 Drying 95  5.0  3.0  no 
2  110  60.0  3.0  no 
3  120  10.0  3.0  no 
4 Pre-Ashing 650  15.0  3.0  no 
5  650  20.0  3.0  no 
6 Ashing 1300  10.0  3.0  no 
7  1300  2.0  3.0  no 
8  1300  2.0  0  no 
9 Atomisation 2700  0.7  0  yes 
10  2700  2.0  0  yes 
11 Cleaning 2700  2.0  3.0  no 
 
During drying and pre-ashing volatile components were eliminated from the sample 
matrix. Ashing followed. To guarantee constant initial temperatures for each analysed 
sample the graphite tube was cooled down following each atomisation and cleaning 
phase. 
The hollow cathode lamp used had a current of 10 mA. The Zeeman correction 
assured the correction of background absorption caused by scattering of particles and 
absorption of organic molecules. The measurement was conducted with and without 
the presence of a magnetic field. Without the magnetic field the absorption of the 
element and background were measured, whereas in the presence of a magnetic field 
only the absorption of the background was measured. The difference of both values 
resulted in the intensity of the element’s signal. Platinum absorbance was measured at 
a wavelength of 265.9 nm with a photomultiplier. 
The described method enableses a sensitive platinum detection. The sample 
stays within the closed tube and is not carried away with the gas stream. This way a 
larger number of atoms can absorb the light of the hollow cathode lamp which leads 
to a lower limit of quantification. This is the particular advantage of the graphit-tube 
furnace (GF)-FAAS compared to conventional flame techniques. 
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3.3.3.4 Validation of the analytical method 
The FAAS analysis was conducted according to a validated method (van Warmerdam 
et al., 1995; Kloft et al., 1999; Pieck, 2004). The lower limit of quantification, LLOQ, for 
platinum was 20 ng/mL in plasma and 5 ng/mL in ultrafiltrate. Recovery, linearity, 
accuracy and precision met the international requirements for the validation of 
bioanalytical methods according to the U.S. Department of Health and Human 
Services (2001) (see appendix L). The results were documented in a GLP-conform 
validation report. 
The quantitative determination of platinum was performed after a single dilution 
step (modified according to Kloft et al. 1999). The chemicals and reagents used are 
listed appendix L. The aliquots of plasma and ultrafiltrate were prepared for the 
analysis. Plasma samples were diluted with an aqueous solution of 1% TritonTM X-100 
to final concentrations in the calibration range. 
 
Tab. 3-8 Sample preparation for platinum analysis 
Plasma Sample I 10 µL + 4990 µL TritonTM X 1% solution 
 Sample II 10 µL + 990 µL TritonTM X 1% solution 
Ultrafiltrate Sample I 10 µL + 4990 µL nitric acid 6.5% solution 
 Sample II 10 µL + 990 µL nitric acid 6.5% solution 
Sample I = taken 15 min after carboplatin infusion 
Sample II = taken 2 h and 45 min after carboplatin infusion 
Samples of ultrafiltered plasma were diluted with nitric acid 6.5% to final 
concentrations in the calibration range (Tab. 3-8). The injection volume was 20 µL. The 
measurement of standards and samples was performed in the ‘PROMT’ mode 
(Precision optimised measurement time). All samples were measured at least twice. 
With a resulting deviation of > 5% a third measurement followed and if necessary a 
fourth one, if the standard deviation still was still < 15%. 
3.3.3.5 Preparation of standards for calibration 
A stock solution of carboplatin containing 10 mg/mL platinum (19.0 mg/10 mL) was 
used to prepare a standard solution containing 50 ng/mL platinum in plasma or 
ultrafiltrate. The stock solution was stable over a period of eight months at –20°C 
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(Pieck, 2004). The calibration standards of 5-50 ng/mL were prepared from blank 
matrix and the highest standard solution (50 ng/mL) by the programmable sample 
dispenser. The preparation was made by diluting the platinum-free plasma with 
TritonTM-X solution 1% in the case of plasma and nitric acid 6.5% in the case of 
ultrafiltrate in the ratio 1:100. The calibration range reached from 500 to 5000 ng/mL. 
The calibration line was generated by performing linear regression analysis from the 
means of the peak heights of the absorption signal minus the zero value. 
3.3.3.6 Quality assurance during the measurement  
Plasma and ultrafiltrate blanks were spiked with adequate amounts of platinum, 
aliquoted and stored at -20°C in order to generated two different types of quality 
control samples. Processed quality controls (PQC) were samples which were 
processed immediately after their preparation in three concentrations (500, 2500 and 
5000 ng/mL). They were stored in aliquots at -20°C until analysis. Spiked quality 
controls (SQC) were plasma or ultrafiltrate samples with concentrations of 500, 2000, 
4000 and 20000 ng/mL. These samples were stored in aliquots at -20°C and were 
processed prior to analysis like clinical samples. Aliquots of PQC and SQC samples 
were analysed with each run. 
According to the specifications of the international requirements for the 
validation of bioanalytical methods, 67% of the QC samples needed to be within 15% 
of their nominal values which was achieved in this study (appendix L).  
3.3.3.7 From elementary platinum concentration to the carboplatin concentration 
By means of FAAS the concentration of elementary platinum was measured. To derive 
the actual carboplatin concentration the measured platinum concentrations were 
converted using the molar mass of platinum (195.09 g/mol) and carboplatin 
(371.2 g/mol). 
3.4 Statistical data analysis 
3.4.1 Patient satisfaction with information on cancer treatment 
Data entry and analysis were carried out using SPSS® 10.0 for Windows (SPSS Inc., 
 79
[3] Material & Methods 
Chicago, Illinois). The collected data were first analysed using descriptive statistics, 
determining frequencies, medians and percentile scores. 
To measure the split-half reliability, the items of the test were first randomly 
divided into two equally large item subsets. The correlation of the sum scores of these 
subsets is an estimate of the reliability of the test halves in order to obtain an estimate 
of the whole test reliability;  the correlation of the test halves is then adjusted using the 
Spearman-Brown formula. If the scale is internally consistent the two halves should 
correlate highly. The Spearman-Brown formula corrects the bias which results from the 
fact that the sub-scales being correlated are only half the length of the full version. This 
would normally result in too low correlations (Streiner and Norman, 2000). The used 
formula is 
12
12
tt r1
r2
r +
⋅=            (Eq. 3-8) 
rtt = Reliability of the complete test 
r12 = Correlation of 1
st and 2nd half of the test 
The split-half reliability should not be the only measure to assess reliability as it does 
not determine the items which contribute to a low reliability. Therefore, it is combined 
with the coefficient alpha. 
The coefficient alpha, in contrast, is based on the ratio of the sum of the single-
item variances to the total test score variance (Lord and Novick, 1968). Cronbach’s 
alpha can be used when there are more than two response alternatives. 
⎥⎥
⎥
⎦
⎤
⎢⎢
⎢
⎣
⎡
−−==
∑
2
2
1
1 x
j
j
tt s
s
c
c
rα         (Eq. 3-9) 
α = Cronbach´s alpha 
rtt = Reliability of the complete test 
c = number of equal parts in which the test is divided 
2
js = Variance of the j-part of the test 
2
xs  = Variance of the test 
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The implication is usually made that the higher the coefficient the better. Both the 
Spearman-Brown corrected split-half coefficient and Cronbach’s alpha can range 
between 0 and 1, with values larger than 0.7 indicating acceptable reliability (De Vellis, 
1991). 
In addition the alpha-if-item-deleted test was performed (Streiner and Norman, 
2000). This way the influence of each item on the homogeneity of the scale was 
tested. Stepwise one after the other item was eliminated from the scale and 
Cronbach’s alpha was determined. Thus, items which influence the reliability can easily 
be identified and if necessary be eliminated from the scale.  
A stepwise multiple regression analysis was performed using the total satisfaction 
scores as the dependent variable to determine the predictors of satisfaction with 
information. 
3.4.2 Pharmaceutical care of patients with gynaecological malignancies 
Since it could be expected that data had a skewed distribution and therefore could not 
be described with a Gaussian distribution, non-parametric two-sample comparisons 
were applied for the hypothesis testing. Some of the data, QoL as well as nausea and 
emesis have a longitudinal dimension. It was evaluated cycle-wise regarding nausea 
and emesis, but also over time as the incidents are dependent. 
3.4.2.1 Primary endpoint 
Quality of life 
The findings of the EORTC QLQ-C30 (v. 3.0) were descriptively evaluated. The relative 
changes in the different scales over the treatment period compared to baseline were 
evaluated by comparing the median and the 25% and 75% percentiles. Boxplots were 
chosen for the graphical presentation. 
The non-parametric rank-sum test according to Mann and Whitney was used to 
compare the means of the two groups. To assess the difference between the two 
groups over time a non-parametric analysis of variance was performed (Brunner et al., 
2001). 
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3.4.2.2 Secondary endpoints 
All secondary endpoints were evaluated in an expolartory manner. Descriptive 
statistics were performed as well as statistical tests to compare the two groups (see 
above). 
Complete control of emesis 
The results of complete control of emesis between the two groups were evaluated 
from different perspective. The complete control was compared cyclewise and the 
achieved complete control rate was described in percent. The two groups were 
compared using contingency tables evaluated with Fisher’s exact test (Motulsky, 1995; 
Bortz and Lienert, 1998). This was also applied when the number of cycles with 
complete response were compared. 
To assess the difference between the two groups over time a non-parametric analysis 
of variance was performed (Brunner et al., 2001). 
Acute and delayed nausea and emesis 
From the collected data sum scores of experienced degrees of nausea and episodes of 
emesis in the acute and delayed phase were compiled. These were evaluated using 
descriptive statistics. 
Acute and delayed  
From the collected data sum scores of experienced in the acute and delayed phase 
can be compiled. These have been presented using descriptive statistics. 
Patient satisfaction with information on cancer treatment 
To compare the two equal sized groups the Mann-Whitney U-test, a robust non-
parametric test, has been used.  
3.4.2.3 Sample size estimation for the main study 
For the pilot phase a sample size of 20 patients per group was chosen. Presuming a 
drop-out-rate of maximum 25%, 25 patients per group were required. This sample size 
was not statistically estimated, as in the pilot phase mainly the feasibility of 
pharmaceutical care was to be shown and knowledge about the distribution of the 
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primary and secondary endpoints should be obtained. The information will then be 
used for the adaptive sample size estimation for the main phase. 
The pilot study was designed as an explorative observation. An alpha adjustment 
for multiple testing was therefore not required although different endpoints were 
evaluated. 
So far no algorithms or programmes are available to calculate the sample size for 
non-parametric analysis of variance. The sample size estimation for the following main 
study was therefore performed by power simulation. For this purpose, different 
combinations of the group size (n), the prevalence in the control group (p) and the 
expected difference (∆) 10,000 simulations were performed at a time and the power 
was calculated for a type I error α = 5%. The simulations were performed by S-Plus® 
2000 (MathSoft Inc., Cambridge, MA). 
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[4] Results 
4 Results 
4.1 Patient satisfaction with information on cancer treatment 
Parts of the following results were generated in the course of the diploma thesis of 
Eckhardt (2002). 
4.1.1 The German version 
Like the original Canadian version, the German questionnaire consists of three parts 
(see appendix J). Part one contains fourteen items and evaluates the patients’ 
perception of the information provided during cancer treatment. On a five point Likert 
scale (‘strongly disagree’ to ‘strongly agree’) patients were instructed to rate how much 
they agree/disagree with the statement made in the item. Part two contains two 
questions referring to the information sources utilised by the patients. Several answers 
are possible. The last part of the questionnaire determines the socio-demographic 
characteristics of the patients. 
4.1.2 Response 
61 questionnaires were returned for the pre-test and 232 questionnaires for the main 
survey. The response rate of the questionnaires distributed by a self-aid group via mail 
was 65%. 47 questionnaires from the pre-test were completed entirely and could be 
used for the psychometric tests. Due to incomplete answering 14 questionnaires were 
excluded from the analysis. The socio-demographic and disease-related patient 
characteristics of the sample in the main survey are listed in Tab. 4-1 and Tab. 4-2. 
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Tab. 4-1 Socio-demographic patient characteristics in the main survey (n=232) 
Socio-demographic variable n % 
< 50 years old 62  26.7  
50-60 years old 83  35.8  
> 60 years old 86  37.1  
Age 
No answer 1  0.4  
Female 171  73.7  
Male 60  25.9  
Sex 
No answer 1  0.4  
Married/partner 170  73.3  
Single 20  8.6  
Divorced 21  9.1  
Marital status 
Widow 21  9.1  
Living alone  47  20.3  
With family or partner 182  78.4  
Current living 
situation 
No answer 3  1.3  
Elementary school 47  20.3  
Secondary school 16  6.9  
O-levels 56  24.1  
Journeyman 23  9.9  
Master of a trade 9  3.9  
Bachelor 14  6.0  
University/ College 62  26.7  
Education 
No answer 5  2.2  
Housewife 32  13.8  
Worker 8  3.4  
Employee 74  31.9  
Self-employed 25  10.8  
Public servant 19  8.2  
Pensioner 65  28.0  
Craftsman 7  3.0  
Profession 
No answer 5  2.2  
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Tab. 4-2 Disease-related patient characteristics in the main survey 
 n % 
Breast cancer 125  53.9  
Ovarian cancer 11  4.0  
Others 53  27.2  
Diagnosis 
No answer 33  14.2  
< ½ year 75  32.3  
½ year to 2 years 79  34.1  
> 2 years 47  20.2  
Time since diagnosis 
No answer 31  13.4  
Inpatient treatment 29  12.5  
Outpatient clinic 94  40.5  
Primary care oncologist 80  34.5  
Therapy setting 
No answer 29  12.5  
Yes 39  16.8  
No 175  75.4  
Self-aid group 
No answer 18  7.8  
 
4.1.3 Psychometric assessments 
The results of the pre-test reliability analysis of the whole scale and of the subscales 
adapted from the Canadian questionnaire are shown in (Tab. 4-3). The whole 
questionnaire and the subscales 1 to 3 obtained reliability coefficients larger than 0.80. 
Only the subscale 4 ‘information sources’ showed rather low reliability coefficients of 
0.57 (split-half reliability) and 0.52 (Cronbach’s alpha). The reliability analysis of the 
main survey revealed convincing reliability coefficients larger than 0.77 for all scales.  
Regarding the face-validity, the consulted experts and the patients rated each 
item and the questionnaire in total as understandable and concordant with its task to 
measure several aspects of satisfaction with information. 
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Tab. 4-3 Reliability coefficients 
Pre-test Main survey 
Scale 
Cronbach’s 
alpha 
Spearman 
Brown  
split-half 
reliability 
Cronbach’s 
alpha 
Spearman 
Brown  
split-half 
reliability 
Global satisfaction 0.92 0.92 0.95 0.91 
Satisfaction with information 
regarding cancer treatment 
(scale 1) 
0.80 0.85 0.88 0.89 
Satisfaction with information 
regarding side effects (scale 2) 
0.88 0.89 0.90 0.87 
Satisfaction with information 
regarding vitamins, herbs and 
complementary therapy  
(scale 3) 
0.90 0.87 0.87 0.84 
Satisfaction with information 
sources and the way 
information is provided (scale 4) 
0.52 0.57 0.78 0.78 
 
4.1.4 Satisfaction with information 
The majority of patients were satisfied with the information given on cancer treatment. 
The detailed results of the agreement/disagreement rating are shown in Tab. 4-4. 
The subscale analysis elucidated the differences in satisfaction among different 
information areas. Overall satisfaction was characterised by a median of 3.5 on a scale 
ranging from 1 to 5. Satisfaction with general cancer treatment information 
(subscale 1) achieved a median score of 3.8. Subscale 2 measuring satisfaction with 
information regarding side effects of the cancer treatment exhibited a median score of 
3.5. In contrast, subscale 3 assessing satisfaction with complementary therapies 
attained a median score of only 3.0. The satisfaction score was highest for subscale 4 
referring to information sources (median score of 4.0). 
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Tab. 4-4 Results for separate items in the main survey 
25
50
75
3.00
4.00
4.00
4.009.915.530.624.612.96.5S3
I am satisfied that I am 
able to make informed 
choices about vitamins, 
herbs, and 
complementary 
therapies.
3.00
4.00
4.00
4.008.215.934.528.49.93.0S2
I am satisfied that I am 
able to make informed 
choices about how to 
manage side effects.
3.00
4.00
5.00
4.004.324.641.817.77.83.9S1
I am satisfied that I am 
able to make informed 
choices about my 
cancer treatment.
4.00
4.00
5.00
4.001.737.144.06.97.82.6S4
Overall, I am satisfied 
with the manner in 
which the information 
is provided. It is 
friendly, respectful and 
non-judgemental.
3.00
4.00
4.00
4.002.620.345.315.512.14.3S4
I am satisfied with the 
available information 
resources such as the 
handouts and staff. 
2.00
3.00
4.00
3.007.315.926.316.423.710.3S3
I am satisfied that I get 
enough opportunity to 
ask questions about the 
use of vitamins, herbs, 
and complementary 
therapies.
3.00
4.00
4.00
4.003.910.735.321.113.45.6S2
I am satisfied that I get 
enough opportunity to 
ask questions about 
how to manage side 
effects.
4.00
4.00
5.00
4.001.331.046.67.811.22.2S1
I am satisfied that I get 
enough opportunity to 
ask questions about my 
cancer treatment.
3.00
4.00
4.75
4.001.724.643.513.412.54.3S4
I am satisfied with the 
way treatment 
information is 
presented to me. It is 
clear and easy to 
understand.
2.00
4.00
4.00
4.009.910.840.115.515.97.8S1
I am satisfied with the 
explanations about 
possible interactions
between my prescribed 
cancer treatment and 
other treatments I am 
using or thinking about 
using.
2.00
3.00
4.00
3.008.69.923.318.128.911.2S3
I am satisfied with the 
answers to my 
questions about 
vitamins, herbs, and 
complementary 
therapies.
2.25
3.00
4.00
3.003.414.731.925.914.79.5S2
I am satisfied with the 
information I have 
been given on what to 
do if side effects
happen.
3.00
4.00
4.00
4.000.917.244.417.714.75.2S2
I am satisfied with the 
information I have 
been given about 
possible side effects of 
my treatment.
3.00
4.00
4.00
4.000.921.647.815.510.83.4S1
I am satisfied with the 
information I have 
been given about my 
cancer treatment.
(5) 1(4) 1(3) 1(2) 1(1)1
PercentileMediann.s.Strongly 
agree
AgreeUncertainDisagreeStrongly 
disagree
 
1 Frequency of responses are indicated as percentages (n.s.=not specified) 
[4] Results 
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4.1.4.1 Predictors of satisfaction with information 
A stepwise multiple linear regression analysis was used to determine the relative 
influence of socio-demographic variables on the satisfaction with information. The 
overall satisfaction score was used as the criterion variable. The stepwise regression 
procedure showed that only a few variables contributed significantly to the satisfaction 
scores of the patients. Patients with breast cancer and patients who received treatment 
through a primary care oncologist seemed to be less satisfied than patients with other 
types of cancer or a different therapy setting. In addition, patients who were diagnosed 
less than half a year ago seemed to be more satisfied compared to those diagnosed 
more than half a year ago. The other variables included in the analysis (including age, 
sex, educational level) did not predict the satisfaction of the patients. As shown in Tab. 
4-5, the predictors included in the regression equations explained a maximum of 22% 
of the variance (corrected R2) in patient satisfaction. These were the predictors 
‘presence of breast cancer’ and ‘diagnosis less than half a year ago’ for the subscale 
‘information regarding side effects’. For the remaining scales, the significant predictors 
explained less than 22% of the variance in patient satisfaction. Obviously, satisfaction 
with treatment information can only partially be explained by the type of disease, the 
time of diagnosis, and socio-demographic variables. It seems that other factors exist 
which are important predictors of satisfaction with treatment information. 
[4] Results 
Tab. 4-5 Results of the stepwise multiple linear regression analysis 
R2 Corr. R2 F Independent 
variable 
Constant
Non- 
standardised 
regression 
coefficient 
Standardised 
regression 
coefficient 
p 
value
Global satisfaction scale 
 4.222    
breast 
cancer  
-0.742 -0.315 0.003
0.158 0.136 7.323 
primary care 
oncologist  
-0.411 -0.231 0.029
Scale 1 : Satisfaction with general treatment information 
 3.825   
breast 
cancer 
 -0.544 -0.243 0.019
0.150 0.130 7.826 
diagnosis  
< ½ year 
 0.450 0.242 0.019
Scale 2: Information regarding side effects  
 0.3686    
diagnosis  
< ½ year 
 0.628 0.321 0.001
0.237 0.220 14.263 
breast 
cancer 
 -0.734 -0.310 0.001
Scale 3: Information regarding vitamins, herbal products and complementary 
therapies 
 3.646    0.045 0.034 4.221 
breast 
cancer 
 -0.611 -0.212 0.043
Scale 4: Satisfaction with information sources and way information provided  
 4.086    
breast 
cancer 
 -0.542 -0.236 0.217
inpatient 
therapy 
 -1.487 -0.262 0.006
0.170 0.145 6.636 
diagnosis  
< ½ year 
 0.394 0.201 0.036
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4.1.4.2 Information sources 
As shown in Fig. 4-1 patients utilised their oncologist, books, family doctors and TV 
programmes as their main sources of information. Pharmacists were scarcely 
perceived as information sources in the patients’ view. 
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Fig. 4-1 Information sources used by cancer patients 
 
4.1.4.3 Free Comments 
Many patients took the opportunity to provide free comments. These were usually in 
line with the results of the first part of the questionnaire. Patients who provided a low 
score on the subscale ‘satisfaction with information on vitamins, herbs and 
complementary therapy’ desired more information on complementary treatment 
options. In general, they would favour a more open-minded discussion about 
complementary therapies with their oncologist. This result supports the validity of the 
questionnaire. In addition, many patients expressed their need for more psychological 
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assistance and for automatic provision of information without having to request it. 
4.2 Pharmaceutical care of patients with gynaecological malignancies 
The patients recruited for the pilot study form a rather homogenous population with 
no major differences in the distribution regarding the socio-demographic variables. The 
patient characteristics are documented in Tab. 4-6. 
Tab. 4-6 Patient characteristics of the pilot study 
Socio-demographic variable Control group Intervention group 
x  SD min max x  SD min maxAge 
51.3 12.1 24 67 52 11.3 27 73 
 n % n % 
Sex Female 21 100 20  100
Married/partner 16 76 16  80
Single 2 9.5 2  10
Divorced 1 5 1  5
Marital 
status 
Widow 2 9.5 1  5
Living alone  1 5 4  20Living 
situation With family/partner 20 95 16  80
Elementary school 8 37 6  30
Secondary school 1 5 2  10
O-levels 5 24 5  25
Journeyman 1 5 2  10
Master of a trade 1 5 0  0
Bachelor 2 9.5 2  10
University 2 9.5 3  15
Education 
No answer 1 5 0  0
to be continued on the following page
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Student 0 0 1  5 
Housewife 6 28 10  50 
Worker 1 5 1  5 
Employee 9 43 5  25 
Self-employed 2 9.5 0  0 
Public servant 1 5 1  5 
Profession 
Pensioner 2 9.5 2  10 
Breast cancer 18 86 19  95 Diagnosis 
Ovarian cancer 3 14 1  5 
< ½ year 16 76 13  65 Time since  
diagnosis ½ year -  
2 years 
5 24 7  35 
Inpatient treatment 3 14 0  0 
Outpatient clinic 15 72 14  70 
Therapy  
setting 
Primary care 
oncologist 
3 14 6  30 
yes 1 5 1  5 Self-aid 
group no 20 95 19  95 
 
4.2.1 Quality of life 
The EORTC QLQ-C30 questionnaire consists of 15 scales. One referring to the global 
health status and quality of life, five functional scales and nine symptom scales. In the 
following the results of the individual scales are presented. 
Global health status /QoL (QL2) 
Compared to the control group the global health status/QoL of patients in the 
intervention group remained in the median on a higher level as illustrated in Fig. 4-2. 
Comparing the absolut median score of the global health status and quality of life, the 
intervention group has initially a far lower level than the control group (CG = 75 vs.  
IG = 58) 
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Fig. 4-2 Relative score of global health status/QoL in the median in control (CG) and 
intervention group (IG) over time (100% at t0) 
The boxplots illustrate that in the median the global health status/QoL decreased less 
in the intervention than in the control group (Fig. 4-3). This applies to both presented 
treatment periods. A remarkable variability of the relative changes was observed.  
Within the first treatment period the global health status/QoL decreased 
relatively to baseline in the median by 20% (25% percentile = - 50%, 75% 
percentile = 0%) in the control group and only by 7% (25% percentile = - 36%, 75% 
percentile = 42%) in the intervention group. The difference of 13% in the relative 
change between the two treatment groups in the first treatment period was not 
statistically significant (p = 0.138, Mann-Whitney U-test). 
Looking at the complete treatment period the global health status/QoL 
decreased in the control group in the median relatively to the baseline by 14% 
(25% percentile = - 53%, 75% percentile = 0%) and in the intervention group by 6% 
(25% percentile = - 57%, 75% percentile = 11%). The difference of 8% in relative 
change between the two groups was not statistically significant (p = 0.563, Mann-
Whitney U-test). 
 
 97
[4] Results 
2019N =
IGCG
Re
la
tiv
e 
ch
an
ge
 in
 Q
L2
 fr
om
 t0
 to
 t1
 [%
]
120
100
80
60
40
20
0
-20
-40
-60
-80
-100
-120
2018N =
IGCG
Re
la
tiv
e 
ch
an
ge
 in
 Q
L2
 fr
om
 t0
 to
 t2
 [%
]
120
100
80
60
40
20
0
-20
-40
-60
-80
-100
-120
 
Fig. 4-3 Relative change of the global health status/QoL in control (CG) and 
intervention group (IG) between baseline and t1 or t2, respectively  
No difference could be detected between the two treatment groups over time 
(p = 0.218; non-parametric analysis of variance). As p < 0.5 H0 cannot be accepted 
according to the decision algorithm (see chapter 3.2.2.4). The p-value ranges between 
α0  =  0.50 and α1  =  0.0233. Therefore the second phase of the study will be carried 
out with a larger sample size. 
 
Physical functioning (PF2) 
The relative scores show that in the median the physical functioning of the patients in 
the intervention group was stable, whereas it decreased slightly in the control group 
(see Fig. 4-4). 
 98
[4] Results 
0
20
40
60
80
100
t0 t1 t2
Re
la
tiv
e 
sc
o
re
 [
 %
]
CG
IG
 
Fig. 4-4 Relative score of physical functioning in the median in control (CG) and 
intervention group (IG) over time (100% at t0) 
The boxplots illustrate that within the first treatment period hardly any difference in the 
relative change was observed between the two groups, whereas for the complete 
treatment period the physical functioning of the patients tended to improve slightly in 
the intervention group (Fig. 4-5).  
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Fig. 4-5 Relative change of physical functioning in control (CG) and intervention 
group (IG) between baseline and t1 or t2, respectively  
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Within the first treatment period physical functioning did neither change in the control 
group in the median (25% percentile = - 22%, 50% percentile = 0%,  
75% percentile = 2%) nor in the intervention group (25% percentile = - 14%,  
50% percentile = 0%, 75% percentile = 10%). The difference between the two groups 
in the first treatment period was not statistically significant (p = 0.465, Mann-
Whitney U-test). Looking at the complete treatment period the physical functioning 
decreased in the control group in the median relatively to baseline by 7% 
(25% percentile = - 26%, 75% percentile = 4%). In the median the intervention group 
remained stable (25% percentile = - 27%, 50% percentile = 0%, 75% percentile = 8%). 
The differences were not statistically significant (p = 0.748, Mann-Whitney U-test). 
Role functioning (RF2) 
As with physical functioning Fig. 4-6 shows that there was no change in the median 
relative scores of role functioning in the intervention group, whereas the relative 
decreased slightly in the control group. 
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Fig. 4-6 Relative score of role functioning in the median in control (CG) and 
intervention group (IG) over time (100% at t0) 
The boxplots also show that there was hardly any difference in the change over the 
treatment period between the two groups (Fig. 4-7). Additionally, the results were 
highly variable. 
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Fig. 4-7 Relative change of role functioning in control (CG) and intervention group 
(IG) between baseline and t1 or t2, respectively  
Within the first treatment period the role functioning of patients in the control and 
intervention group in the median remained stable (CG: 25% percentile = - 100%, 
50% percentile = 0%, 75% percentile = 100%; IG: 25% percentile = - 63%, 
50% percentile = 0%, 75% percentile = 100%). The difference in the relative change 
between the two groups in the first treatment period was not statistically significant 
(p = 0.637, Mann-Whitney U-test). Looking at the complete treatment period the role 
functioning decreased in the control group in the median relatively to the baseline by 
8% (25% percentile = - 100%, 75% percentile = 100%) and remained stable  
in the intervention group (25% percentile = - 100%, 50% percentile = 0%, 
75% percentile = 35%). The differences, however, were not statistically significant 
(p = 0.760 Mann-Whitney U-test). 
Emotional functioning (EF) 
Fig. 4-8 illustrates that the emotional functioning of patients in the intervention group 
was considerably higher in the first treatment period compared to the patients in the 
control group. This difference was not observed anymore at the end of the treatment 
period. 
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Fig. 4-8 Relative score of emotional functioning in the median in control (CG) and 
intervention group (IG) over time (100% at t0) 
The boxplots show that the change of emotional functioning in the first half of the 
treatment period improved in the median for the intervention group by 50% (25% 
percentile = 0%, 75% percentile = 50%) compared to a deterioration in the control 
group of 6% in the median (25% percentile = - 32%, 75% percentile = 20%) (Fig. 4-9). 
The improvement of emotional functioning in the intervention group over the first 
treatment period compared to the control group was statistically significant (p=0.011, 
Mann-Whitney U-test). Looking at the complete treatment period the emotional 
functioning decreased in the control group in the median relatively to the baseline by 
5% (25% percentile = - 38%, 75% percentile = 32%). In the median the emotional 
functioning in the intervention group remained stable (25% percentile = - 27%, 
50% percentile = 0%, 75% percentile = 35%). The difference was not statistically 
significant (p = 0.551, Mann-Whitney U-test). 
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Fig. 4-9 Relative change of emotional functioning in control (CG) and intervention 
group (IG) between baseline and t1 or t2, respectively  
Cognitive functioning (CF) 
No difference in cognitive functioning was observed when comparing relative scores 
of the the median of the two groups (Fig. 4-10). 
There was hardly any relative change in cognitive functioning in the median over 
the treatment period comparing the two groups. Particularly the data of the 
intervention group scattered widely as shown in Fig. 4-11. 
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Fig. 4-10 Relative score of cognitive functioning in the median in control (CG) and 
intervention group (IG) over time (100% at t0) 
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Within the first treatment period there was no change in cognitive functioning in the 
control group (25% percentile = 0%, 50% percentile = 0%, 75% percentile = 0%). In 
the intervention group it also remained stable in the median (25% percentile = - 25%, 
50% percentile = 0%, 75% percentile = 25%). The difference between the two groups 
regarding the relative change in the first treatment period was not statistically 
significant (p = 0.677, Mann-Whitney U-test). Looking at the complete treatment 
period the cognitive functioning was unchanged in the control group 
(25% percentile = - 20%, 50% percentile = 0%, 75% percentile = 0%) as well as in the 
intervention group (25% percentile = - 17%, 50% percentile = 0%, 
75% percentile = 43%). The differences were not statistically significant (p = 0.331, 
Mann-Whitney U-test). 
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Fig. 4-11 Relative change of cognitive functioning in control (CG) and intervention 
group (IG) between baseline and t1 or t2, respectively 
 
Social functioning (SF) 
The patients of the intervention group deteriorated in terms of social functioning 
towards the end of the treatment whereas the patients of the control group improved 
in the median towards the end (Fig. 4-12). 
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Fig. 4-12 Relative score of social functioning in the median in control (CG) and 
intervention group (IG) over time (100% at t0) 
The boxplots (Fig. 4-13) show that in the median the intervention group remained 
stable in the first treatment period (25% percentile = - 19%, 50% percentile = 0%, 75% 
percentile = 25%) whereas the patients of the control group deteriorated in the 
median by 17% (25% percentile = - 33%, 75% percentile = 0%). Looking at the whole 
treatment period the control group deteriorated by 8% in the median (25% 
percentile = - 40%, 75% percentile = 0%) whereas the patients of the intervention 
group deteriorated in the median by 21% (25% percentile = - 75%, 75% 
percentile = 0%). The differences in change were neither for the first treatment period 
(p = 0.078, Mann-Whitney U-test) nor for the completed treatment period statistically 
significant (p=0.529, Mann-Whitney U-test). 
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Fig. 4-13 Relative change of social functioning in control (CG) and intervention group 
(IG) between baseline and t1 or t2, respectively  
Fatigue (FA) 
In both groups patients increasingly experienced fatigue. The scores show that in the 
median the patients in the intervention group experienced more fatigue than in the 
control group. In both groups fatigue worsened within the first treatment period and 
emeded towards the end of the treatment. 
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Fig. 4-14 Development of fatigue in the median in control (CG) and intervention 
group (IG) over time (100% at t0) 
The boxplots illustrate the changes in fatigue over time (Fig. 4-15).  
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Fig. 4-15 Absolute change of fatigue score in control (CG) and intervention group (IG) 
between baseline and t1 or t2, respectively  
Looking at the first treatment period the score of experienced fatigue increased in the 
median by 22 compared to baseline (25% percentile = 11, 75% percentile = 44) in the 
control group as well as in the intervention group (25% percentile = 0, 75% 
percentile = 53). The difference in the change between the two groups in the first 
treatment period was not statistically significant (p = 0.943, Mann-Whitney U-test). 
Overlooking the complete treatment period the difference between the two groups 
was even larger. The score of experienced fatigue in patients of the control group in 
the median increased compared to the baseline by 11 (25% percentile = - 3, 
75% percentile = 56) and in the intervention group by 22 (25% percentile = 0, 
75% percentile = 57). The difference between the two groups was not statistically 
significant (p = 0.711, Mann-Whitney U-test). 
 
Pain (PA) 
Fig. 4-16 illustrates that in the median little reduction could be achieved in the 
experience of pain of patients in the control group, whereas pain of patients in the 
intervention group was reduced within the first treatment period. Pain increased again 
in the intervention group towards the end of the treatment, but did in the median not 
reach the initial value. Patients in the intervention group presented initially with higher 
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scores of pain than patients in the control group. 
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Fig. 4-16 Development of pain in the median in control (CG) and intervention group 
(IG) over time (100% at t0) 
The boxplots show for the intervention group in the median a decrease of 17 score 
points (25% percentile = - 58, 75% percentile = 0) in the first treatment period as well 
as over the complete treatment period (25% percentile = - 33, 75% percentile = 0) 
(Fig. 4-17). The control group does not present considerable changes neither in the first 
half (25% percentile = - 17, 50% percentile = 0, 75% percentile = 0) nor over the 
whole treatment period (25% percentile = - 21, 50% percentile = 0, 
75% percentile = 17). Data exhibited large variability. In both observed treatment 
periods the differences between the two groups were not statistically significant 
(p = 0.153 and p = 0.402, Mann-Whitney U-test). 
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Fig. 4-17 Absolute change of pain scores in control (CG) and intervention group (IG) 
between baseline and t1 or t2, respectively 
Constipation (CO) 
The median scores in the control group suggest that patients experienced a constant 
deterioration of constipation over the treatment period. The experienced constipation 
in the intervention group increased during the first treatment period but ameliorated 
towards the end (Fig. 4-18).  
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Fig. 4-18 Development of constipation in the median in control (CG) and intervention 
group (IG) over time (100% at t0) 
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The boxplots illustrate that the patients of the control group had an increased 
experience of constipation in the median by 33 score points compared to baseline 
(25% percentile = 0, 75% percentile = 100); compared to 17 score points in the 
intervention group (25% percentile = 0, 75% percentile = 33) in the first half of the 
treatment period (Fig. 4-19).  
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Fig. 4-19 Absolute change of constipation score in control (CG) and intervention 
group (IG) between baseline and t1 or t2, respectively  
This difference even amplified looking at the whole treatment period. Patients of the 
control group had an increased experience of constipation in the median by 33 score 
points (25% percentile = 0, 75% percentile = 67%); compared to no change  
(25% percentile = 0, 50% percentile = 0, 75% percentile = 58) in the intervention 
group. The data scattered widely and the differences in change between the two 
groups were not statistically significant for both observed periods (p = 0.069 and 
p = 0.188, Mann-Whitney U-test) 
The results of the scales dyspnoea (DY), insomnia (SL), appetite loss (AP), 
diarrhoea (DI) and financial difficulties (FI) are not presented as these symptoms were 
rare and hence no influence of pharmaceutical care could be expected for this 
particular group of patients. Nausea and vomiting (NV) was not evaluated in this 
context as a far more precise instrument was used to elucidate this aspect (see 4.1.1). 
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4.2.2 Nausea and emesis 
The strongest criterion to assess the success of the prevention of nausea and emesis is 
the complete response (CR) to the antiemetic treatment. Looking at the full treatment 
period the chi-square trend test showed that in the intervention group an increase in 
the number of cycles with CR in emesis could be achieved. This increase was not 
statistically significant (p = 0.155). 
Tab. 4-7 Number of cycles with complete antiemetic response (CR) 
  total 
Number of chemotherapy cycles with CR 0 1 2 3 4   
Control group Number of patients 5 4 2 2 8 21 
  % 23% 19% 9% 9% 38% 100% 
Intervention group Number of patients 1 2 3 7 7 20 
  % 5% 10% 15% 35% 35% 100% 
Looking at the separate cycles, Fig. 4-20 illustrates that in each cycle the CR rate could 
be improved. However, none of the cycle-wise improvements in CR was statistically 
significant (pcycle I =0.058, pcycle II =1.000, pcycle III =0.505, pcycle IV =0.326, Fisher’s exact 
test). 
43%
57%
62%
57%
75%
60%
75% 75%
0%
10%
20%
30%
40%
50%
60%
70%
80%
Cycle I Cycle II Cycle III Cycle IV
C
om
pl
et
e 
re
sp
on
se
 [%
]
Control group
Intervention group
 
Fig. 4-20 Complete response to the antiemetic drugs (cycle-wise) 
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Acute and delayed emesis 
Acute and delayed emesis are presented descriptively. The sumscores of acute and 
delayed emesis are presented in Fig. 4-21. The boxplots show that patients of the 
control group experienced in the median 2 acute emetic episodes (25% percentile = 0, 
75% percentile = 10) whereas the patients of the intervention group experienced no 
acute emetic episode in the median (25% percentile = 0, 75% percentile = 3). The 
scattering of data was less in the intervention group than in the control group where 
one patient suffered from 29 emetic episodes. The data regarding the delayed phase 
indicated no difference between the two groups. 
2021 2021N =
IGCG
Su
m
sc
or
e
of
 e
m
et
ic
ep
is
od
es
30
20
10
0
Acute emesis
Delayed emesis
 
Fig. 4-21 Sumscores of acute and delayed emesis 
Acute and delayed nausea 
Acute and delayed nausea are presented descriptively. The results indicate no 
improvement for the patients of the intervention group. It rather seems that the 
patients of the intervention group suffered more from nausea in both phases. 
[4] Results 
 113
2021 2021N =
IGCG
Su
m
sc
or
e
of
 d
eg
re
e
of
 n
au
se
a
250
200
150
100
50
0
Acute nausea
Delayed nausea
 
Fig. 4-22 Sumscore of acute and delayed nausea 
4.2.3 Patient satisfaction with information on cancer treatment 
The basic survey indicated that although the global satisfaction was rather high there 
still seemed to be possibilities to improve patients’ satisfaction with information on 
cancer treatment. Fig. 4-23 illustrates the effect of the pharmaceutical care intervention 
on the satisfaction with information. Even the scales which showed good satisfaction in 
the control group were improved in the intervention group. 
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Fig. 4-23 Descriptive evaluation of patient satisfaction with information on cancer 
treatment 
The global satisfaction with information on cancer treatment was in the control group 
in the median 3.94 (25% percentile = 3.58, 75% percentile = 4.13) compared to a 
median of 4.41 in the intervention group (25% percentile = 3.98, 
75% percentile = 4.91). The difference was statistically significant (p = 0.014, Mann-
Whitney U-test).  
The relations were similar looking at the different subscales. With the information 
on the cancer treatment itself the intervention group was in the median more satisfied 
than the control group (IG: 25% percentile = 4.00, 50% percentile = 4.35, 75% 
percentile = 4.80; CG: 25% percentile = 4.00, 50% percentile = 4.00, 75% 
percentile = 4.2). For this subscale the difference was not statistically significant 
(p = 0.074, Mann-Whitney U-test). Patients of the intervention group also rated their 
satisfaction with the information on side effects higher as the patients in the control 
group (IG: 25% percentile = 3.81, 50% percentile = 4.63, 75% percentile = 5.00; CG: 
25% percentile = 3.31, 50% percentile = 4.00, 75% percentile = 4.19). For this 
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subscale the difference was statistically significant as well (p = 0.013, Mann-Whitney U-
test). The satisfaction with the information on complementary treatment options did 
not differ as much between the two groups (IG: 25% percentile = 3.25, 50% 
percentile = 4.17, 75% percentile = 5.00; CG: 25% percentile = 3.00, 50% 
percentile = 3.83, 75% percentile = 4.25). For this subscale the difference was not 
statistically significant (p = 0.188, Mann-Whitney U-test). The results shows that the 
patients of the intervention group were much more satisfied with the way the 
information was presented to them compared to the control group (IG: 25% 
percentile = 4.50, 50% percentile = 5.00, 75% percentile = 5.00; CG: 25% 
percentile = 3.50, 50% percentile = 4.00, 75% percentile = 4.50). For this subscale the 
difference was statistically significant (p = 0.002, Mann-Whitney U-test). 
The basic survey indicated the limited perception of pharmacists as a source of 
information by the patients. This observation was confirmed in the pilot study. Only 
15% of the patients in the control group described the pharmacist as one of their most 
important sources of information. In the intervention group 68.4% called pharmacists 
one of their most important sources of information. This increase was statistically 
significant (p = 0.001, Mann-Whitney U-test). It is also striking that the intervention 
group referred to the oncologist as a most important source of information a lot more 
than the control group. Fig. 4-24 illustrates all information sources which were most 
valuable to the cancer patients for both the control and intervention group. 
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Fig. 4-24 Important sources of information utilised by the patients in control and 
intervention group (patients could choose more than one source) 
4.2.4 Drug-related problems and pharmacist’s interventions 
During the intervention phase the caring pharmacists coded the detected drug-related 
problems and the according interventions using the PI-Doc® System (Schaefer, 2002). 
The detected drug-related problems are listed in the following tables (Tab. 4-8 to Tab. 
4-13). 
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Tab. 4-8 Inappropriate drug choice 
 ∑ 
Unsuitable drug for indication 2 
Physiological contraindication not considered 3 
Contraindication by other disease not considered 1 
Unsuitable package size 3 
Tab. 4-9 Inappropriate drug use by patient/compliance 
 ∑ 
Insufficient knowledge about the application of the drug 1 
Handling problems 1 
Patient does not use a recommended drug (primary non-compliance) 6 
Self-reliant change of the recommended dose by the patient 7 
Unsuitable period of use 1 
Unsuitable time of application 1 
 
Tab. 4-10 Inappropriate dosage 
 ∑ 
Patient does not know his or her dosage 3 
Underdosage 5 
 
Tab. 4-11 Drug-drug interaction 
 ∑ 
Reference to an interaction by literature 1 
 
Tab. 4-12 Adverse drug reaction 
 ∑ 
Patient's fear of adverse drug reactions 2 
Symptoms of an adverse drug reaction 78 
Medication stopped due to unacceptable adverse drug reaction 1 
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Tab. 4-13 Other problems 
 ∑ 
Patient-related   
Dissatisfaction with current treatment 3 
Patient does not receive a drug although an indication exists 2 
Patient vomits the taken drugs 1 
Technical and/or logistical  
Problems with the sickness funds (refunding) 1 
 
According to the drug-related problems the following interventions were undertaken 
by the caring pharmacists. Interventions had often a preventive character and were 
also initiated if no DRPs previously occurred. Interviewing and counselling of the 
patient, as well as documenting symptoms of adverse drug reactions were performed 
in every regular meeting with the patient. The interventions with a higher 
denomination such as ‘interviewing and counselling of the patient’ and 
‘documentation of symptoms of an adverse drug reaction’, were part of the routine 
care programme. All interventions are summarised in Tab. 4-14 to Tab. 4-19. 
Tab. 4-14 General interventions 
 ∑ 
Contacting the physician 21 
Refer a patient to a general practitioner 8 
Refer a patient to a specialist 1 
Recommending other health care professionals 3 
Refer a patient to self-help groups 1 
Interview and counselling of the patient's relatives 10 
Recommendation of a drug 19 
Recommendation to change a drug 2 
Recommendation of a preventive measure 39 
Information regarding complementary treatment options 14 
Drug information search 16 
Recommendation of a non-medical measure 20 
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Tab. 4-15 Intervention: inappropriate drug choice 
 ∑ 
Selecting or recommending an appropriate drug for the indication 3 
Clarification with regard to a physiological contraindication 4 
Clarification with regard to a contraindication due to concomitant 
diseases 
2 
 
Tab. 4-16 Intervention: inappropriate drug use by the patient/compliance 
 ∑ 
Advice for correct application 2 
Searching for the reasons for primary non-compliance and counselling 7 
Searching for the reasons to change a recommended dosage by the 
patient and counselling 
7 
Advice with regard to optimal duration of use 22 
Advice with regard to optimal time of application 20 
 
Tab. 4-17 Intervention: inappropriate dosage 
 ∑ 
Advice to the patient with regard to dosing 24 
Clarification with regard to an underdosage 5 
 
Tab. 4-18 Intervention: adverse drug reaction (ADR) 
 ∑ 
Counselling patients fearing adverse drug reactions 2 
Documentation of symptoms of an adverse drug reaction 74 
Clarification with the physician 4 
Suggesting a change in medication to the physician 1 
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Tab. 4-19 Intervention: other problmes 
 ∑ 
Patient-related  
Reducing fears and prejudices of a drug therapy 5 
Searching for reasons for dissatisfaction with current treatment 2 
Advice to the patient with regard to a health-supporting life style 2 
Information about nutrition 23 
Information about physical training 23 
Advice with regard to treatment opportunities of 
ailments/recommendation to see a physician 
1 
Recommendation regarding adaequate subsequent dosage 1 
Technical and logistical problems  
Clarification with the sickness fund 1 
Ensuring a seamless therapy continuation 4 
 
4.2.5 Time spent on appointments and rework 
Fig. 4-26 and 4-27 illustrate the scattering of the time spent on the care appointments 
and on the rework.  
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Fig. 4-25 Time for appointments    Fig. 4-26 Time for rework 
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The time necessary for the care appointments levelled in the median off at about an 
hour for the first appointment and at half an hour for the following appointments (see 
Tab. 4-20). For the rework after the appointments in the median between 0 to 10 
minutes after each cycle were needed whereas there was seldom the need for rework 
after the first appointment (see Tab. 4-21). 
Tab. 4-20 Time for appointments [min] 
 Mean Median Min Max 
Prior Cycle I 55 63 0  85 
Cycle I 38 30 10  100 
Cycle II 35 30 5  80 
Cycle III 36 30 5  110 
Cycle IV 30 25 10  90 
 
Tab. 4-21 Time for rework [min] 
 Mean Median Min Max 
Prior Cycle I 5 0 0  15 
Cycle I 10 10 0  40 
Cycle II 10 10 0  30 
Cycle III 8 0 0  60 
Cycle IV 5 0 0  20 
 
4.2.6 Sample size estimation for the main study 
The sample size for the main study was calculated adaptive based on the results of the 
present pilot study. Other than in the present study a different endpoint has been 
chosen. This was declared in an amendment for the study protocol. For the future 
primary endpoint ‘complete control of emesis’, with a sample size of n = 50 per group 
and a prevalence of 40% to 60%, given an overall α of 5% (for both phases), an 
improvement of ∆=15% in the intervention group can be detected with and a power 
(1-β) of more than 99%. 
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4.3 Monitoring of carboplatin 
During the pilot study four patients donated blood for the pharmacokinetic analysis. 
These patients presented with characteristics summarised in Tab. 4-22. 
Tab. 4-22 Patient characteristics 
Patient code KOM01 KOD01 KOK11 KOS01 
Age [years] 48 41 69 61 
sex female female female female 
Type of cancer EOC EOC EOC EOC 
TNM pT3c pN0, pMx, 
G3 
pT1c, N0, M0, 
G2 
pT3b, Nx, M1, 
G2-3 
pT3c, G3 
FIGO stage IIIc Ic IIIb IIIc 
Chemotherapy 
regimen 
Paclitaxel  
175 mg/m² 
Carboplatin  
AUC5 
Paclitaxel  
175 mg/m² 
Carboplatin  
AUC5 
Paclitaxel  
175 mg/m² 
Carboplatin  
AUC5 
Paclitaxel  
175 mg/m² 
Carboplatin  
AUC5 
Pre-treatment none none none none 
Height [cm] 166 170 159 154 
Weight [kg] 60 61 68 53 
BSA [m²] 1.67 1.71 1.7 1.5 
 
In all observed cycles for these four patients the achieved AUCs [according to 
Sørensen et al.] did not reach the level of the intended target AUC as shown in Fig. 
4-27. The AUCs were determined based on the carboplatin concentration in the 
ultrafiltrate in order. The mean AUC had a variance of 23% (7.2-38.4%, SD 7.66%). In 
the median the AUC differed 21.7% with a 25% percentile of 20.4% and a 75% 
percentile of 25.3%. The measured platinum concentrations in plasma and ultrafiltrate 
and the resulting AUCs are documented in appendix M. 
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Fig. 4-27 Actual AUC (ultrafilterable plasma) vs. target AUC [mg·min/mL] 
To get an idea of what doses would have been calculated with the other introduced 
methods these calculations were performed based on the available serum creatinine 
levels and the patient characteristics of sex, weight and age. Using the rule of 
proportion the according AUCs which would have resulted from these doses were 
also calculated. The results are listed in Tab. 4-23. The doses necessary to achieve the 
target AUC would need to be in the mean 31.1% (7.7-62.3%, SD 13.65%) higher than 
the actual dose given. All available serum creatinine levels are documented in Tab. M-2 
of the appendix M. For some cycles there were no actual serum creatinine levels 
available. In these cases the doses and accordingly the AUCs could not be determined. 
In all cases the calculated dose was higher than the actual dose given, however, even 
with these higher doses the target AUC would still probably not have been achieved. 
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Tab. 4-23 Actually received carboplatin doses and measured AUCs and  
according calculated values 
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 In order to look for possible relationships between platinum exposure and toxic 
effects, myelotoxicity, in particular the platelet and white bood cell (WBC) counts were 
analysed in detail. As summarised in Tab. 4-24 the available laboratory data indicate 
that none of the participating patients suffered from thrombocytopenia. Neutropenia 
experienced can be considered as mild in most cases. In one case a grade 3 
neutropenia was observed. However, AUC was not particularly high in this patient. 
For patient KOM01 too few data were available to list in the table. This patient 
was not included in the evaluation of the experienced myelotoxicity. The common 
toxicity criteria according to the NCI v.2.0 for platelets and leukocytes are listed in Tab. 
M-3 of appendix M. 
Tab. 4-24 Myelotoxicity observed in ovarian cancer patients 
 KOD01 KOK11 KOS01 
Platelet count  
[⋅109/L]  
NCI 
CTC 
Grade
days 
post 
CT  
NCI 
CTC 
Grade
days 
post 
CT  
NCI 
CTC 
Grade 
days 
post 
CT 
Before therapy 207 0  343 0  461 0  
CI 278 0 20 285 0 22 292 0 19 
CIII 164 0 12 292 0 11 215 0 11 
CVI n.d. n.d. n.d. 270 0 13 n.d. n.d. n.d.
WBC count 
[⋅109/L]          
Before therapy 4.7 0  8.3 0  5.3  0  
CI 4.4 0 20 9.1 0 22 2.7  2 19 
CIII 3.0 n.d. 12 3.2 1 11 2.7  2 11 
CVI n.d. n.d. n.d. 1.6 3 13 n.d.  n.d. n.d.
n.d. = not determined 
Normal ranges: Platelets 150–400⋅109/L; WBC 4-9⋅109/L 
For platelets the nadir usually occurrs between days 14 and 22 after the 
chemotherapy, whereas the WBC nadir occurs between days 14 and 28.
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5 Discussion 
5.1 Patient satisfaction with information on cancer treatment 
The basic survey primarily aimed at assessing the suitability of a German adaptation of 
the Canadian PS-CaTE questionnaire. Results on test homogeneity and test reliability 
indicated good psychometric properties of the German version. However, data 
concerning the validity of the instrument are still scarce and should be complemented 
by future research. Nevertheless, there are several reasons for accepting the current 
version for the time being. First, the German questionnaire appears to be 
psychologically equivalent to the original Canadian version which has already been 
used successfully for assessing patient satisfaction with treatment information. Second, 
the item content is obviously face-valid. Third, the spontaneous written comments of 
the patients were generally in agreement with the quantitative questionnaire results. It 
thus seems reasonable to use the adapted questionnaire for assessing patient 
satisfaction in Germany. 
Strong validity criteria, such as criterion-related validity or construct validity, 
cannot be assessed at this time. One possible way of establishing criterion-related 
validity would be to compare results from this instrument with results of other patient 
satisfaction measures. Since the instruments intend to assess the same concept, patient 
scores should correlate highly. However, currently no other patient satisfaction with 
information measurement instrument exists in Germany that could serve as a 
reference. Moreover, construct validity is not fully applicable to our instrument as the 
concept behind the construct of patient satisfaction is not yet completely understood. 
Although Annunziata et al. found a positive correlation between satisfaction and 
quality of life, it does not seem to be advisable to use this result for validity 
assessments until further studies verify it (Annunziata et al., 1998). 
One possible objection against the 5-point rating scales used in this instrument is 
that they might provoke a tendency for giving judgments corresponding to the mean 
rating category (Cassileth et al., 1980). However, as is well-known from the test 
construction literature, this tendency is typically a problem for bipolar rating scales 
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only that require decisions between two qualitatively different attitudes, opinions, or 
values (love-hate, fast-slow etc.). It is less of a problem in unipolar rating scales that 
require decisions between different degrees of a single attribute. Consistent with this 
view, our results show that patients did not tend to favour the third rating category. 
Future research should also address the aspects of socially-desirable answering, 
correlation of patient satisfaction with information to measured quality of life and 
correlation between patient satisfaction with information on cancer treatment and the 
actual knowledge of the patient. 
As previous studies illustrate, important information needs of patients include 
information about diagnosis, treatment, cure rate, side effects and complementary 
treatments (Gustafson et al., 1993; Luker et al., 1996;  Pimentel et al., 1999; Hope et 
al., 2000; Bonnet et al., 2000). In general, needs regarding treatment information were 
obviously met in the present study population as the rather high satisfaction scores 
show. Since studies revealed that patients want as much information as possible 
(Dodd, 1983), the patients’ role has become a more active one. A trend towards 
competent, well informed patients can generally be observed and patients are 
becoming increasingly involved in treatment decisions. The patients’ responses in this 
study support this observation. Patients demand transparent information about all 
aspects of their treatment. They complained that a lot of information was supplied to 
them only upon request, which they experienced as tiring and unsatisfactory.  
Our results reveal that the provision of information on side effects and 
complementary treatment options could be improved. It would be interesting to assess 
whether patients de facto receive less information about such aspects, or whether they 
simply perceive the information in a different way. Ried et al. found that patients’ 
satisfaction can also be influenced by personal attention (Ried et al., 1999a). Perhaps 
information about side effects and complementary treatment options was not 
provided with the same emphasis as information regarding cancer treatment. Health 
care providers should increasingly offer this kind of information to cancer patients.  
Whereas this part of the study showed that age, sex, educational status and living 
situation seemed to have no impact on patient satisfaction with information, other 
investigations have found that at a younger age patients seem to have higher 
information needs (Cassileth et al., 1980; Gustafson et al., 1993; Bonnet et al., 2000).  
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Breast cancer patients seem to be less satisfied than patients with other types of 
cancer. This result should be interpreted with caution. It could be biased due to the 
fact that most of the patients in our study were breast cancer patients and that other 
types of cancer were underrepresented. Breast cancer and especially mastectomies 
have a major impact on a woman’s self-perception. Thus, compared to other cancer 
patients, breast cancer patients might generally have a lower satisfaction level, which, 
as a by-product, may induce lower satisfaction with information scores. In Germany, 
an increasingly stronger lobby is emerging especially for breast cancer patients. 
Modern mass media provide information about this disease, the diagnosis and 
treatment options and the patients’ rights. In this way, lower satisfaction scores of 
breast cancer patients could be caused by the fact that media depictions lead to high 
expectations. If these expectations are not fully met, dissatisfaction could be the 
consequence. 
Cancer patients with recent diagnosis (< six months) seem to be more satisfied 
than patients who were diagnosed longer ago. These results are consistent with the 
findings of Jänel et al. (2000). After about six months patients seem to realise that 
important information has been omitted, a fact that leads to dissatisfaction. 
Our findings show that among the information sources used by patients, 
pharmacists still seem to play a minor role. This low score is of particular concern 
considering that patients knowing the background of the researchers undertaking a 
study tend to answer in a socially desirable manner. This could have resulted in higher 
scores since the professional background of the research group was not disclosed. It 
might well be, however, that patients were not able to draw the connection between 
the pharmaceutical institute mentioned in the heading of the enclosed letter and the 
questions regarding community pharmacists in the questionnaire since the two have 
different wordings in German. A reason for the low awareness of pharmacists as 
information source might be that in the patients’ perception, pharmacists still focus 
primarily on the distribution of drugs. Unless additional information about the 
treatment, potential side effects and complementary treatment options is offered 
actively, patients cannot recognise the pharmacist as a valuable source of information. 
In particular, pharmaceutical care provides an opportunity to actively offer 
individualised information to patients. Häggmark et al. (2001) showed that 
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individualised information programmes significantly affect the satisfaction of cancer 
patient with information. Most importantly, all health care providers should cooperate, 
in order to offer such individualised information to their patients. 
5.2 Pharmaceutical care of patients with gynaecological malignancies 
Pharmaceutical care in oncology aims at reducing treatment-associated toxicity and at 
improving patients’ quality of life. The aim of this project is to develop a specific 
pharmaceutical care model for breast and ovarian cancer patients including patient 
counselling on the management of treatment-associated side effects, optimisation of 
supportive medication and the implementation of a therapeutic algorithm for 
antiemetic prophylaxis. Already in the beginning of the 1990s outcome orientation 
and quality assurance in pharmaceutical care was claimed by several authors (Penna, 
1990, Angaran, 1991, Donabedian, 1992). Especially in research it is important to 
support the proposed hypotheses with meaningful outcome parameters. Nevertheless, 
the main objective of this pilot study was to assess the feasibility of pharmaceutical 
care for cancer patients in the outpatient setting and to estimate its benefit for the 
patients as the number of patients whose data could be evaluated is by far too small to 
draw secluding conclusions. 
5.2.1 Quality of life 
Senn and Glaus described the paradigm shift from cure to care in oncology which 
reflects the change of attitudes and treatment goals (2002). Other outcomes than the 
standard endpoints survival and tumour response gain importance. Health-related 
quality of life is an aspect of the personal well-being of individuals. It can be described 
as a complex of functional and symptomatic experiences of patients. By definition 
health-related quality of life includes physical, psychological and social as well as 
functional dimensions (Ravens-Sieberer, 2002). The EORTC QLQ-C30 questionnaire is 
a disease-specific instrument which reflects all these dimensions. Rusthoven 
emphasised the importance of a differenciated interpretation of health-related quality 
of life data (1997). He called attention to the fact that the different dimension (either 
single items or scales) could be considered in its own rights. Thus, the investigator 
 132
[5] Discussion 
must decide which of these dimensions are primary to the particular study. The present 
findings were evaluated accordingly. 
Regarding the quality of life two hypotheses were set up prior to the present 
study. For one it was assumed that the global quality of life of patients can be 
improved by the enhancement of communication regarding drug treatment by 
pharmaceutical care. This hypothesis could not be confirmed with the present results. 
However, there were tendencies for a better preservation of quality of life during 
chemotherapy compared to the control group.  
The other hypothesis was that the minimisation of treatment-associated toxicity 
improves the specific quality of life in terms of the symptomatology. This could actually 
be achieved although not statistically significant for the symptoms pain and 
constipation. These findings can be explained as follows. Regarding pain control, 
patients in the intervention group made use of the opportunity to ask about the 
compatibility of analgesics with the antineoplastic therapy. Pharmacists, after 
reconsulting with the physicians, suggested appropriate medication for the respective 
situation.  
Constipation is a common adverse drug reaction associated with the use of 
5HT3 receptor antagonists which have been used far more extensively in the control 
than in the intervention group. In addition to the controlled use of the 5HT3 receptor 
antagonists, mild laxatives were recommended as soon as patients suffered from 
constipation. Patients tended to not mention problems with their digestion of their 
own accord as they felt uncomfortable. It was important to ask them directly in order 
to get the information and to start the necessary measures. 
As an alternative to the 5HT3 receptor antagonists high doses of metoclopramide 
were used to prevent delayed nausea and emesis in the intervention group. This 
caused most probably the obvious deterioration of the experienced fatigue in the 
intervention group compared to the control group (see chapter 1.2.7.2). The increased 
fatigue symptomatology in the intervention group is particularly concerning as this 
symptom complex was ranked 3rd of the worst adverse events from patients 
perspective (Carelle et al., 2002). With a change of medication according to the 
international guidelines in favour of dexamethasone as main component of the 
antiemetic prophylaxis in the subsequent study and additional information for patients’ 
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everyday life such as physical exercise and nutrition this symptomatology should be 
positively influenced. 
The present data showed a large variability. This might be due to potential 
bottom and ceiling effects. No definite prediction can be made on which of these 
effects were predominant, though. These effects are often observed in QoL 
measurements when patients tend to choose the extreme values. Additionally, 
patients’ differing coping strategies and personalities do affect the answering. This bias 
is difficult to avoid and it is even reinforced by additional incidents (positive as well as 
negative) which the patients experience. These experiences influence the results of 
quality of life measurements in particular as health-related quality of life is a 
multidimensional construct and thus tangent to a variety of areas of patients’ lives. It is 
conceivable that for example the emotional functioning is negatively affected by the 
recent death of a family member, or in a positive way by the marriage of son or 
daughter. Examples like this exist for every dimension. This has also been shown by 
Determann et al. (2004). They observed in a prospective, randomised, controlled trial 
106 patients with colorectal cancer which received in the intervention group 
additional psychooncological support. The assessment of the psychometric properties 
of the EORTC QLQ-C30 showed illustration of situational influences and therefore an 
insufficient illustration of effects of specific interventions. It would be worth 
considering a general QoL instrument which would possibly show less variability but 
probably also a reduced sensitivity. A comparison between a general and a health 
related QoL instrument would be useful to address this question in future studies. 
Another aspect worth discussing is the sensitivity of the selected instrument. The 
sensitivity is the ability of measurement instruments to detect differences between 
patients or groups of patients (Fayers and Machin, 2000). Just as with the variability it is 
difficult to judge the sensitivity of the EORTC QLQ-C30 questionnaire in this context. 
With a larger number of patients the variability would even out and maybe a better 
predication of the sensitivity would be possible.  
Another methodological question is the optimal time of administration of the 
questionnaire. Pater et al. addressed this question in a large antiemetic trial (1998). 
They found that the time of administration as well as the time frames have an impact 
on the results. The administration close to the maximum of experienced toxicity would 
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enhance the detection of the impact of the symptoms on QoL. As different types of 
toxicity occur at different times post-chemotherapy there is a risk of overlooking these 
in case they are not in the chosen time frame. The time of administration in this study 
was a week after chemotherapy looking at a timeframe of 7 days. This covers acute 
toxicity such as nausea and emesis but not delayed toxicity such as for example 
mucositis. As for this study the main focus was put on the prophylaxis of nausea and 
emesis the time of administration seemed to be reasonable. 
It is questionable what impact on quality of life can be attributed to 
pharmaceutical care interventions, in such a short period of time and observing only a 
limited number of patients. Osoba discussed this in a review on this topic (1997). To 
date it is still uncertain to what extent health-related quality of life is actually affected 
for example by post-chemotherapy nausea and emesis or whether other factors such 
as the underlying disease have a greater effect. 
Experts seem to agree upon the fact that the expressiveness of findings from 
quality of life measurements is much depending on the methodology of the 
questioning and the evaluation of the collected data (Osoba, 1997; Rusthoven, 1997; 
Ravens-Sieberer, 2002). Nevertheless, it is important to ask for patients’ feelings in 
particular when aspiring an even partnership between health care professionals and 
patients. 
As primary endpoint QoL does not seem to be appropriate, though, as it is 
influenced in various ways as mentioned above. Thus it is not capable of reflecting the 
influence of the intervention in a meaningful way. The decision was made to change 
the primary endpoint to ‘complete control of emesis’ as it is a much stronger 
parameter and the interdependency of intervention and change in this parameter is 
much better to interprete. 
5.2.2 Nausea and emesis 
The results of this study indicate that it is possible to optimise the antiemetic treatment 
and influence the outcome in a positive manner. To interpret the results it is necessary 
to distinguish between nausea and emesis as two different symptoms. Regarding 
emesis, patients in the intervention group had a clear benefit compared to patients in 
the control group. Although not statistically significant, the number of cycles with a 
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complete response to the antiemetic prophylaxis could be enhanced in the 
intervention group. The cycle-wise consideration and the comparison of the sumscores 
of experienced emetic episodes show the same tendency. In particular, acute emesis 
could be improved. The improvement of the antiemetic prophylaxis is the result of 
different interventions. First, the application of the evidence-based therapeutic 
algorithm was a mandatory presupposition. The physicians were asked to report and at 
best specify the reason for altering the antiemetic prophylaxis or treatment. Second, 
pharmaceutical care might have contributed by improving patients’ knowledge and 
discernment in the therapy and thus enhancing the concordance to the suggested 
prophylaxis. In particular for the antiemetic prophylaxis patients received additional 
written information on how to take their medication and were asked to fill in the 
patient diary about their experience with nausea and emesis including the medication 
taken. 
In contrast to emesis, nausea could practically not be affected in the intervention 
group. Looking at the results it even seems that the patients in the intervention group 
experienced higher degrees of nausea compared to the control group. This might be 
due to the fact that patients of the intervention group did not suffer emesis as much 
which might have led to a more sensitive rating of the experienced nausea compared 
to patients in the control group which experienced more emetic episodes and thus 
might not have experienced nausea as bad in comparison. In line with the current 
literature on patients’ perception of side effects in cancer chemotherapy it is more 
important to control emesis as it is rated more distressing by the patients than nausea 
(Carelle et al., 2002). Still, in the early 21st century the patients’ perception of cancer 
therapy-associated adverse events has changed considerably compared to 20 years 
ago. When at the beginning of the 1980’s emesis and nausea were ranked first and 
second worst adverse events nowadays psychosocial aspects, alopecia and fatigue 
lead the list. Emesis is now on rank 11 and nausea even below 15. However, any effort 
should be made to minimise this toxicity. 
Our results, that acute emesis can be influenced most, is in agreement with the 
current literature. Herrstedt discussed the present state of the antiemetic prophylaxis in 
an editorial (2002). He pointed out that delayed emesis and particularly acute and 
delayed nausea have remained to be unsolved problems. In the case of the present 
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study population at least delayed emesis might be controlled better by changing the 
therapeutic algorithm in favour of dexamethasone which will be applied in the 
subsequent study. 
Additionally the recently approved NK1-receptor antagonist aprepitant has been 
implemented in current international guidelines of the MASCC (Gralla, 2004). It is 
indicated for the prophylaxis of acute and delayed nausea and emesis in highly 
emetogenic chemotherapy. However, currently published data show that it might also 
be effective in moderately emetogenic chemotherapy. Warr et al. conducted a 
worldwide multicentre randomised, double-blinded, controlled trial with breast cancer 
patients receiving an anthracycline in combination with cyclophophamide. Aprepitant 
was given to one group in addition to the standard antiemetic prophylaxis before 
chemotherapy and on days 2 to 3 after chemotherapy in order to prevent both acute 
and delayed emesis (day 1: aprepitant 125mg, ondansetron (OND) 8mg, and 
dexamethasone 12mg before chemotherapy and ondansetron 8mg 8 hours later; days 
2-3: aprepitant 80mg four times daily). The other group received a standard treatment 
(day 1: ondansetron 8mg and dexamethasone 20mg before chemotherapy and 
ondansetron 8mg 8 hours later; days 2-3: ondansetron 8mg twice daily). The 
aprepitant regimen proved to be significantly more effective in both acute and delayed 
emesis compared to the standard treamtent (Warr et al., 2004). These findings are very 
promising and might lead to the application of this drug in the subsequent study. 
The importance of the application of standardised and evidence-based 
therapeutic guidelines or treatment algorithms was shown in previous national and 
international studies. Dranitsaris et al. (2001), Kämmerer (2002) and Freidank (1999) 
initiated the implementation of such guidelines out of their pharmacy departments and 
achieved an improvement of the therapeutic outcome for the patients. As an 
additional effect considerable amounts of money were saved by implementation of 
guidelines. Kämmerer described savings of 100,000 € annually for the hospital by 
simply reducing the administered dose of granisetron from 3 mg to 1 mg as 
recommended in the literature (2002). The question whether there is a need for an 
update of the currently available therapeutic guidelines has been discussed by Roila, 
who was member of the panel of experts for the Antiemetic Subcommittee of the 
MASCC, in an editorial (2002). The currently available drugs are taken into 
consideration in the present guidelines. Attempts to set up new guidelines with the 
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available drugs do not let expect major new insights but may lead to more confusion 
among the practitioners.  
5.2.3 Patient satisfaction with information on cancer treatment 
The contents of the pharmaceutical care process for patients with gynaecological 
malignancies have been adapted according to the conclusions from the basic survey 
regarding information deficiencies of cancer patients. The results showed that in the 
intervention group the patients’ satisfaction with the information improved. In four of 
five sub-scales the differences were statistically significant.  
In the intervention group patients chose pharmacists as one of their most 
important sources of information significantly more often than in the control group. 
This is not surprising as the regular appointments with a pharmacist were a mandatory 
part of the pharmaceutical care process and usually took place in a familiar 
environment with enough privacy and time to ask questions. Still, the results showed 
that the information provided was not only accepted but also perceived as particularly 
valuable. Another aspect that should be taken into account is that the study 
pharmacists observed that often patients did not perceive them as ‘pharmacists’, as 
they did not meet the general image of a ‘white coat’ pharmacist in the pharmacy. This 
would explain why only 80% of all patients from the intervention group indicated the 
pharmacist as a utilised source of information. 
Three important questions need to be addressed: 
1) Did the pharmaceutical care intervention improve patients’ satisfaction with 
information on the cancer treatment? 
To answer this, some general considerations regarding the outcome variable ‘patient 
satisfaction’ need to be made. It is important to be aware of the many uncertainties still 
connected to the term ‘patient satisfaction’ when interpreting the data.  
From the scientific point of view patient satisfaction should only be applied as an 
outcome parameter if its theoretical construct can be precisely described. The 
literature describes a variety of approaches which try to explain the construct of 
patient satisfaction (Cleary and McNeil, 1988; Leimkühler and Müller, 1996; Jackson 
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and Kroenke, 1997). They emphasise the many interdependencies of patient 
satisfaction with other influencing factors. Also the possible correlation between 
patient satisfaction and other outcome parameters such as quality of life and 
compliance have been discussed.  
Patient satisfaction can be influenced by a variety of objective and subjective 
factors such as attitudes and expectations, relation to the caregiver, health status prior 
to care, patient characteristics such as age, social class, race or gender. At present no 
meaningful answers can be presented, though, which specify the impact of these 
factors on patient satisfaction. 
The consulted literature introduces a fulfilment theory which suggests that the 
more the provided care conforms to patients’ expectations the higher is the resulting 
satisfaction (Jackson and Kroenke, 1997). Transferring this to the present study it 
would support the conclusion that the pharmaceutical care intervention met the 
expectations of the study patients as intended. 
It also has to be taken into account that the health status at baseline influences 
satisfaction. Applied to the available data this would even strengthen the observed 
difference as the intervention group had a median global health status below the 
control group. The influence of patient characteristics on patient satisfaction has been 
discussed under 5.1. 
Diener et al. describe satisfaction as one of three major components of 
subjective well-being (SWB) (Diener et al., 1997). The other components are pleasant 
affect and low levels of unpleasant affect. People tend to experience similar levels of 
well-being across different aspects of their lives. If global satisfaction is measured the 
results will more likely be influenced by other components. Whereas the more narrow 
the measure is laid out the more sensitive the measure is to causal variables. 
Leimkühler and Müller point out that many studies measure global satisfaction which 
generally tends to be fairly high (Leimkühler and Müller, 1996). Cleary and McNeill 
describe the same observation in their review (1988). If the questionnaire is more 
differentiated other aspects may differ from the global satisfaction by all means. This 
assumption is supported by the observation of Williams and Calnan (1991). They 
compared the global and specific satisfaction and found out that although 95% of the 
patients were generally satisfied, 35% felt that the hospital doctors did not give 
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sufficient information. Our questionnaire refered to this aspect of care. Compared to 
instruments which measure only global satisfaction with health care service this can be 
considered an advantage. Although global satisfaction was at a high level as expected, 
the subscales provided different results. The results especially reflect that in terms of 
complementary treatment options, the satisfaction with the information received was 
still not as high as for the other scales. More attention should be paid in the future to 
this aspect. 
Another phenomenon that has to be considered and may have influenced the 
response is that patients received the questionnaires from the pharmacists who 
provided the care. This could cause a socially-desirable answering. Although this held 
for both, the control and intervention group, the effect might be stronger in the 
intervention group as the relationship to the pharmacist is far more intense compared 
to the control group. This would consequently lead to improved outcomes in the 
intervention group.  
Considering the potential bias discussed, it cannot be concluded that the 
pharmaceutical care intervention alone improved patients’ satisfaction. Further 
research in this area will be necessary to elucidate the interdependencies and 
correlations of patient satisfaction in relation to other parameters. 
2) Do the results allow the inference on the quality of the delivered pharmaceutical 
care in general? 
For one thing ‘quality’ needs to be defined. One approach is to describe it as a 
composite of technical expertise, interpersonal skills and the ability to transfer 
information. Patients surely have difficulties to judge the technical expertise of the 
caregiver, whereas the interpersonal skills have a major influence on satisfaction 
(Jackson and Kroenke, 1997). Ried et al. showed that patients’ satisfaction can be 
influenced by personal attention (Ried et al., 1999). This observation is in accordance 
with Cleary and McNeil (1988). They concluded that the more ‘personal’ the provided 
care is, the higher satisfaction levels are reached. This probably applies to the 
pharmaceutical care intervention. The authors emphasise that in terms of quality 
assessment an improved personal attention can be interpreted as improved caregiver-
patient communication which is considered part of a high quality standard in health 
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care. Medical treatment depends to a great extent on accurate patient communication 
and active involvement in the treatment process. 
Furthermore, the majority of studies interpret results based on two unproven 
assumptions. One assumption emanates from the fact that an objectively good reality 
is perceived as such and consequently results in high satisfaction and the second is 
that subjective satisfaction can be gathered from the declared satisfaction. Leimkühler 
and Müller discuss the topic in detail in their review (Leimkühler and Müller, 1996). 
They doubt whether patient satisfaction as it has been used in studies so far actually 
contributes to quality assurance as intended. At this time there seems to be no valid 
outcome parameter available which would allow the inference from patient’s 
perception to the quality of health care services. Still it is true that there cannot be high 
quality care unless the patient is satisfied. Also patient satisfaction may serve as a 
valuable monitoring parameter of the quality of care over time. 
3) Finally, do the results reveal whether the patients in the intervention group are 
actually better informed or educated about their disease? 
The results from the patient satisfaction questionnaire alone do not allow this 
conclusion. Taking into account other outcome parameters evaluated in this study, the 
assumption that the patients from the intervention group might be better informed 
about their treatment is supported. In terms of nausea and emesis the intervention 
group experienced less toxicity than the control group. This effect cannot only be 
attributed to medication changes but also requires a good adherence to the suggested 
medication plan. The better the knowledge of the patient regarding her treatment is 
the more likely there will be good adherence to the medication plan. 
Even if at this time the construct ‘patient satisfaction’ can not be sufficiently 
described it still seems reasonable to ask for the patients’ subjective perception. 
Analogous, unevaluated conclusions, however, should not be drawn. 
5.2.4 Drug-related problems and pharmacists’ interventions 
In the present study the drug-related problems and according pharmacists’ 
interventions were documented descriptively in order to elucidate where the main 
contribution for this particular patient collective is. The major drug-related problem 
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were obviously the adverse drug reactions which, to a different extent, were 
experienced by every patient in almost every cycle. Knowing the antineoplastic 
treatment this was expectable. The PI-Doc®-system does not allow the classification of 
the degree of experienced adverse drug reactions. It would be interesting to document 
the drug-related problems also for the control group to be able to compare the two 
groups. Other drug-related problems occurred to a minor extent. Suseno et al. showed 
in their study that the systematical documentation of pharmacists’ interventions does 
not only affect the quality of health care but has also an impact on cost savings (1998). 
The corresponding interventions made by the pharmacists do show a certain pattern. It 
is obvious that activities such as interviewing and counselling of the patient, 
recommendations on preventive or complementary measures as well as advice on the 
optimal duration of use of the medication, especially regarding the supportive therapy, 
were part of the routine care. These findings are valuable for the conception of care 
standards in the future. The amount of time spent on the care appointments adjusted 
at similar levels. In the median about one hour is necessary to educate the patient 
before the therapy starts. The follow-up appointments took in the median about half an 
hour time. The suggestion is that these times can even be reduced in everyday practice 
considering the increasing expertise of the caring pharmacist as well as the different 
working conditions in a study. The research pharmacists had many appointments in 
the private environment of the patients. Which might have lead to longer 
conversations as if held in a clinic or pharmacy. This defiinately biased these results. 
Still they give a rough estimation of what to expect if pharmaceutical is applied to this 
kind of patient collective. 
5.2.5 Limitations of pharmaceutical care research 
Data from pharmacy practice studies have to be interpreted with caution. Mobach 
explains the traps of pharmaceutical care research (PCR) (2001). He described it as a 
relatively new scientific field which needs to be defined and suggests that standards 
need to be created. PCR ranges between natural science and social sciences. Each of 
these directions have their own rules which need to be linked and adapted to achieve 
representative results. It is science in the field rather than in the laboratory and thus 
much more exposed to a variety of environmental influences. For these conditions 
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specific rules need to be established through studies. Van Mil emphasised in an 
editorial that this kind of research is often, in addition to the general problems 
connected to research, subject to uncontrolled settings, uncontrolled interventions 
and uncontrolled populations. This obviously increases the risk of influencing the 
reproducibility of the data (van Mil, 2003). When interpreting data from pharmacy 
practice studies van Mil calls for the consideration of an effect well known in 
sociological and psychological research as the ‘Hawthorne effect’. This effect was 
observed in a series of studies undertaken between 1924 to 1927 at the Western 
Electric Company in Hawthorne, Illinois which aimed at finding conditions under 
which the productivity of the workers could be increased. Eventually they found that it 
were not the changes in the working conditions itself that resulted in increased 
productivity, but rather the fact that workers were influenced by the management’s 
perception and the team spirit among co-workers. This effect was applied to a variety 
of situations in personel management but it is also transferable to sociological, 
psychological, medical and pharmacy practice research. What can be observed is that 
patients who participated in studies regardless of the treatment and whether they are 
assigned to the control or intervention group, seem to benefit. This is probably due to 
the fact that special attention is paid to them (Gnant, 2000). Di Blasi et al. described a 
similar effect referred to as ‘context effect’. They concluded in their review that the 
manner in which patients are cared for in terms of emotional and cognitive care has a 
considerable effect on the treatment outcome. When interpreting study results these 
aspects have to be taken into account. It is a lot more difficult to show an effect of an 
intervention such as pharmaceutical care, since the patients of the control group are 
more likely to have better outcomes than the overall population. Nevertheless this is a 
problem which applies to all study populations. However, when results show statistical 
significance even in a small study population, the effect can probably be accredited to 
the intervention.  
The present study was affected by all the effects mentioned above. They had to 
be considered when interpreting the data. In future research projects further effort 
should be made to test methods in order to reduce the bias discussed above. 
Nevertheless, the selected sequential control group design proved to be a suitable 
design for this kind of question. It oriented much on the research standards in cliinical 
trials. Due to the conditions in the clinical routine a randomisation was not possible. 
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This was a clear disadvantage. When planning subsequent studies it would be 
worthwhile thinking about randomising the study centres which would be 
unproblematic with a larger number of participating centres. However, sometimes it is 
difficult to convince study centres (e.g. participating pharmacies) to be the control 
group, as they hope to learn from the experience in participating in a study. Blinding, 
however, still remains a problem. One approach may be the ‘placebo care’ concept 
where patients in the control group also get contacted by an additional person who 
spends the same amount of time with them as for the provision of pharmaceutical care 
would take up in the intervention group. Someone without a pharmaceutical or 
medical education would have to perform the care to assure the ‘placebo effect’. This 
might be difficult to achieve in daily practice for several reasons. First, people would 
need to be hired and somehow integrated into the routine so that it would not be 
obvious to the patient. Second, it is difficult to fulfil the expectations of patients 
participating in a study. Third, and perhaps most important is the ethical issue. Patients 
often exchange their experiences with other patients and it can thus easily end up 
discovering to which study group they belong. Under these circumstances it would not 
be justifiable to deprive extended care from one group of patients. 
As described for quality of life research and research on patient satisfaction 
pharmaceutical care research faces the similar methodological uncertainties which 
have to be overcome in the future. So far very limited scientific evidence is available to 
judge the significance of the concept within health care particularly in cancer care. 
Mainly opinions of members of the pharmacy profession are available rather than 
profound scientific findings.  
5.2.6 Pharmacoeconomic aspects 
In recent times due to cost pressure in the health care sector treatment costs play an 
increasingly important role in supportive care. Pharmaceutical care of cancer patients 
seems to have potentials of saving costs in different ways. Two aspects have already 
been indicated above.  
First, the antiemetic treatment has proven cost saving potential. Guidelines have 
been established which are not only based on randomised clinical trials but also 
include pharmacoeconomic evaluations. The general ability to reduce treatment costs 
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by implemeting pharmaceutical care in the ambulatory setting was shown by Lobas et 
al. (1992). In this particular case even more distinguished approaches are applicable. 
The 5-HT3 antagonists in the treatment of chemotherapy-induced nausea and vomiting 
are a good example. Whereas for acute emesis 5-HT3 antagonists show a 
pharmacoeconomic benefit compared to high doses of metoclopramide, they should 
not be used for the treatment of delayed emesis. A study by Berard and Mahoney 
showed that the implementation of a treatment algorithm for antiemetic prophylaxis, 
incorporating aspects such as treating delayed nausea and vomiting without using 
serotonin receptor antagonists or matching antiemetic prophylaxis with the 
emetogenic potential of the chemotherapy regimen led to a cost reduction of about 
205,000 $ (US) in a 719-bed medical center in the first year (Berard and Mahoney, 
1995). Thus, the right choice of treatment can save a substantial amount of money. 
Furthermore, the route of administration has a great impact on the treatment costs. 
Oral administration frequently is as efficient as intravenous administration but at 
significantly lower costs. Engstrom et al. showed that the implementation of an oral 
antiemetic regime saved about 18,000 $ (US) within the nine months study period on 
52 patients both in in- and outpatient settings (1999). As mentioned earlier Kämmerer 
managed to save about 100,000 € by simply changing the dose of the 5HT3 receptor 
antagonist granisetron according to the guidelines (2002). A pharmacoeconomic 
analysis will be included in the subsequent study. 
The second cost-saving effect by documented pharmacists’ interventions was 
described by Suseno et al. (1998). These cognitions might not only have pronounced 
effects on the successful implementation of pharmaceutical care, but also for the 
future offering of supportive care to cancer patients. Elting and Tina Shih describe the 
economic burden of supportive care of cancer patients and call for more cost-
effectiveness analyses in order to be able to judge the different measures (2004). 
Moreover, the proof of a pharmacoeconomic benefit of pharmaceutical care may be 
an additional argument for a reform of the current payment system (Rappaport, 2002).  
5.2.7 Future prospect 
Crooks et al. (2004) identified the gap in supportive care between the care delivery 
and the often unknown patients’ needs. They developed and introduced the ‘Initial 
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Health Assessment’ form which helps the clinician to identify patients’ supportive care 
needs systematically. A similar approach has been followed by Scottish scientists. 
Simons describes in his thesis the so called ‘care issues’ of cancer patients which are 
identified systematically and translated into a number of potential drug therapy 
problems in order to standardise the pharmaceutical care process for cancer patients. 
The findings of the present work showed that there is obviously a need of patients for 
optimised supportive care and individualised information. Nevertheless it is important 
to elaborate in more detail the particular needs of certain groups of patients in future 
projects. This could be for example for different cancer entities or for different age 
groups of patients. The results of the patient satisfaction questionnaire showed that 
with individual information the satisfaction can be significantly improved. It would be 
interesting to further investigate the areas of pharmaceutical information which are 
most valuable to patients. The care models could then be standardised for these 
groups which would support the broad application in the practice settings. These 
approaches seem to be particularly reasonable when considering the future 
developments in health care systems as mentioned in the introduction. Pharmaceutical 
care is a concept which is comparable to other approaches as DMPs and other 
integrated care models. To develop it in a sustainable manner and make it attractive to 
third party payers further effort has to be made in order to standardise the process. 
Patients are the consumers of pharmaceutical care for whom the models have to 
be customised. Nevertheless the other parties should also be kept in mind when 
reflecting upon the results of this work. Although not measured in a scientific sense 
experiences were made regarding the cooperation with the participating physicians. 
The often undeveloped relationship among pharmacists and physicians in Germany is 
often considered a main obstacle in the realisation of pharmaceutical care. Correlative 
prejudices were by all means present at the beginning of the study. Through intensive 
discussions these prepossessions were removed after only a short time and yielded a 
constructive cooperation. As mentioned above this experience was not quantified in 
the frame of this work. Future projects could focus on this aspect in order to find out 
more about physicians perceptions of the value of a cooperation with pharmacists in 
the area of oncology.  
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Last but not least the pharmacists themselves play a role in the development of 
pharmaceutical care. In the present project there were very controlled conditions. The 
main focus was to survey the concept of pharmaceutical care. Not to underestimate is 
the attitude the majority of pharmacists has towards pharmaceutical care. Within the 
pharmacy profession obstacles have to be overcome, too. Angaran realised already at 
the beginning of the 1990s that it is an arduous and slow process to improve quality 
and change a profession. It requires a long lasting commitment to the previously 
mentioned goals to realise a change (1991). The profession has to identify the 
obstacles and develop strategies to successfully overcome them (McDonough et al., 
1998). These can for example be pharmacists’ attitudes, a lack of advanced practice 
skills or interprofessional obstacles. Referring to an article in the Harvard Business 
Review Tice addressed the question whether pharmaceutical care has the potential of 
being a ‘disruptive innovation’ in health care (2002). He challenged the pharmacy 
profession to create systems which guarantee that society could rely upon the 
pharmacy profession for their expertise in managing drug therapy problems and 
achieving desired therapeutic goals.  
5.3 Monitoring of carboplatin 
The results of this feasibility study support the formerly described observations of 
inaccuracies in dosage when estimations of the creatinine clearance are being used. 
Principle conclusions cannot be drawn due to the small number of observed patients 
(four patients with twelve observed cycles). However, the results suggest a tendency 
towards an under-dosage of patients treated with carboplatin when the Calvert 
equation is being used in combination with the Cockcroft-Gault equation for the 
estimation of creatinine clearance.  
A systematic error in the application of the equations by the physicians who 
determined the dose is very unlikely as the four patients were treated in three different 
settings with changing staff. One aspect that should be mentioned however, is that 
different infusion techniques were applied. In some cases an infusion pump was used 
while in other cases the normal infusion based on gravity was applied. With the latter, 
a rest of the infusion solution often remains in the tube. Depending on the length of 
the tube and the volume of the solution it is conceivable that the AUC of the 
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administered drug might be reduced. However, this phenomenon cannot explain the 
extent of under-dosing observed. The limited sampling method of Sørensen et al. that 
was used in this study had been validated by other groups and showed good precision 
and little bias (van Warmerdam et al., 1994; Huitema et al., 2000b). These groups 
tested the one-sample method. The two-sample method used in this study presented in 
the original paper had even better values for precision and was unbiased (Sørensen et 
al., 1993). The required conditions were met. An exact sample timing was achieved 
which was followed by an immediate sample preparation. The analytical method was 
validated and QC samples proved precise and unbiased measurements. 
These results raise the question of alternative dosage strategies. A number of 
publications address the question of whether the commonly used dosage methods 
lead to the desired drug exposure in an individual patient. Van Warmerdam et al. 
performed a pharmacokinetic study to evaluate the Calvert equation estimating the 
creatinine clearance based on either the 24-h urine collection or the Cockcroft-Gault 
equation as well as the Chatelut equation. They found an approximate underexposure 
of 10% for the Calvert equation used in combination with the Cockcroft-Gault 
equation whereas the combination with the 24-h urine collection led to an 
overexposure of approximately 10%. According to van Warmerdam et al. the Chatelut 
equation seemed to be the least biased one (1996). Panday and colleagues compared 
the modified Calvert equation in combination with the Jelliffe equation or the 
Cockcroft-Gault equation as well as the Chatelut equation. Their results showed a poor 
precision for all three dosage strategies which all led to an underexposure of 
carboplatin In comparison the Chatelut equation predicted the AUC closest to the 
actually achieved AUC (Panday et al., 1998). The group concluded that the original 
Calvert equation, though inconvenient, still should remain the ‘gold standard’. Huitema 
and colleagues used a population pharmacokinetic data set to evaluate the commonly 
used methods. The modified Calvert equation based on the creatinine clearance 
estimated by the Jelliffe, Cockcroft-Gault or Wright equation and also the Chatelut 
equation resulted in poor precision and the Jelliffe equation especially provided a 
biased prediction. They tested the one-sample method from Sørensen et al. which 
turned out to be slightly biased but precise (Huitema et al., 2000). These results are in 
accordance with many studies that evaluated these equations. The modified Calvert 
equation which uses estimations for the GFR based on Jelliffe or Cockcroft and Gault 
 148
[5] Discussion 
leads to underexposure of carboplatin. The Chatelut equation seems to predict the 
AUC more precisely, compared to the original Calvert equation and is applicable to 
clinical practice (Ozols, 1995; Calvert et al., 1995; Langer et al., 1995; Izquierdo et al., 
1997; Donahue et al., 2001). 
However, there are also some studies which found contrasting results. Okamoto 
et al., for example, compared the Chatelut equation with the modified Calvert 
equation using the 24-h urine collection or the Cockcroft-Gault equation to estimate 
the GFR. They found that both variations of the modified Calvert equation were 
superior to the Chatelut equation in terms of accuracy and precision (Okamoto et al., 
1998). 
Investigations on the pharmacokinetics and pharmacodynamics of carboplatin 
have led to the proposal of other methods of tailoring dosage to individual patients, 
particularly in clinical studies. Calvert already proposed in 1994 that TDM should be 
used to ensure an optimal exposure to the desired AUC of carboplatin for the patient. 
From his point of view a limited sampling method would expedit the TDM and 
therefore be more practical. To find a way to integrate TDM for carboplatin into 
clinical practice a variety of limited sampling methods were developed (van 
Warmerdam et al., 1994; Miyazaki et al., 1997; Panday et al., 1999; Chatelut et al., 
2000). In this study the limited sampling method of Sørensen et al. was used. 
Compared to other methods the limited sampling according to Sørensen et al. seemed 
applicable as the sampling times were reasonably close together (0.25h and 2.75h 
post infusion). This allowed integration into clinical practice without significant patient 
burden, keeping in mind that the advantage of the applied chemotherapy regimen 
(paclitaxel/carboplatin) is its application in outpatient settings. In order to improve the 
precision the two-sample method was chosen. This method proved to be unbiased 
(MPE% ± SD, -2.2% ± 2.1%) and precise (RMSE%, 9.4%) (Sorensen et al., 1993). 
Patients tolerated the blood sampling well, although they did not have an immediate 
personal benefit from the intervention. It also integrated without difficulty into the 
usual clinical routine. Limited sampling models such as this rely on accurate sampling 
times so this might sometimes be a limitation in everyday clinical practice (van 
Warmerdam et al., 1994; Miyazaki et al., 1997; Panday et al., 1999; Chatelut et al., 
2000). 
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Huitema and colleagues introduced an advanced method to predict carboplatin 
exposure. They developed and validated a sparse data Bayesian method for the 
estimation of carboplatin exposure (Huitema et al., 2000a). An open two-compartment 
model with first-order elimination from the central compartment underlies this method. 
The data was fitted with the NONMEM population pharmacokinetic programme. The 
advantage of their model is the independence of exact infusion and sampling times. 
The method allows an unbiased and precise prediction of the carboplatin exposure of 
high-dose chemotherapy regimens. 
Calvert and Egorin just recently published an editorial on the evaluation of 
carboplatin dosing equations (Calvert and Egorin, 2002a). They conclude that all 
predictive dosage methods lack precision. They support the results of the studies 
discussed above, especially that the use of the Cockcroft-Gault equation and the 
Jelliffe equation lead to immense under-exposure of carboplatin. They deem the 
Chatelut equation as being more precise in the prediction of carboplatin clearance and 
more useful for everyday clinical practice. Calvert and Egorin (2002) judged the 
various limited sampling methods as accurate methods to predict carboplatin 
exposure, but think that due to the necessity of rapid measurements their use might be 
limited to special circumstances such as paediatric practice or high-dose regimens. 
They point out that future investigations should focus on deriving more convenient 
methods for estimating renal function than the 51Cr-EDTA method, and on developing 
precise methods for achieving a target AUC. Future studies should also focus on 
validating equation-based dosing in combination therapies where there may be 
pharmacokinetic or -dynamic interactions. Duffull and Robinson additionally point out 
that any discussion about precise and unbiased dosing is idle as long as relationships 
between AUC and outcome are not clearly defined (Duffull and Robinson, 1997).  
The relationship between AUC and haematological toxicity has been described 
in a few studies (Egorin et al., 1984; Jakobsen et al., 1997). Jodrell et al. showed that 
the risk of developing a grade 3 thrombocytopenia increased rapidly at AUC values 
above 5-6 mg⋅min/mL (Jodrell et al., 1992). The documentation of the haematological 
toxicity in this study is too fragmentary to derive conclusions, but the available data 
suggests that the dosage of the antineoplastic agents never reached levels that would 
cause dose-limiting toxicities. Either the potential protective effect of paclitaxel or the 
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fact that all patients were under-exposed to carboplatin could have contributed to this 
(Kearns et al., 1995; Kearns and Egorin, 1997). The principles of antineoplastic 
therapies that the maximum tolerated dose that has proved to be effective should be 
given to the patient, was not met in this observed patient collective. 
The inaccuracy of the individual dosage is only the end of the chain of 
deficiencies in the complexities of carboplatin dosing. Many of the clinical studies 
conducted to find the optimal dose of carboplatin for the treatment of epithelial 
ovarian cancer are based on estimations rather than on pharmacokinetically guided 
dosage (du Bois et al., 1997; Neijt et al., 2000; Ozols et al., 2003). Therefore it can be 
assumed that the described dosage inaccuracies already apply for the studies. The 
conclusions drawn from those studies based on observed outcome parameters are 
most probably scattered due to variability in the actual AUC and biased due to 
systemati differences between actual and target AUC of the study population. 
Additionally, among studies and even within some studies the dosage methods vary 
(Neijt et al., 2000). This leads to additional variability and questionable results. Thus, 
knowledge about the inaccuracies of many of the commonly used dosage methods 
alone does not seem to solve the problem. The exact relationship between the 
carboplatin AUC and the antitumour effect remains to be established. Duffull and 
Robinson discuss in their review the problem of insufficient AUC-response data. 
Retrospective studies suggest a response plateau at AUC 5-7 mg⋅min/mL. Newer 
studies consider the possibility of response enhancement when increasing the AUC up 
to 12 mg⋅min/mL (Duffull and Robinson, 1997). Therefore, large-scale PK/PD studies 
are necessary to investigate this issue. In order to achieve interpretable data it is 
mandatory to not only calculate the AUC with the variable estimations but to 
determine the achieved AUC as accurately as possible utilising pharmacokinetic 
methods.  
Overall, patients are under-treated with carboplatin, not due to intolerable side 
effects, but due to suboptimally used dosage strategies. It can therefore be suggested 
that the common practice should be reconsidered and every effort should be made to 
minimise interpatient variability. In practice the available options are not yet fully 
utilised. From what most studies and reviews conclude, the original Calvert equation 
remains the gold standard in predicting the carboplatin exposure. Chatelut provided a 
suitable and more practical alternative. This feasibility study showed that a limited 
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sampling method to support an optimal individual dosing is well tolerated by patients 
and can be integrated into the daily clinical routine. A combination of an estimation 
method with a pharmacokinetically guided dosage on the basis of a limited sampling 
model seems to be a reasonable approach. Here either limited sampling models or 
Bayesian approaches can be considered. These efforts are only exploited to an 
optimum if also the AUC-response relationship is characteriseded in 
pharmacokinetically guided clinical studies. 
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[6] Summary 
6 Summary 
Pharmaceutical care in oncology aims at reducing treatment-related toxicity and 
improve patients’ quality of life. The objective of this pilot study was to develop a 
specific pharmaceutical care model for breast and ovarian cancer including patient 
counselling, optimisation of supportive medication and the implementation of a 
therapeutic algorithm for antiemetic prophylaxis. Additionally, it is the objective of this 
pilot study to assess the value and feasibility of therapeutic drug monitoring in 
outpatient settings for patients treated with antineoplastic agents, in particular 
carboplatin and its contribution to pharmaceutical care. 
Patients with breast or ovarian cancer treated with chemotherapy for the first 
time were included. The feasibility and outcome of this pharmaceutical care model 
was investigated using a prospective, multi-centred, sequential control group design. 
Quality of life (QoL) served as the primary endpoint. Patient satisfaction with the 
information on cancer treatment and the response to the antiemetic treatment were 
evaluated as secondary endpoints.  
The results regarding the health-related quality of life were difficult to interprete. 
Looking at the complete treatment period the global health status/QoL decreased in 
the control group in the median relatively to the baseline by 14% compared to only 
6% in the intervention group by (p = 0.563, Mann-Whitney U-test). The quality of life 
could not be improved but stabilised in comparison to the control group. For certain 
symptom scales an improvement could be achieved (e.g. pain, constipation) which 
was not statistically significant. 
The global satisfaction with information on cancer treatment was significantly 
improved throughout the study (CG: median = 3.94, IG: median = 4.41, p = 0.014, 
Mann-Whitney U-test). Two of the 4 subscales also improved significantly. The 
patients’ perception of pharmacists much improved throughout the study. Only 15% 
of the patients in the control group described the pharmacist as one of their most 
important sources of information compared to 68.4% in the intervention group. This 
increase was statistically significant (p = 0.001, Mann-Whitney U-test). 
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The strongest criterion to assess the success of the prevention of nausea and 
emesis is the complete response (CR) to the antiemetic treatment. Looking at the full 
treatment period for the intervention group an increase in the number of cycles with 
CR in emesis could be achieved (p = 0.155). The incidence of nausea could not be 
improved by the intervention. 
The monitoring of carboplatin confirmed results of previous earlier publications 
on this topic. In the median the achieved AUC differed from the target AUC by 21.7%. 
The doses necessary to achieve the target AUC would have needed to be in the mean 
31.1% (SD 13.65%) higher than the actual dose given.  
This pilot study can be rated as an inital contribution to the development of 
pharmaceutical care models in oncology. Patients with breast and ovarian cancer 
seem to benefit from pharmaceutical care as demonstrated by improved clinical and 
subjective outcomes. The pharmaceutical care model was feasible and integrated in 
the daily routine. It was well accepted by patients and health care providers.  
The results of the TDM show a necessity to reconsider the individual dosing 
strategies for carboplatin in combination with paclitaxel. It proved to be feasible in the 
outpatient setting and was tolerated by the patients. 
In future pharmaceutical care research in oncology further effort should be made 
to develop improved outcome parameters which are capable of reflecting the impact 
of pharmaceutical care and allow conclusions on the quality of care. Additionally it 
should focus on additional aspects such as further patient needs, pharmacoeconomic 
aspects and standardisation for the integration into disease management programmes. 
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Appendix A 
Patient satisfaction with information on cancer treatment 
Tab. A- 2 Alpha-if-item deleted values of the pre-test 
 
 Alpha-if-item deleted
I am satisfied with the information I have been given about my 
cancer treatment. 
0.92  
I am satisfied with the information I have been given about 
possible side effects of my treatment. 
0.92  
I am satisfied with the information I have been given on what to 
do if side effects happen. 
0.91  
I am satisfied with the answers to my questions about vitamins, 
herbs, and complementary therapies. 
0.91  
I am satisfied with the explanations about possible interactions 
between my prescribed cancer treatment and other treatments 
I amusing or thinking about using. 
0.92  
I am satisfied with the way treatment information is presented 
to me. It is clear and easy to understand. 
0.92  
I am satisfied that I get enough opportunity to ask questions 
about my cancer treatment. 
0.91  
I am satisfied that I get enough opportunity to ask questions 
about how to manage side effects. 
0.91  
I am satisfied that I get enough opportunity to ask questions 
about the use of vitamins, herbs, and complementary therapies.
0.91  
I am satisfied with the available information resources such as 
the handouts and staff.  
0.92  
Overall, I am satisfied with the manner in which the information 
is provided. It is friendly, respectful and non-judgemental. 
0.92  
I am satisfied that I am able to make informed choices about 
my cancer treatment. 
0.92  
I am satisfied that I am able to make informed choices about 
how to manage side effects. 
0.92  
I am satisfied that I am able to make informed choices about 
vitamins, herbs, and complementary therapies. 
0.92  
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Tumour classification and staging 
Tab. B-1 TNM classification of breast cancer 
TNM Diagnostic findings 
TX  Primary tumour cannot be assessed 
T0  No evidence of primary tumour 
Tis  Carcinoma in situ 
T1  Tumour is 2cm or less in greatest dimension 
 T1a 0.5 cm or less in greatest dimension 
 T1b 0.5-1cm in greatest dimension 
 T1c 1-2cm in greatest dimension 
T2  2-5cm in greatest dimension 
T3  More than 5cm in greatest dimension 
T4  Tumour of any size with direct extension to chest wall or skin 
 T4a Extension to chest wall 
 T4b Edema or ulceration of the skin 
 T4c Both 4a and 4b 
 T4d Inflammatory carcinoma 
N Nx Regional lymph nodes cannot be assessed 
 N0 No regional lymph node metastasis 
 N1 Metastasis to ipsilateral axillary nodes 
 pN1a Only micrometastasis (<0.2cm) 
 pN1b Metastasis to lymph nodes any larger than 0.2cm 
 N2 Metastasis to ipsilateral axillary nodes fixed to one another or to other 
structures 
 N3 Metastasis to ipsilateral internal mammary lymph nodes 
MX  Distant metastasis cannot be assessed 
M0  No evidence of distant metastasis 
M1  Distant metastasis are present 
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Tab. B-2 Stages of ovarian cancer according to TNM and FIGO 
TNM FIGO Diagnostic findings 
T1  I  Tumour is limited to one or both ovaries 
 T1a  Ia Tumour is limited to one ovary. The capsule, or outer wall of 
the tumour, is intact, there is no tumour on the ovarian surface, 
and there are no cancer cells in ascites (abdominal fluid build-
up) or peritoneal lavage (“washings” from the abdominal 
cavity). 
 T1b  Ib Tumour is limited to both ovaries. The capsule is intact, there is 
no tumour on the ovarian surface, and there are no cancer 
cells in ascites or peritoneal lavage. 
 T1c  Ic Tumour is limited to one or both ovaries with any of the 
following: ruptured capsule (burst outer wall of the tumour), 
tumour on ovarian surface, or cancer cells in the ascites or 
peritoneal lavage. 
T2  II  Tumour involves one or both ovaries with spread into the 
pelvis. 
 T2a  IIa Tumour has spread and/or attaches to the uterus and/or 
fallopian tubes. There are no cancer cells in ascites or 
peritoneal lavage. 
 T2b  IIb Tumour has spread to other pelvic tissues. There are no cancer 
cells in ascites or peritoneal lavage. 
 T2c  IIc Tumour has spread to pelvic tissues, with cancer cells in ascites 
or peritoneal lavage. 
T3  III  Tumour involves one or both ovaries, with microscopically 
confirmed peritoneal metastasis outside the pelvis and/or 
metastasis to regional (nearby) lymph node(s). 
 T3a  IIIa Microscopic peritoneal metastasis beyond the pelvis. 
 T3b  IIIb Macroscopic (visible to the naked eye) peritoneal metastasis 
beyond the pelvis, 2 cm or less in greatest dimension. 
 T3c  IIIc Peritoneal metastasis beyond the pelvis, more than 2 cm in 
greatest dimension. 
N Nx   Regional lymph nodes not judgable 
 N0   Regional lymph nodes contain no metastasis. 
 N1   Evidence of lymph node metastasis. 
M1  IV  Distant metastasis are present 
Appendix 
Appendix C 
Levels of evidence and grades of recommendation 
Tab. C-1 Levels of evidence (Gralla et al., 1999) 
Level Type of Evidence 
I Evidence is obtained from meta-analysis of multiple, well-designed, controlled 
studies. Randomised trials have low false-positive and low false-negative 
errors (high power). 
II Evidence is obtained from at least one well designed experimental study. 
Randomised trials have high false-positive and/or –negative errors (low 
power). 
III Evidence is obtained from well-designed, quasi-experimental studies such as 
non-randomised, controlled, single group, pre-post, cohort, time or matched 
case-control series. 
IV Evidence is from well designed, non-experimental studies, such as 
comparative and correlational descriptive and case studies. 
V Evidence is from case reports and clinical examples. 
 
Tab. C-2 Grades of recommendation (Gralla et al., 1999)  
A There is evidence of type I or consistent findeings from multiple studies of 
types II, III, IV. 
B There is evidence of types II, III and IV and findings are generally consistent. 
C There is evidence of types II, III and IV, but findings are inconsistent. 
D There is little or no systematic empirical evidence. 
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Appendix D 
Standard operating procedures 
Standard Operating Procedure – SOP 01
Aufnahme der Patientinnen in das Projekt
Der Prüfarzt, der die Rekrutierung der Patientinnen für das Projekt 
"Pharmazeutische Betreuung onkologischer Patienten vor, während und nach 
ambulanter Chemotherapie" vornimmt, sollte die im folgenden dargestellten 
Aspekte beachten.
Die Patientinnen, die in das Projekt einbezogen werden, müssen folgenden 
Kriterien gerecht werden:
Einschlusskriterien:
1. Ärztliche Diagnose eines Mamma- oder Ovarialkarzinoms
2. Erstmalige Behandlung mit Zytostatika
3. Alter von 18 bis 65 Jahren
4. Schriftliche Einwilligung der Patientin
5. Kenntnis der deutschen Sprache
Ausschlusskriterien:
Erkrankungen, die es ausschließen, dass die Patientin die Aufklärung zu Art und 
Inhalt der Studie versteht und die ausschließen, dass  die Fragebögen richtig 
verstanden werden und eigenständig ausgefüllt werden können. (z.B. Morbus 
Alzheimer)
Die Patientin muss, gemäß der „Good Clinical Practice for Trials on Medicinal
Products in the European Community“ (Note for Guidance
(11.07.1990):III/3976/88-EN, Anlage 2), mündlich und schriftlich informiert 
werden. Die Information muss angemessen, vollständig und gut verständlich 
sein und die Patientin über die Studie, ihre Ziele, den voraussichtlichen Nutzen, 
die voraussichtlichen Risiken und Unannehmlichkeiten, sowie die Patientin über 
ihre Rechte und Verantwortlichkeiten in Kenntnis setzen.
Für die Patientin sind, abhängig vom Primärtumor und dem Zeitpunkt der 
Rekrutierung, Informationsmaterialien vorbereitet, die ihr während des 
Informationsgespräches ausgehändigt werden. Jede Patientin wird die 
Information zu den Hintergründen und Zielen des Projektes erhalten. 
 
To be continued on the following page 
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Zusätzlich bekommen die Patientinnen Informationen entsprechend dem 
Primärtumor und der Gruppenzugehörigkeit:
I.Mamma-Karzinom
a) Kontrollgruppe Patienteninformation-„Brustkrebs-Kontrolle“
b) Interventionsgruppe Patienteninformation-„Brustkrebs-Intervention“
II.Ovarial-Karzinom
a)  Kontrollgruppe Patienteninformation-„Eierstockkrebs-Kontrolle“
b) Interventionsgruppe Patienteninformation-„Eierstockkrebs-Intervention“
Die Informationsmaterialien sind dem beigefügten Datenträger im 
Prüfarztordner zu entnehmen.
Der Patientin ist bis zur Entscheidung über die Teilnahme am Projekt 
angemessen Zeit einzuräumen (etwa bis zum folgenden Arzttermin). 
Die Einwilligungserklärung (ebenfalls vom Datenträger zu entnehmen) muss 
sowohl 
vom Prüfarzt mit aktuellem Datum versehen und eigenhändig unterzeichnet 
werden, als auch von der Patientin.
Unterschrift des Unterschrift des Unterschrift des
leitenden Prüfarztes Projektleiters Wiss. Mitarbeiters
_________________ ___________________   ___________________
Ort, Datum Ort, Datum Ort, Datum
Dr. med. Jan Dünnebacke Prof. Dr. Ulrich Jaehde Andrea Liekweg
_____________________________________________________________________
Rheinische Friedrich-Wilhelms-Universität Bonn
Pharmazeutisches Institut
Klinische Pharmazie
Prof. Dr. U. Jaehde
Appendix 
 
 
Standard Operating Procedure – SOP 02
Erhebung allgemeiner Patientendaten mit Hilfe des Prüfbogens
Um die Ergebnisse der Untersuchung angemessen darstellen zu können, ist es 
wichtig, dass eine vollständige Zusammenfassung der Information über die an 
der Studie teilnehmende Person verfügbar ist. Dies wird durch die Verwendung 
eines Prüfbogens gemäß „Good Clinical Practice for Trials on Medicinal
Products in the European Community“ (Note for Guidance
(11.07.1990):III/3976/88-EN, Anlage 2) erreicht, der die Ziele des Prüfplans 
berücksichtigt. 
Für jede in die Studie aufgenommene Patientin werden alle auf dem Prüfbogen 
vermerkten Daten eingetragen. 
Ein Exemplar des Prüfbogens verbleibt beim behandelnden Prüfarzt, eine 
weitere Kopie wird an den betreuenden Apotheker weitergeleitet.
Änderungen, die sich über den Behandlungszeitraum ergeben, werden im 
Prüfbogen vermerkt und an alle mitverantwortlichen Personen weitergeleitet.
Eine Liste der Adressen aller an der Studie mitwirkenden Personen befindet sich 
im Prüfungsordner.
Eine Dokumentenvorlage des Prüfbogens ist dem Datenträger des 
Prüfungsordners zu entnehmen.
Unterschrift des Unterschrift des Unterschrift des
leitenden Prüfarztes Projektleiters Wiss. Mitarbeiters
_________________ ___________________   ___________________
Ort, Datum Ort, Datum Ort, Datum
Dr. med. Jan Dünnebacke Prof. Dr. Ulrich Jaehde Andrea Liekweg
_____________________________________________________________________
Rheinische Friedrich-Wilhelms-Universität Bonn
Pharmazeutisches Institut
Klinische Pharmazie
Prof. Dr. U. Jaehde
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tandard Operating Procedure – SOP 03
Ärztliche Dokumentation
Das Projekt “Pharmazeutische Betreuung onkologischer Patienten vor, während 
und nach ambulanter Chemotherapie” erfordert über den gesamten 
Prüfungszeitraum eine fortlaufende Dokumentation seitens der beteiligten 
Ärzte.
Dokumentiert werden müssen:
•die verabreichte Therapie (Chemotherapie und Begleittherapie)
•der anschließend an die Therapie erhobene Befindungszustand der Patientin
mit Hilfe der Common Toxicity Criteria des NCI, Version 2.0 Publish Date:    
April 30, 1999 
•die Ausgabetermine der Fragebögen
Um eine einheitliche Dokumentation gewährleisten zu können, stehen 
Dokumentationsbögen zur Verfügung.
Die Dokumentenvorlagen der jeweiligen Exemplare (siehe Anhang) sind dem 
Datenträger im Prüfungsordner zu entnehmen.
Nach Bearbeitung der jeweiligen Dokumentationsbögen ist eine Kopie an den 
betreuenden Apotheker weiterzuleiten. Das Original verbleibt im 
Prüfungsordner. 
Unterschrift des Unterschrift des Unterschrift des
leitenden Prüfarztes Projektleiters Wiss. Mitarbeiters
_________________ ___________________   ___________________
Ort, Datum Ort, Datum Ort, Datum
Dr. med. Jan Dünnebacke Prof. Dr. Ulrich Jaehde Andrea Liekweg
_____________________________________________________________________
Rheinische Friedrich-Wilhelms-Universität Bonn
harmazeutisches Institut
Klinische Pharmazie
Prof. Dr. U. Jaehde
S
P
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Standard Operating Procedure – SOP 04
Ausgabe und Rückfluss des EORTC QLQ-C30 Fragebogens
Im Rahmen des Projektes "Pharmazeutische Betreuung onkologischer Patienten 
vor, während und nach ambulanter Chemotherapie" werden Daten zur 
Lebensqualität der Patientinnen erhoben.
Dies geschieht mit Hilfe des EORTC QLQ-C30 Fragebogens (Version 3.0).
Der Fragebogen soll zu drei Zeitpunkten von der Patientin ausgefüllt werden. 
• Vor Beginn der zytostatischen Therapie
• Nach der 1. Hälfte der Zyklen
• Nach Abschluss der Therapie
Die Ausgabe der Fragebögen erfolgt am Anfang der Studie. Der Prüfarzt wird 
gebeten, der Patientin einen Ordner mit drei unausgefüllten, durch-
nummerierten Fragebögen und den dazugehörigen frankierten und adressierten 
Rückumschlägen auszuhändigen. Der Fragebogen soll erläutert und mögliche 
Fragen der Patientin beantwortet werden. Die Ausgabe sollte auf dem 
Dokumentationsbogen für Fragebögen festgehalten werden.
Der Arzt soll die Patientin bitten, den ersten Fragebogen noch am Tag der 
Ausgabe zu Hause auszufüllen und in einen der Rückumschläge zu stecken und 
an die Universität Bonn zu schicken. Die Aufforderung die weiteren 
Fragebögen auszufüllen, wird der Patientin telefonisch, bzw. postalisch durch 
den betreuenden Apotheker mitgeteilt. Die Fragebögen sollen jeweils etwa 
eine Woche nach dem jeweiligen Zyklus ausgefüllt werden.
Eine Kopie des Fragebogens wird dem Prüfarzt von der Universität Bonn 
zugesendet.
Die Fragebögen gehen gesammelt bei der Universität Bonn ein und werden 
dort mit Hilfe des Scoring Manuals ausgewertet. 
Unterschrift des Unterschrift des Unterschrift des
leitenden Prüfarztes Projektleiters Wiss. Mitarbeiters
_________________ ___________________   ___________________
Ort, Datum Ort, Datum Ort, Datum
Dr. med. Jan Dünnebacke Prof. Dr. Ulrich Jaehde Andrea Liekweg
_____________________________________________________________________
Rheinische Friedrich-Wilhelms-Universität Bonn
Pharmazeutisches Institut
Klinische Pharmazie
Prof. Dr. U. Jaehde
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Standard Operating Procedure – SOP 05
Ausgabe und Rückfluss des Fragebogens zu Nausea und Emesis
Im Rahmen des Projektes "Pharmazeutische Betreuung onkologischer Patienten 
vor, während und nach ambulanter Chemotherapie" werden Daten zu Übelkeit 
und Erbrechen der Patientinnen erhoben.
Dies geschieht mit Hilfe eines Fragebogens, der die beiden Parameter über 
einen Zeitraum von 5 Tagen nach der Therapie abfragt.
Der Fragebogen soll nach jedem Therapiezyklus von der Patientin ausgefüllt 
werden. 
Die Ausgabe der Fragebögen erfolgt am Therapietag durch den Prüfarzt. Der 
Fragebogen soll erklärt werden und möglich Fragen der Patientin beantwortet 
werden. Mit jedem Fragebogen wird gleichzeitig ein frankierter und adressierter 
Rückumschlag ausgegeben, in dem die ausgefüllten Bögen an die Universität 
Bonn zurückgesendet werden sollen. Vor der Ausgabe sind die Details der 
Patientin und die Medikation vom Prüfarzt in den Fragebogen einzutragen. Die 
Ausgabe sollte auf dem Dokumentationsbogen für Fragebögen festgehalten 
werden.
Der Arzt soll die Patientin bitten noch am Tag der Ausgabe mit dem Ausfüllen 
des Fragebogens zuhause zu beginnen, ihn nach 5 Tagen in den Rückumschlag 
zu stecken und an die Universität Bonn zu schicken.
Eine Kopie des Fragebogens wird dem Prüfarzt von der Universität Bonn 
zugesendet.
Die Fragebögen gehen gesammelt bei der Universität Bonn ein und werden 
dort mit Hilfe des Scoring Manuals ausgewertet. 
Unterschrift des Unterschrift des Unterschrift des
leitenden Prüfarztes Projektleiters Wiss. Mitarbeiters
_________________ ___________________   ___________________
Ort, Datum Ort, Datum Ort, Datum
Dr. med. Jan Dünnebacke Prof. Dr. Ulrich Jaehde Andrea Liekweg
_____________________________________________________________________
Rheinische Friedrich-Wilhelms-Universität Bonn
harmazeutisches Institut
Klinische Pharmazie
Prof. Dr. U. Jaehde
P
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Standard Operating Procedure – SOP 06
Ausgabe und Rückfluss des Fragebogens zur Patientenzufriedenheit
Im Rahmen des Projektes "Pharmazeutische Betreuung onkologischer Patienten 
vor, während und nach ambulanter Chemotherapie" werden Daten zur 
Zufriedenheit der Patientinnen mit der Information bezüglich ihrer 
Krebserkrankung erhoben.
Dies geschieht mit Hilfe eines Fragebogens, der verschiedene Bereiche abfragt.
•Krebsbehandlung
•Mögliche Nebenwirkungen und deren Management
•Alternativtherapien
•Informationsquellen
Der Fragebogen soll nach Beendigung aller Zyklen von der Patientin ausgefüllt 
werden. 
Die Ausgabe der Fragebögen erfolgt durch den betreuenden Apotheker. Der 
Fragebogen soll erklärt werden und mögliche Fragen der Patientin beantwortet 
werden. Mit dem Fragebogen wird gleichzeitig ein frankierter und adressierter 
Rückumschlag ausgegeben, in dem der ausgefüllte Fragebogen an die 
Universität Bonn zurückgesendet werden soll. 
Eine Kopie des Fragebogens wird dem Prüfarzt von der Universität Bonn 
zugesendet.
Die Fragebögen gehen gesammelt bei der Universität Bonn ein und werden 
dort mit Hilfe des Scoring Manuals ausgewertet. 
Unterschrift des Unterschrift des Unterschrift des
leitenden Prüfarztes Projektleiters Wiss. Mitarbeiters
_________________ ___________________   ___________________
Ort, Datum Ort, Datum Ort, Datum
Dr. med. Jan Dünnebacke Prof. Dr. Ulrich Jaehde Andrea Liekweg
_____________________________________________________________________
Rheinische Friedrich-Wilhelms-Universität Bonn
Pharmazeutisches Institut
Klinische Pharmazie
Prof. Dr. U. Jaehde
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Standard Operating Procedure – SOP 07
Therapeutisches Drug Monitoring – TDM
Schema zur Entnahme der Blutproben
Im Rahmen des Projektes "Pharmazeutische Betreuung onkologischer Patienten 
vor, während und nach ambulanter Chemotherapie" wird für die an Ovarial-
Karzinom leidenden Patientinnen, die mit einer Kombination aus Paclitaxel
und Carboplatin behandelt werden, ein Therapeutisches Drug Monitoring
durchgeführt. Dazu ist die Entnahme zweier außerroutinemäßiger 
Blutproben notwendig. 
Die Proben müssen in PVC-freie heparinisierte Monovetten® aufgezogen 
werden. Die Monovetten® werden bereits beschriftet an die Praxis 
geliefert. Das Probenvolumen sollte 10 mL nicht unterschreiten.
Folgende Probenentnahmezeiten sind wichtig und möglichst einzuhalten:
1. Probe 15 min. nach Beendigung der Carboplatin-Infusion
2. Probe 2h 45 min. nach Beendigung der Carboplatin-Infusion
Unmittelbar nach den Probennahmen sind diese im vorliegenden 
Dokumentationsbogen festzuhalten. Der Dokumentationsbogen wird mit 
den Proben zusammen an die Universität Bonn geliefert. Innerhalb einer 
Stunde nach der Entnahme muss die Probenaufarbeitung (siehe SOP 08) 
abgeschlossen sein.
Unterschrift des Unterschrift des Unterschrift des
leitenden Prüfarztes Projektleiters Wiss. Mitarbeiters
_________________ ___________________   ___________________
Ort, Datum Ort, Datum Ort, Datum
Dr. med. Jan Dünnebacke Prof. Dr. Ulrich Jaehde Andrea Liekweg
_____________________________________________________________________
Rheinische Friedrich-Wilhelms-Universität Bonn
harmazeutisches Institut
Klinische Pharmazie
Prof. Dr. U. Jaehde
P
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Standard Operating Procedure – SOP 08
Therapeutisches Drug Monitoring – TDM
Probenaufarbeitung
Im Rahmen des Projektes "Pharmazeutische Betreuung onkologischer Patienten 
vor, während und nach ambulanter Chemotherapie" wird für die an Ovarial-
Karzinom leidenden Patientinnen, die mit einer Kombination aus Paclitaxel und 
Carboplatin behandelt werden, ein Therapeutisches Drug Monitoring
durchgeführt. Die für diesen Zweck entnommenen Blutproben müssen nach 
einem vorgegeben Schema aufgearbeitet werden.
Probenaufarbeitungsprotokoll
Einfrieren
-20°C
Abfüllung von Plasma
mind. 5 x 500 µl in mit dem Probencode 
beschriftete Röhrchen 
Blutprobe 
10 ml Blut (siehe Protokoll), 
heparinisierte, PVC-freie Gefäße verwenden 
(Monovetten®)
Plasmagewinnung
Zentrifugation
5 min, 3200 g, Raumtemperatur
Ultrafiltratgewinnung
aus zwei Aliquoten 
von je 1ml Plasma 
in Centrifree-Ultrafiltrationsröhrchen Amicon® Millipore
No. 4104
20 min, 2000 g , Raumtemperatur
Abfüllung von Ultrafiltrat
mind. in 2 mit dem Probencode beschriftete 
Röhrchen 
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Die Entnahmezeitpunkte richten sich nach den Zeitpunkten der Beendigung 
der jeweils letzten Infusion. Diese sind genau zu dokumentieren.
Blut soll aus dem, der Injektionsstelle gegenüberliegenden Arm entnommen 
werden.
Eine Kontamination mit der Infusionslösung muss ausgeschlossen werden.
Alle Arbeitsschritte müssen innerhalb einer Stunde abgeschlossen sein.
Die Vorgänge sollten genau dokumentiert werden und das Formular mit den 
Proben mitgeliefert werden. (siehe SOP 07)
Unterschrift des Unterschrift des Unterschrift des
leitenden Prüfarztes Projektleiters Wiss. Mitarbeiters
_________________ ___________________   ___________________
Ort, Datum Ort, Datum Ort, Datum
Dr. med. Jan Dünnebacke Prof. Dr. Ulrich Jaehde Andrea Liekweg
_____________________________________________________________________
Rheinische Friedrich-Wilhelms-Universität Bonn
Pharmazeutisches Institut
Klinische Pharmazie
Prof. Dr. U. Jaehde
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Appendix E 
Patient information material 
Was Sie über diese Studie wissen sollten!
Patientinneninformation
Pilotstudie 
zur Pharmazeutischen Betreuung
onkologischer Patienten vor, während und nach 
ambulanter Chemotherapie
Prospektive, kontrollierte, multizentrische Studie 
zu Durchführbarkeit und Nutzen 
Pharmazeutischer Betreuung
von Tumorpatienten einschließlich
des Therapeutischen Drug Monitorings ausgewählter 
Zytostatika.
ti ti i f ti
il t t i  
r r ti  tr
l i r ti t  r, r    
l t r t r i
r s ti , tr lli rt , ltiz tris  t i  
z  r f r r it  tz  
r z tis r tr
 T r ti t  i s li li
s T r tis  r  it ri s s lt r 
t st ti .
Pharmazeutisches Institut
Klinische Pharmazie
Prof. Dr. Ulrich Jaehde
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Pharmazeutische Betreuung onkologischer Patienten
Einführung
Sehr geehrte Patientin,
Sie sind dabei eine Chemotherapie zu beginnen. Sie sind im Moment sicher 
besorgt über das, was nun auf Sie zukommen mag. In der kommenden Zeit 
wird sich ein Team aus Ärzten, Pflegenden und anderen besorgten Menschen 
um Sie kümmern, um Ihre Behandlung möglichst gut und belastungsarm zu 
gestalten.
Wir möchten in dieser Studie herausfinden, ob es sinnvoll ist 
Chemotherapiepatientinnen rund um ihre Therapie zusätzlich durch einen 
Apotheker zu betreuen und zu informieren; ob diese neue Form der
Unterstützung den Patientinnen wirklich nützt, oder sie eher belastet.
Um dies herauszufinden sind wir auf Ihre Hilfe angewiesen.
In dem Ihnen vorliegenden Informationsmaterial wird Ihnen die geplante Studie 
genau vorgestellt. Es wird beschrieben, welche Überlegungen zur Planung der 
Studie geführt haben, wie die Studie ablaufen soll und was eine Teilnahme für 
Sie als Patientin ganz praktisch bedeuten würde.
Nehmen Sie sich für das Lesen ruhig viel Zeit. Legen Sie die Unterlagen 
zwischendurch beiseite, um darüber nachzudenken. Machen Sie sich überall im 
Heft Notizen zu den Dingen, die Sie gerne noch mit uns klären würden.
Sollte Ihnen während des Lesens irgend etwas unklar erscheinen oder Fragen 
aufwerfen, so scheuen Sie sich nicht, Ihren behandelnden Arzt, oder die 
verantwortliche Apothekerin Andrea Liekweg anzusprechen.
Vielen Dank für Ihr Interesse und Ihre Mühe und viel Erfolg bei Ihrer 
Behandlung!
Dr. med. Jan Dünnebacke Andrea Liekweg
(Leitender Prüfarzt) (Studien-Apothekerin) 
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1. Hintergründe und Ziele des Projektes
Diese Studie ist ein Projekt der Arbeitsgruppe „Klinische Pharmazie“ der 
Universität Bonn. Pharmazie ist das Fach, welches Apotheker für ihren Beruf 
ausbildet. Klinische Pharmazie ist ein relativ neues Gebiet innerhalb der 
Pharmazie. Durch die Entwicklung des Gesundheitssystems haben sich neue 
Anforderungen an den Apothekerberuf ergeben. Die Rolle des Patienten und 
auch seine Bedürfnisse haben sich gewandelt. Das Fach Klinische Pharmazie soll 
daher dazu beitragen, die Ausbildung und Berufsausübung der Apotheker 
verstärkt im Dienste der Patienten auszurichten. In diesem Zusammenhang 
werden Untersuchungen durchgeführt, anhand derer der Nutzen und die 
Durchführbarkeit patienten-orientierter Leistungen des Apothekers unter Beweis 
gestellt werden sollen.
In Deutschland sind heute ca. 45.000 zugelassene Arzneimittel am Markt 
erhältlich. Mit der wachsenden Zahl an Medikamenten gehen verschiedene 
Probleme einher. Zum einen wird es immer schwieriger, das Angebot zu 
überblicken und alle Neuerungen kritisch zu bewerten, zum anderen steigt die 
Gefahr, Medikamente zu kombinieren, die sich in ihrer Wirkung gegenseitig 
beeinflussen, was möglicherweise zu unerwünschten Wirkungen führen kann.
Diese Entwicklung macht es notwendig, dass alle an einer Therapie Beteiligten, 
also sowohl Sie als Patientin, wie auch die Ärzte und Apotheker, möglichst gut 
zusammenarbeiten, um eine optimale Therapie zu erreichen.
Die Hauptaufgabe des Apothekers besteht darin, Sie rund um Ihre 
Arzneimitteltherapie zu informieren und zu beraten. gerade in einer 
Dauertherapie ist es wichtig, dass der Patient durch den Apotheker begleitet wird 
und möglicherweise aufkommende Fragen und Probleme zu den Medikamenten
direkt beantwortet und beseitigt werden können. 
Die Realität der gegenwärtigen Apothekenpraxis sieht jedoch häufig anders aus. 
Patienten erwerben die vom Arzt verordneten, oder selbst gewählten 
freiverkäuflichen Arzneimittel in der Apotheke und erhalten zu den 
Medikamenten Einnahme- oder Anwendungshinweise. Danach besteht jedoch oft 
wochenlang kein Kontakt mehr zum behandelnden Arzt oder Apotheker.
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Um dieser Aufgabe gerecht zu werden, wurde das Konzept der 
Pharmazeutischen Betreuung entwickelt. Durch eine fortlaufende Betreuung 
soll der Apotheker eine sinnvolle und sichere Arzneimitteltherapie für Sie als 
Patientin gewährleisten.
Da die Idee der Pharmazeutischen Betreuung noch recht jung ist, werden 
derzeit zahlreiche Studien durchgeführt, die Durchführbarkeit und Nutzen 
dieser erweiterten Apotheker-Dienstleistung für verschiedene 
Patientengruppen ermitteln sollen.
Für Krebspatienten hat es bislang in dieser Form noch keine Untersuchung 
gegeben, obwohl gerade diese Patientengruppe besonders 
betreuungsbedürftig ist.
Ziel dieser Untersuchung ist es:
• die Qualität und Sicherheit der Arzneimitteltherapie zu erhöhen
• die Zusammenarbeit von Arzt, Patient und Apotheker zu verbessern
• die Patientenbetreuung in Apotheken weiter zu entwickeln
• die Lebensqualität der Krebspatientinnen zu steigern
• durch Analyse der Konzentrationen der Arzneistoffe im Blut 
Informationen zur optimalen individuellen Dosierung zu erhalten
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Was bedeutet das konkret für Sie als Krebspatientin?
In Ihrem Fall ist eine Chemotherapie - nach dem heutigen Stand der 
wissenschaftlichen Erkenntnisse - Teil einer optimalen Behandlung Ihrer Erkrankung. 
Üblicherweise wird die Chemotherapie mit einer Kombination verschiedener 
Arzneimittel durchgeführt. Die für Sie vorgeschlagene Therapie sieht die Gabe von 
Paclitaxel (Taxol®) in Verbindung mit Carboplatin (Carboplat®) vor. Diese Therapie 
zeichnet sich, wie die Erfahrungen gezeigt haben, durch eine gute Wirksamkeit aus.
Es ist schwierig, die Wirkung der Krebsbehandlung auf die Krebszellen allein zu 
beschränken. Das hat zur Folge, dass auch gesunde Zellen geschädigt werden, was 
zu unangenehmen Nebenwirkungen führen kann.
Das Ausmaß der Nebenwirkungen bei der einzelnen Patientin bei gleich bleibender 
Wirksamkeit der Behandlung zu senken, ist das Ziel dieser Studie. Das bedeutet, 
dass Apotheker sich mehr als bisher üblich in die Gestaltung und Durchführung der 
Therapie einbringen und durch ihr Wissen Ihnen als Patientin einen weiteren Nutzen 
bringen sollen. 
Wenn im Zusammenhang mit dieser Studie von Therapieverbesserung gesprochen 
wird, so ist damit vor allem die so genannte „Supportivtherapie“ gemeint. 
„Supportiv“ bedeutet im eigentlichen Sinne „unterstützend“. Auf die Therapie einer 
Krebserkrankung bezogen sind damit alle Behandlungsmaßnahmen gemeint, die zur 
Vorbeugung und/oder Therapie von unerwünschten Wirkungen (z. B. Übelkeit und 
Erbrechen) eingesetzt werden, die mit der eigentlichen Therapie der 
Krebserkrankung einhergehen können. Auf diese unterstützenden Therapien soll 
besonderes Augenmerk gerichtet werden.
Es soll an dieser Stelle ausdrücklich darauf hingewiesen werden, dass es sich bei der 
geplanten Studie zwar um eine klinische Prüfung handelt, jedoch keine neuen, noch 
nicht erprobten Arzneimittel zum Einsatz kommen.
Des weiteren möchten wir Sie darauf aufmerksam machen, dass sich die betreuende
Apothekerin zwar mit Ihrer Arzneimitteltherapie befasst und diese gemeinsam mit 
Ihnen und den behandelnden Ärzten zu optimieren sucht, es aber keine Rolle spielt, 
woher Sie Ihre Arzneimittel beziehen. Sie können also auch während der Teilnahme 
an dieser Studie, so wie Sie es gewohnt sind, weiter bei den von Ihnen bevorzugten 
Apotheken die Arzneimittel beziehen.  
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2. Konzept der Studie
a) Studiendesign
Der Ausdruck „Studiendesign“ beschreibt,  welche Untersuchungs-Methode der 
Studie zugrunde liegt und auf welche Weise die Ergebnisse zustande kommen sollen.
Diese Studie basiert auf dem sogenannten „ sequenzierten Kontrollgruppen-Design“.
Dieser Ausdruck bedeutet, wie auch aus der oben gezeigten Grafik hervorgeht, dass 
zunächst nur eine Gruppe Patientinnen in die Studie aufgenommen wird, bei der die 
Therapie wie bisher üblich durchgeführt wird. Die Patientinnen dieser 
„Kontrollgruppe“ werden gebeten, bestimmte Fragebögen zu festgelegten 
Zeitpunkten auszufüllen. Außerdem werden alle möglicherweise auftretenden 
Nebenwirkungen von den Ärzten in speziell für die Studie erarbeiteten 
Dokumentationsbögen festgehalten. Dieses Verfahren ist notwendig, um 
Vergleichswerte zu erhalten, die es später ermöglichen, Veränderungen, die durch 
die neu eingesetzte Betreuungsmaßnahme eingetreten sein könnten, zu messen. 
Sobald diese Vergleichswerte vorliegen, wird die nächste Gruppe Patientinnen in die 
Studie aufgenommen. Diese Patientinnen gehören der „Interventionsgruppe“ an. 
Diese Patientinnen werden zusätzliche durch die Studienapothekerin betreut. Eine 
genaue Beschreibung des Betreuungs-ablaufes finden Sie unter Punkt 3. dieses 
Heftes. Auch diese Patientinnen werden gebeten, die gleichen Fragebögen zu den 
gleichen Zeitpunkten im Laufe ihrer Therapie auszufüllen, wie vorher die Patientinnen 
in der Kontrollgruppe. 
Auch bei Patientinnen der Interventionsgruppe werden von den behandelnden 
Ärzten alle möglicherweise auftretenden Nebenwirkungen genau aufgezeichnet.
Abschließend werden die Ergebnisse der Fragebögen und Aufzeichnungen beider 
Gruppen verglichen. Dieser Vergleich wird dann zeigen, ob die zusätzliche 
Betreuung durch einen Apotheker für Krebspatientinnen einen Nutzen hat, oder 
nicht.
Kontrollgruppe
Ergebnisqualitäts-Messung
Interventionsgruppe
Ergebnisqualitäts-Messung
+ Pharmazeutische Betreuung
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Ärzte
Apotheker
Pflegende
Familie/Freunde Patientin
b) Kommunikation
Rund um die Therapie Ihrer Erkrankung sind viele Menschen in sehr 
unterschiedlichen Funktionen darum bemüht, Ihnen die bestmögliche Versorgung 
zukommen zu lassen. Im Zusammenhang mit dieser Studie sind es mehr Personen 
als in der allgemeinen Praxis üblich. Es wird daher angestrebt, alle an Ihrem 
Betreuungsprozess Beteiligten in ein Kommunikationsnetzwerk einzubinden (siehe 
Grafik). Dadurch soll gewährleistet werden, dass keine wichtigen Informationen 
verloren gehen, die für Ihre Behandlung von Bedeutung sein könnten.
3. Ablauf der Studie
Die Betreuung findet im Rahmen Ihrer Chemotherapie statt. 
Die Studien-Apothekerin steht zur Beantwortung aller aufkommenden Arzneimittel-
bezogenen Fragen zur Verfügung und wird versuchen, die Therapie in Abstimmung 
mit dem Arzt und Ihnen als Patientin zu verbessern.
Eine fortlaufende Dokumentation der aktuellen Medikation ist erforderlich, um 
einen Überblick zu bekommen, wie die Arzneimittel vertragen werden.
Die Daten werden ständig verarbeitet und ausgewertet, so dass eine bestmögliche 
Therapiegestaltung erfolgen kann.
Der Nutzen der durchgeführten Betreuung soll durch einen Vergleich mit der 
bisherigen Betreuungssituation gezeigt werden. Hierzu soll die Qualität der 
durchgeführten Betreuung mit verschiedenen Fragebögen zu Lebensqualität, 
Arzneimittelnebenwirkungen und Patienten-Zufriedenheit überprüft werden .
Die Pharmazeutische Betreuung im Rahmen dieser Studie wird von einer 
Apothekerin durchgeführt, die als wissenschaftliche Mitarbeiterin an der Universität 
Bonn tätig ist. Der Kontakt zu ihr wird über Ihren behandelnden Arzt hergestellt, der 
Sie auch über die Möglichkeit informiert hat, an dieser Studie teilzunehmen. 
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a) Studienverlaufsplan
Die Betreuung soll sich dadurch auszeichnen, dass sie Ihren individuellen Bedürfnissen 
gerecht wird. Einen Eindruck, wie Sie sich den Ablauf dieser Studie in etwa vorstellen 
können, soll der folgende Studienverlaufsplan vermitteln.
Im Aufklärungsgespräch werden Sie von der betreuenden Apothekerin über die 
Ziele und Hintergründe der geplanten Studie informiert. 
◊ In diesem Gespräch sollte Ihnen vermittelt werden, was Sie von der Studie 
erwarten können und was als Patientin auf Sie zukommt.
◊Sie erhalten Informationsmaterial zur Studie, welches Sie zu Hause in Ruhe 
lesen können, bevor Sie eine Entscheidung über Ihre Teilnahme treffen.  
Im Verlauf dieses Gespräches haben Sie die Gelegenheit, Fragen zu stellen und sich 
Dinge erläutern zu lassen, die Ihnen unklar erscheinen.
Im folgenden Gespräch können Sie Ihre Entscheidung mitteilen, ob Sie bereit sind, 
an der Studie teilzunehmen, oder lieber davon absehen möchten. Zuvor besteht die 
Möglichkeit, weitere Fragen zu klären.
Falls Sie bereit sind, an der Studie teilzunehmen
◊werden Sie gebeten, Ihr Einverständnis zur Teilnahme an der Studie 
schriftlich zu bestätigen.
◊werden Sie gebeten Ihr Einverständnis zur Speicherung Ihrer persönlichen 
Daten schriftlich zu bestätigen.
◊werden Ihnen die Studienunterlagen (z.B. Fragebögen) ausgehändigt und 
vollständig erläutert sowie Ihre Fragen diesbezüglich beantwortet.
⇒ Die Patientinnen der Kontrollgruppe werden von diesem Gespräch an 
hauptsächlich telefonisch mit der Studien-Apothekerin in Kontakt stehen, 
wenn es zum Beispiel um das Ausfüllen der Fragebögen geht. Außerdem 
werden auch von ihnen bestimmte personenbezogene Daten erhoben (z. B. 
Alter usw.)
⇒ Für die Patientinnen der Interventionsgruppe verläuft der Betreuungsplan 
etwa wie folgt: 
◊ Zunächst wird ein Termin und der Ort für das erste 
Betreuungsgespräch vereinbart.
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Das erste Betreuungsgespräch sollte vor dem ersten Therapiezyklus stattfinden. 
Wenn dies nicht möglich sein sollte, wird ein anderer passender Termin gesucht. 
Während des Gespräches ist geplant
◊ Ihre persönlichen Daten, die für die Betreuung sinnvoll sind (z.B. Alter 
u.ä.) aufzunehmen.
◊ eine Übersicht über die Arzneimittel, die Sie regelmäßig einnehmen, zu 
erstellen.
◊ Fragen zur Arzneimitteltherapie zu klären.
◊ Ihre persönlichen Ziele und Hoffnungen verbunden mit der 
Arzneimitteltherapie zu erörtern und daraus gemeinsam einen Plan zu 
erstellen.
Für die jeweils verabredeten Termine wird Ihnen ein Terminplan mitgegeben.
Die folgenden Betreuungsgespräche sollten möglichst mindestens ein Mal 
zwischen den Therapiezyklen stattfinden. Während dieser Gespräche werden
◊ in der Zwischenzeit aufgekommene Fragen zur Arzneimitteltherapie
geklärt.
◊ Probleme und Wünsche im Zusammenhang mit der Arzneimitteltherapie 
gemeinsam erörtert.
◊Ziele gesteckt, um Ihren Bedürfnissen bestmöglich gerecht zu werden.
◊ Sie über zusätzliche Maßnahmen informiert, die Sie zur Vermeidung von 
Nebenwirkungen, die möglicherweise eintreten können, ergreifen können 
(z.B. gegen Übelkeit und Erbrechen). 
Die Betreuung im Rahmen der Studie endet nach dem letzten Zyklus der derzeit 
verordneten Chemotherapie.
b) Ergebnisqualitätsmessungen
Die im folgenden vorgestellten Fragebögen stellen die „Messinstrumente“ dar, mit 
denen ermittelt werden soll, ob die Pharmazeutische Betreuung in diesen Punkten 
eine Verbesserung herbeiführen kann. Die Fragebögen sind so konzipiert, dass Sie 
von den Patientinnen selbständig ausgefüllt werden können. 
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i. Fragebogen zur Messung der Lebensqualität
Man stellt immer wieder fest, dass die Lebensqualität der Patientinnen für den 
Therapieverlauf von entscheidender Bedeutung ist. Um einen Eindruck zu 
bekommen, inwieweit die Therapie Einfluss auf die Lebensqualität hat, soll zu dieser 
Fragestellung ein Fragebogen ausgefüllt werden. Dieser Fragebogen  wurde speziell 
für Krebspatienten entwickelt. Während der Studienphase wird der Fragebogen zu 
drei Zeitpunkten ausgefüllt.
ii. Fragebogen zur Messung von Übelkeit und Erbrechen
Da die Nebenwirkungen bei jeder Patientin unterschiedlich sein können und auch 
anders empfunden werden, soll mit Hilfe eines Fragebogens zu Übelkeit und 
Erbrechen ermittelt werden, wie gut in jedem einzelnen Fall
die Maßnahmen zur Vermeidung dieser Nebenwirkungen greifen. Dieser 
Fragebogen soll nach jedem Zyklus über 5 Tage (wie eine Art Tagebuch) geführt 
werden. Dadurch soll erfasst werden, ob sowohl das akute Erbrechen (innerhalb der 
ersten 24 Stunden nach Beginn eines Therapiezyklus), als auch das verzögerte 
Erbrechen (Tag 2 bis 5 nach Beginn eines Therapiezyklus) zufriedenstellend
behandelt wird. Die Einträge erfolgen strichlistenartig, so dass kein allzu großer 
Zeitaufwand zu befürchten ist.
iii. Fragebogen zur Messung der Patientenzufriedenheit mit der Information        
zu ihrer Behandlung
Nicht zuletzt ist auch Ihre Zufriedenheit ein Ziel der Studie. Es ist das Anliegen der 
Apotheker, die Betreuung möglichst nach Ihren Bedürfnissen zu gestalten. Um die 
Qualität der Betreuung festzustellen, soll nach Beendigung der Studie die 
Patientenzufriedenheit ermittelt werden. Hierbei wird ein besonderes Augenmerk 
auf die Information gelegt, die Sie zu Ihrer Behandlung erhalten. Anhand der 
ermittelten Ergebnisse können Strategien entwickelt werden, wie Patienten gemäß 
Ihrer individuellen Bedürfnisse informiert werden sollten. Dieser Fragebogen wird 
nur einmal, am Ende der Behandlung, ausgefüllt.
iv.     Verlaufsplan–Ergebnisqualitätsmessungen
Der Verlaufsplan gibt Ihnen eine Übersicht über die verschiedenen 
Ergebnisqualitätsmessungen über den gesamten Zeitraum der Studie.
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c)    Therapeutisches Drug Monitoring
Der Ausdruck „Therapeutisches Drug Monitoring“ kommt aus dem Englischen und 
wird für eine Methode verwendet, bei der die Arzneistoff-Konzentrationen im Blut 
des Patienten zu festgelegten Zeitpunkten bestimmt werden. Häufig können aus 
diesen Werten Rückschlüsse auf den Werdegang des Arzneistoffs im individuellen 
Patienten gezogen werden, was bei der Anpassung der Arzneistoff-Dosis hilfreich 
sein kann.
Im Rahmen dieser Studie soll patientenindividuell überprüft werden, ob zwischen 
den im Blut der einzelnen Patientin auftretenden Konzentrationen Arzneistoff und 
den eintretenden Nebenwirkungen ein Zusammenhang besteht. Diese Information 
soll helfen in Zukunft die individuelle Dosierung der untersuchten Arzneistoffe zu 
optimieren.
Für diese Untersuchung ist es erforderlich, zusätzlich zu den 
Routineuntersuchungen 2 weitere Blutproben von je maximal 10 ml zu entnehmen, 
aus denen die Konzentrationen der Arzneistoffe (Paclitaxel und Carboplatin) 
bestimmt werden. 
Um aussagefähige Messwerte zu erhalten, ist es notwendig, die Proben aus einer 
von der Injektionsstelle verschiedenen Stelle zu entnehmen.
Die Zeitpunkte der Entnahme liegen im Fall der ersten Probe direkt im Anschluss an 
die Beendigung der Infusionen, während die zweite Probe etwa 3 Stunden nach der 
ersten Probe entnommen wird. 
Die Blutproben werden in der Praxis ihres Onkologen, oder in der Ambulanz des 
Krankenhauses entnommen, in der Sie betreut und behandelt werden. 
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4.     Schutz der Patientin
Die Teilnahme an dieser Studie birgt für Sie keine zusätzliche Risiken.
Sie haben selbstverständlich das Recht, jederzeit und ohne Angabe von Gründen 
von der Teilnahme an der Studie zurückzutreten. Es entstehen Ihnen dadurch keine 
Nachteile in Ihrer Behandlung.
a)     Patienteneinverständnis
Wenn Sie dieses Informationsmaterial eingehend gelesen haben und die Ihnen 
aufgekommenen Fragen beantwortet wurden, können Sie frei über die Teilnahme an 
der Studie entscheiden. Ihre Teilnahme bestätigen Sie schriftlich mit einer so 
genannten Patienten-Einverständniserklärung.
b)    Datenschutz
Die Information, die Sie bisher über diese Studie erhalten haben, lässt schon 
vermuten, dass eine Vielzahl von Daten über Ihre Person im Zusammenhang mit 
dieser Studie erfasst werden sollen. Das geschieht allerdings erst, wenn Ihr 
schriftliches Einverständnis dazu vorliegt. 
Zum einen sollen bestimmte, für die Betreuung notwendige Daten aus
Ihrer vom Arzt geführten Patientenakte übertragen werden (z.B. Laborwerte u. ä.). 
Dann sollen hilfreiche Informationen, die gemeinsam mit Ihnen im Gespräch erörtert 
werden, gespeichert werden (z.B. Schwierigkeiten 
oder Unsicherheiten mit der  Arzneimitteltherapie). Außerdem sollen Daten 
gespeichert werden, die neben Ihrer Betreuung speziell zur Auswertung der Studie 
benötigt werden. Das sind zum Beispiel die Ergebnisse der Fragebögen.
Alle Informationen, die zu Ihrer Person erfasst werden sollen, werden in einer 
Computergestützten Datenbank gespeichert. Diese Datenbank wurde speziell für 
diese Studie entwickelt und unterstützt die Apothekerin bei Ihrer Aufgabe Sie 
umfassend zu betreuen. Die Ergebnisse der Studie sollen mit einem 
Statistikprogramm (SPSS®) ausgewertet werden. Dadurch soll auch in Zahlen 
dargestellt werden können, ob die Betreuung durch Apotheker einen Nutzen 
gezeigt hat.
 
 
 
 
to be continued on the following page 
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Die im Zusammenhang mit dieser Studie erhobenen Daten unterliegen den 
Bestimmungen des Datenschutzes und werden ausschließlich zum Zweck der 
Durchführung der Studie erhoben und ausgewertet. Das bedeutet, dass Sie der 
Verwendung Ihrer Daten für Studienzwecke zustimmen müssen, bevor mit der 
Dokumentation begonnen wird. 
Außerdem ist gewährleistet, dass aus Veröffentlichungen der in der Studie 
erhobenen Daten Ihr Name nicht hervorgeht. Die Ergebnisse der Studie werden 
anonymisiert veröffentlicht und stehen Ihnen dann selbstverständlich auf Anfrage 
zur Verfügung.
Nach dem Landesdatenschutzgesetz ist die Durchführung einer solchen Studie 
jedoch nur zulässig, wenn Sie sich mit der Aufzeichnung Ihrer Krankheitsdaten und 
deren Weitergabe an die zentrale Auswertungsstelle einverstanden erklären. Die 
zentrale Anlaufstelle dieser Studie ist die Abteilung Klinische Pharmazie an der 
Universität Bonn. Dort werden alle für Ihre Betreuung und für die abschließende 
Auswertung der Studie notwendigen Daten zusammenlaufen.
c)   Versicherungsschutz
Für die Studie besteht eine Patientenversicherung bei Gerling Industrie Service 
GmbH West, Düsseldorf unter der Versicherungs-Nummer 
70-005539942-2. Um den Versicherungsschutz nicht zu gefährden, darf eine andere 
medizinische Behandlung nur mit dem Einverständnis des Prüfarztes durchgeführt 
werden. Eine Gesundheitsschädigung, die als Folge der Therapie eingetreten sein 
könnte, sollten Sie unverzüglich Ihrem Arzt melden.
Sollten Sie nach der Lektüre dieser Informationen weitere Fragen haben, wenden Sie 
sich bitte jederzeit an Ihren behandelnden Arzt, oder Ihre betreuende Apothekerin.
Sollten Sie nach der Lektüre dieser Informationen weitere Fragen haben, wenden Sie 
sich bitte jederzeit an Ihren behandelnden Arzt, oder Ihre betreuende Apothekerin.
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Appendix F 
Informed consent 
Pharmazeutische Betreuung onkologischer Patienten
vor, während und nach ambulanter Chemotherapie
Patienten-Einverständniserklärung
Hiermit erkläre ich, ______________________________, an der oben genannten 
Studie teilzunehmen.
Ich bestätige, dass ich von Dr. med.__________________ und der/dem Apotheker(in) 
____________________ in Anwesenheit des Zeugen ________________________ 
über diese Studie aufgeklärt wurde. Mir wurde ausreichend Zeit für die Entscheidung 
über die Teilnahme an der Studie eingeräumt.
Ich bin bereit, die an mich ausgegebenen Fragebögen zu "Lebensqualität", "Übelkeit 
und Erbrechen" und „Patientenzufriedenheit“ ordnungsgemäß auszufüllen und die 
Beratungstermine mit der Prüfapothekerin wahrzunehmen.
Ich bin damit einverstanden, dass mir jeweils am Tag der Chemotherapie zwei 
zusätzliche Blutproben entnommen werden.
Ich wurde darüber aufgeklärt, dass ich die Teilnahme an dieser Untersuchung 
ablehnen kann und dass mir aus der Ablehnung keine Nachteile für die weitere 
Therapie entstehen.
Ich habe ein Exemplar des Aufklärungsbogens und dieser Einwilligungserklärung 
erhalten. Die Aufklärung über die Studie war mir in allen Punkten verständlich.
_____________ , den ____________ _____________________
Ort Datum Unterschrift der Patientin
___________________ __________________ _____________________
Unterschrift Unterschrift Unterschrift 
des Arztes des Apothekers des Zeugen
Rheinische Friedrich-Wilhelms-Universität Bonn
Pharmazeutisches Institut, Klinische Pharmazie
Prof.  Dr. Ulrich Jaehde
 
Appendix 
 
Appendix G 
Privacy statement 
Pharmazeutische Betreuung onkologischer Patienten
vor, während und nach ambulanter Chemotherapie
Datenschutz-Erklärung
Ich, _______________________________, erkläre mich damit einverstanden, dass 
meine im Rahmen des Projektes erhobenen Krankheitsdaten (Studiendaten) 
aufgezeichnet und zur Überprüfung an die Studienzentrale zur Auswertung 
weitergegeben werden. Ich bin damit einverstanden, dass vom Projektleiter 
bevollmächtigte Personen meine originalen Krankenakten sowie die originalen 
Studiendaten beim Prüfarzt einsehen.
Ich erkläre außerdem, dass ich mit der im Rahmen der Studie erfolgenden 
Aufzeichnungen von Krankheitsdaten/Studiendaten und ihrer anonymisierten
Weitergabe zur Überprüfung an die zuständige Überwachungsbehörde und, soweit 
es sich um personenbezogene Daten handelt, mit deren Einsichtnahme durch zur 
Verschwiegenheit verpflichtete Beauftragte oder der Behörden einverstanden bin. 
Hierbei wird §4, Abs. 3 des Landesdatenschutzgesetzes berücksichtigt. 
_____________ , den ____________ _____________________
Ort Datum Unterschrift der Patientin
Rheinische Friedrich-Wilhelms-Universität Bonn
Pharmazeutisches Institut, Klinische Pharmazie
Prof.  Dr. Ulrich Jaehde
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Coding system of drug-related problems: PI-Doc®, Version September 2000 
Tab. H-1 Main groups of drug-related problems (Schaefer, 2002) 
A Inappropriate drug choice 
A1 Unsuitable drug for indication 
A2 Physiological contraindication not considered 
A3 Contraindication by other disease not considered 
A4 Unintended use of two drugs with the same active substance 
A5 Unintended use of two drugs from the same therapeutic group 
A6 Missing or wrong application aids 
A7 Wrong strength 
A8 Unsuitable preparation 
A9 Unsuitable package size 
A10 Wrong spelling of the brand name on unreadable prescription 
A11 Drug out of the market 
C Inappropriate drug use by the patient/compliance 
C1 Insufficient knowledge about the application of the drug 
C2 Handling problems 
C3 Patient uses drug without an indication 
C4 Patient does not use a recommended drug (primary non-compliance) 
C5 Self-reliant change of the recommended dose by the patient 
C6 Unsuitable period of use 
C7 Unsuitable time of application 
C8 No or insufficient drug monitoring, where necessary 
D Inappropriate dosage 
D1 Patient does not know his or her dosage 
D2 No strength given, when more than one available 
D3 Overdosage 
D4 Underdosage 
D5 Unsuitable dosage intervals                                      to be continued on the next page 
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E Drug–drug interaction 
E1 Reference to an interaction by literature 
E2 Symptoms of an interaction 
E3 Patient’s fear of an interaction 
F Adverse drug reaction 
F1 Patient’s fear of adverse drug reactions 
F2 Symptoms of an adverse drug reaction 
F3 Medication stopped due to unacceptable adverse drug reaction 
G Other problems 
Patient-related 
GP1 Limited knowledge about the nature of the disease 
GP2 Non-specific fear of drug use in general 
GP3 Dissatisfaction with current treatment 
GP4 Unsuitable lifestyle of the patient 
GP5 Patient does not want to change his or her medication 
GP6 Patient does not receive a drug although an indication exists 
Physician-related 
GA1 Missing or incomplete information about drug use by the prescribing 
physician 
Communication-related 
GC1 Text of the package insert is too difficult to understand 
GC2 Information supplied by other health care professionals misinterpreted 
GC3 Language problems 
Technical and/or logistical 
GT1 Prescription for the wrong patient 
GT2 Problems with the sickness funds (refunding) 
GT3 Incomplete prescription 
GT4 Special distribution activities to get certain medicines 
GT5 Damaged packages, devices or application aids 
Appendix 
Tab. H-2 Main groups of drug-related interventions (Schaefer, 2002) 
I General interventions 
I0 Checking factual databases, books etc. 
I1 Interview and counselling 
I1a  Interviewing and counselling of the patient 
I1b Interview and counselling of the patient’s relatives 
I1c Educational programme for the patient 
I2 Contacting the physician 
I3 Referrals 
I3a  Refer a patient to a general practitioner 
I3b  Refer a patient to a specialist 
I3c  Refer a patient to self-help groups 
I3d  Recommending other health care professionals 
I4  Filling out a medication box for the patient in the pharmacy 
IA Intervention: inappropriate drug choice 
IA1 Selecting or recommending an appropriate drug for the indication 
IA2 Clarification with regard to a physiological contraindication 
IA3 Clarification with regard to a contraindication due to concomitant diseases 
IA4 Clarification of use of two drugs with the same active substance 
IA5 Clarification of use of two drugs of the same therapeutic group 
IA6 Clarification with regard to missing or wrong application aids 
IA7 Determination of the appropriate strength 
IA8 Determination of the appropriate administrative form 
IA9 Determination of the appropriate package size 
IA10 Clarification of a wrong spelling or unreadable prescription 
IA11 Clarification with regard to a prescribed drug which is out of the market 
 
 
 
 
 
to be continued on the following page
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IC Intervention: inappropriate drug use by the patient/compliance 
IC1 Advice for correct application 
IC2 Demonstration of the correct application, practicing with the patient 
IC3 Information about the risk of drug use without appropriate indication 
IC4 Searching for the reasons for primary non-compliance and counselling 
IC5 Searching for the reasons to change a recommended dosage by the patient 
and counselling 
IC6 Advice with regard to optimal duration of use 
IC7 Advice with regard to optimal time of application 
IC8 Initiating drug monitoring, information for the physician 
ID Intervention: inappropriate dosage 
ID1 Advice to the patient with regard to dosing 
ID2 Clarification with regard to the correct strength 
ID3 Clarification with regard to an overdosage 
ID4:  Clarification with regard to an underdosage 
ID5 Clarification with regard to suitable dosage intervals 
IE Intervention: drug interactions 
IE1 Attempt to clarify the clinical relevance of a drug interaction 
IE2 Observation of the symptoms of an interaction 
IE3 Advice to the patient in fear of an interaction 
IE4 Information about possible interactions and countermeasures 
IF Intervention: adverse drug reaction (ADR) 
IF1 Counselling patients fearing adverse drug reactions 
IF2 Documentation of symptoms of an adverse drug reaction 
IF3 Suggesting a change in medication to the physician 
IG Intervention: other problems 
 
 
 
 
 
 
to be continued on the following page
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Patient-related 
IGP1 Information from the patient about the nature of a disease 
IGP2 Reducing fears and prejudices of a drug therapy 
IGP3 Searching for reasons for dissatisfaction with current treatment 
IGP4 Advice to the patient with regard to a health-supporting life style 
IGP5 Clarification of the difference between a former and a current drug 
IGP6 Advice with regard to treatment opportunities of ailments/recommendation 
to see a physician 
Physician-related 
IGA1 Information to the physician about changes of the drug assortment 
Communication-related 
IGC1 Explanation of the package insert 
IGC2 Evaluation of information from different sources 
IGC3 Clarification of language problems 
Technical and logistical problems 
IGT1 Clarifying whether the patient got the right prescription 
IGT2 Clarification with the sickness fund 
IGT3 Clarification with regard to an incomplete or unreadable prescription 
IGT4 Measures taken to obtain certain drugs for the patient (esp. from abroad) 
IGT5 Replacement of damaged packages, devices or application aids 
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Appendix I 
Care material  
Patient information on expected side effects 
Was Sie darüber wissen sollten,
wie Sie Nebenwirkungen vorbeugen können,
und was Sie im Falle des Falles tun können!
Chemotherapie und die Nebenwirkungen
Sehr geehrte Patientin,
im Rahmen Ihrer Behandlung bekommen Sie eine 
Chemotherapie. Anders als die Operation und die Strahlen-
therapie wirken die in der Chemotherapie eingesetzten 
Wirkstoffe im ganzen Körper (systemisch), da sie über das Blut 
verteilt werden. Die Wirkstoffe sind gegen möglicherweise im 
Körper verteilte Krebszellen gerichtet. Die Wirkstoffe können 
jedoch nicht zwischen kranken und gesunden Zellen 
unterscheiden, so dass auch gesunde Zellen betroffen sein 
können. Das führt zu unerwünschten Nebenwirkungen.  
Hiervon sind hauptsächlich die Zellen in Ihrem Körper 
betroffen, die sich häufig teilen und dadurch erneuern. Dazu 
gehören zum Beispiel Haarzellen, Schleimhautzellen des 
Mundes und des Magen-Darmtraktes, Hautzellen und auch 
Zellen des Knochenmarks, welches Ihr Blut bildet. 
Wichtig für Sie zu wissen ist, dass nicht alle der beschriebenen 
Nebenwirkungen auch tatsächlich auftreten. Falls es jedoch 
dazu kommen sollte, ist es gut, wenn Sie bereits davon gehört 
haben und wissen, was Sie dagegen tun können.
Im Zweifel sprechen Sie Ihren betreuenden Arzt an und 
unterrichten ihn genau über die Nebenwirkung und die 
Maßnahmen, die Sie dagegen eingeleitet haben.
Die Wirkstoffe, die Sie in Ihrer Chemotherapie erhalten, 
heißen:        Epirubicin
Cyclophosphamid
Die Wirkstoffe werden eigens für Sie dosiert und die 
Infusionslösung wird speziell für Sie hergestellt. 
oBei Anzeichen einer 
Mundschleimhautentzündun
g rechtzeitig den Arzt 
informieren
oMundhygiene entsprechend 
der Vorbeugung fortsetzen
oVom Arzt verordnete 
entzündungshemmende und 
schmerzlindernde 
Spüllösungen und 
Pinselungen verwenden 
oWeiche Speisen 
bevorzugen
oEiswürfel aus Ananassaft 
lutschen
oZusätzliche Verletzungen 
vermeiden
oZahnsanierung beim Zahnarzt
oGründliche, schonende Mundhygiene
oWeiche Zahnbürsten verwenden
oAlkoholfreie Mundwässer verwenden
oSpülung mit lauwarmem Salbeitee
oZahnreinigende Kaugummis zur 
Speichelanregung kauen
oAusreichend trinken
oNikotin und Alkohol vermeiden
oScharfe, heiße und sehr saure Speisen 
vermeiden
Entzündungen 
im Mundraum 
(Mukositis)
oUrsache mit dem Arzt 
klären, evtl. Abführmittel 
einnehmen
oViel trinken!
oAusreichend trinken! (Pflaumensaft, Tee, 
Wasser)
oBewegung (z.B. Spazieren gehen)
oJedem Reiz, zur Toilette zu gehen, 
nachgeben
oBallaststoffreiche Ernährung (Vollkornbrot, 
Gemüse, Weizenkleie usw.) 
Verstopfung
(Obstipation)
oAusreichend trinken
oUrsache mit dem Arzt 
klären, evtl. Medikamente 
(Loperamid) einnehmen
oWeiches Toilettenpapier 
und feuchte Tücher 
verwenden
oBei Durchfallneigung Ernährung umstellen
(auf z.B. Weißbrot, Kartoffeln, Bananen, Äpfel, 
Mais usw.)
oVermeiden: Süßstoffe, Vollkornbrot, Kaffee, 
stark gewürzte Speisen, Fruchtsäfte, Obst (mit 
Ausnahmen   
s. o.), rohe Milch
oMineralwässer mit geringem Sulfatgehalt 
(SO4
-)trinken
Durchfall 
(Diarrhoe)
oViel frische Luft zuführen
oAusruhen
oBedarfsmedikation 
einnehmen
oAusreichend trinken
oVorbeugende Medikation wie verordnet 
einnehmen (nicht nur im Bedarfsfall!)
oGenerell gilt: Essen Sie, worauf Sie Appetit 
haben!!
oGroße Mahlzeiten vermeiden; 5-6 kleinere 
Mahlzeiten pro Tag essen
oKalte Speisen werden häufig besser toleriert 
als warme, ebenso gekühlte Flüssigkeiten
oAppetit durch säuerliche Bonbons, Speisen 
oder Getränke anreizen
oAusreichend frische Luft
oSchlaf, entspannende Musik oder 
Spaziergänge im Freien
oSüße, fette, stark gewürzte und gebratene 
Speisen vermeiden
oStarke Gerüche vermeiden
Übelkeit und 
Erbrechen
(Nausea und 
Emesis)
Im Falle des FallesVorbeugende MaßnahmenMögliche 
Nebenwirkung
oBei länger anhaltender 
Erschöpfung und Müdigkeit, die 
auch durch ausreichende 
Ruhepausen nicht deutlich 
verringert wird, den Arzt 
informieren
oVorbeugende Maßnahmen 
weiter verfolgen
oEntspannungsübungen
oRuhephasen einplanen
oAngemessene körperliche Bewegung 
(Spaziergänge im Freien)
oKoffein und Alkohol vor dem 
Einschlafen vermeiden
oAlltagspflichten auf andere übertragen 
(z.B. Familienmitglieder)
Müdigkeit und 
Erschöpfung 
(Fatigue)
oBei Schmerzen beim Wasser 
lassen und häufigem Harndrang 
den Arzt informieren
oBei Krämpfen eventuell 
Wärmeanwendung durch 
Heizkissen
oKeine Sitzbäder machen
oSorgfältige Intimhygiene
oSlipeinlagen verwenden
oViel trinken
oDen Drang zur Blasenentleerung nicht 
unterdrücken. Wenn  immer möglich 
Blase entleeren.
oNikotin, Koffein, Alkohol und scharfe 
Gewürze vermeiden 
oMilchprodukte essen
Blasenentzündung 
(Zystitis)
oBei Fieber > 38°C sofort den 
Arzt verständigen!
oErkältungsanzeichen genau 
beobachten 
oBei längerer Heilungsdauer 
üblicher Erkrankungen den Arzt 
aufsuchen
oVom Arzt verordnete 
Antibiotika regelmäßig und 
gemäß der Verordnung 
einnehmen
oAusreichende Ruhephasen
oUngekochtes Obst/Gemüse 
vermeiden
oGründliche Körperhygiene
oKontakt meiden zu:
-Menschen mit ansteckenden 
Erkrankungen 
-Frisch geimpften Menschen
Infektionen
oKopfhaut vor Kälte, Hitze und 
direkter Sonneneinstrahlung 
schützen
oBei Verlust der Wimpern, das 
Auge vor intensivem Licht und 
Staub bewahren
Haarausfall ist leider nicht durch 
vorbeugende Maßnahmen zu 
vermeiden oder zu lindern.  Sorgen Sie 
vorsorglich für geeigneten Haarersatz 
oder Kopfbedeckung anderer Art, die 
Ihnen gefällt. Die Haare werden nach 
Beendigung der Therapie wieder zu 
wachsen beginnen. 
Haarausfall
(Alopezie)
Im Falle des FallesVorbeugende MaßnahmenMögliche 
Nebenwirkung
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Questionnaires 
EORTC QLQ-C30 (v. 3.0) 
4321Haben Sie erbrochen?15.
4321War Ihnen übel?14.
4321Hatten Sie Appetitmangel?13.
4321Fühlten Sie sich schwach?12.
4321Hatten Sie Schlafstörungen?11.
4321Mussten Sie sich ausruhen?10.
4321Hatten Sie Schmerzen?9.
4321Waren Sie kurzatmig?8.
4321Waren Sie bei Ihren Hobbys oder anderen 
Freizeitbeschäftigungen eingeschränkt?
7.
4321Waren Sie bei Ihrer Arbeit oder bei anderen tagtäglichen 
Beschäftigungen eingeschränkt?
6.
SehrMäßigWenig
Überhaupt
nicht
Während der letzten Woche:
4321Brauchen Sie Hilfe beim Essen, Anziehen, Waschen oder 
Benutzen der Toilette?
5.
4321Müssen Sie tagsüber im Bett liegen oder in einem Sessel sitzen?4.
4321
Bereitet es Ihnen Schwierigkeiten, eine kurze Strecke ausser
Haus zu gehen?
3.
4321
Bereitet es Ihnen Schwierigkeiten, einen längeren
Spaziergang zu machen?
2.
4321
Bereitet es Ihnen Schwierigkeiten sich körperlich anzustrengen 
(z.B. eine schwere Einkaufstasche oder einen Koffer zu tragen?)
1.
SehrMäßigWenig
Überhaupt
nicht
Das heutige Datum (Tag, Monat, Jahr):
Ihr Geburtstag (Tag, Monat, Jahr):
Bitte tragen Sie Ihre Initialen ein:
Wir sind an einigen Angaben interessiert, die Sie und Ihre Gesundheit betreffen. Bitte beantworten Sie die folgenden 
Fragen selbst, indem Sie die Zahl ankreuzen, die am besten auf Sie zutrifft. Es gibt  keine “richtigen” oder “falschen”
Antworten. Ihre Angaben  werden streng vertraulich behandelt.
EORTC QLQ-C30 (version 3.0)
German
to be continued on the following page
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Continuation 
ausgezeichnetsehr schlecht
75432 61
Wie würden Sie insgesamt Ihre Lebensqualität während der letzten Woche einschätzen?30.
5432 761
ausgezeichnetsehr schlecht
Bitte kreuzen Sie bei den folgenden Fragen die Zahl zwischen 1 und 7 an, die am 
besten auf Sie zutrifft
© Copyright 1995 EORTC Study Group on Quality of Life. Alle Rechte vorbehalten. Version 3.0
Wie würden Sie insgesamt Ihren Gesundheitszustand während der letzten Woche einschätzen?29.
4321Hat Ihr körperlicher Zustand oder Ihre medizinische Behandlung
für Sie finanzielle Schwierigkeiten mit sich gebracht?
28.
4321Hat Ihr körperlicher Zustand oder Ihre medizinische
Behandlung Ihr Zusammensein oder Ihre gemeinsamen
Unternehmungen mit anderen Menschen beeinträchtigt?
27.
4321Hat Ihr körperlicher Zustand oder Ihre medizinische
Behandlung Ihr Familienleben beeinträchtigt?
26.
4321Hatten Sie Schwierigkeiten, sich an Dinge zu erinnern?25.
4321Fühlten Sie sich niedergeschlagen?24.
4321Waren Sie reizbar?23.
4321Haben Sie sich Sorgen gemacht?22.
4321Fühlten Sie sich angespannt?21.
4321Hatten Sie Schwierigkeiten sich auf etwas zu konzentrieren,
z.B. auf das Zeitunglesen oder das Fernsehen?
20.
4321
Fühlten Sie sich durch Schmerzen in Ihrem
alltäglichen Leben beeinträchtigt?
19.
4321
Waren Sie müde?18.
4321Hatten Sie Durchfall?17.
4321Hatten Sie  Verstopfung?16.
SehrMäßigWenig
Überhaupt
nicht
Während der letzten Woche:
German
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Nausea and emesis questionnaire including patient information 
Rheinische-Friedrich-Wilhelms Universität Bonn
Pharmazeutisches Institut
Klinische Pharmazie
Prof. Dr. U. Jaehde
Sehr geehrte Patientin,
die Chemotherapie, die Sie bekommen wird häufig von Übelkeit und Erbrechen begleitet.
Um diesen sehr unangenehmen Nebenwirkungen vorzubeugen, hat Ihnen Ihr behandelnder 
Arzt einige Medikamente verordnet, die, wenn sie in der vorgesehenen Art und Weise 
eingenommen werden, eine optimale Wirkung erzielen, damit Sie auch während Ihrer 
Therapie ein Leben mit Lebensqualität führen können.
Um einen Eindruck zu bekommen, wie gut die ausgewählte Therapie bei Ihnen Wirkung zeigt 
und ob es eventuell sinnvoll ist, Veränderungen vorzunehmen, bitten wir Sie, diesen 
Fragebogen sorgfältig auszufüllen.
1. Tragen Sie bitte in der Zeile „Erbrechen“ in Form einer Strichliste ein, wie oft Sie sich 
übergeben bzw. würgen mussten. 
(Einzelne Ereignisse liegen etwa 1 Minute auseinander. Wenn Sie länger als 5 Minuten 
kontinuierlich erbrechen und/oder würgen müssen, wird ab 5 Minuten ein neues 
Ereignis gezählt. Beispiel: 7 Minuten = 2 Ereignisse)
Berücksichtigen Sie bitte die Uhrzeit, zu der das Ereignis eingetreten ist und machen 
Sie in der entsprechenden Spalte einen Strich.
1. In Folge der Chemotherapie muss es nicht zwingend zum Erbrechen kommen.
In den ersten Tagen nach der Behandlung kann es allerdings gelegentlich zu Gefühlen 
von Übelkeit kommen.
Die Stärke der Übelkeit kann unterschiedlich ausgeprägt sein.
0 Ich empfinde keine Übelkeit
1 Die empfundene Übelkeit ist nur leicht und beeinträchtigt mich nicht in 
meinem normalen Tagesablauf
2 Die empfundene Übelkeit ist mäßig und beeinträchtigt mich in meinem 
normalen Tagesablauf.
3 Die empfundene Übelkeit ist schwer und beeinträchtigt mich in meinem 
normalen Tagesablauf
4 Die empfundene Übelkeit ist schwer und macht einen normalen 
Tagesablauf unmöglich.
3. Alle unmarkierten Felder werden als ereignisfrei gewertet.
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Appendix 
Patient satisfaction questionnaire (PS-CaTE) 
 
 
Untersuchung der Patientenzufriedenheit 
mit der Information zur Krebsbehandlung
Sehr geehrte Patientin,
mit diesem Schreiben bitten wir Sie, an einer von uns initiierten interessanten 
Studie teilzunehmen. Wir versuchen herauszufinden, wie zufriedenstellend die 
Informationen waren, die Sie (und andere Betroffene) bis zum heutigen Tage 
über Ihre Krebsbehandlung erhalten haben.
Mit dieser Untersuchung wollen wir zum einen feststellen, inwieweit die 
Bereitstellung von Informationen Ihren Erwartungen entspricht und wo Sie 
noch verbessert werden könnte. Zum anderen können uns Ihre Auskünfte und 
Anregungen dazu dienen, künftig bessere, auf Sie als Patienten 
zugeschnittene Informationsbroschüren zu entwickeln.
Die vorliegende Untersuchung gliedert sich in drei Abschnitte. Abschnitt eins 
fragt Sie anhand vorgegebener Aussagen nach Ihrer Meinung zu den
erhaltenen Informationen. Abschnitt zwei beschäftigt sich mit den von Ihnen 
genutzten Informationsquellen. Schließlich werden in Abschnitt drei noch 
allgemeine Daten abgefragt, die für die wissenschaftliche Auswertung wichtig 
sind.
Alle Daten werden anonymisiert ausgewertet, deswegen ist es wichtig, dass 
sie weder Namen noch Anschrift auf einem der Bögen vermerken. Wir 
versichern Ihnen, dass zu keiner Zeit Rückschlüsse von den Daten auf eine 
bestimmte Person möglich sind.
Wir würden uns sehr freuen, wenn Sie uns Ihre Kommentare und Vorschläge 
auf der letzten Seite mitteilten.
Wir bedanken uns schon im Voraus für Ihre Mithilfe und Ihre Mühe.
Mit freundlichen Grüßen
Ihre
Meike Eckhardt Andrea Liekweg
(Diplomandin) (Wissenschaftliche Mitarbeiterin)
Bei Rückfragen stehen wir Ihnen gerne zur Verfügung.
Rheinische-Friedrich-Wilhelms
Universität Bonn
Pharmazeutisches Institut
Klinische Pharmazie
Prof. Dr. U. Jaehde
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Documentation 
Patient profile I 
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Appendix 
Patient profile II 
Basisdaten
m2kgm
m2kgm
m2kgm
m2kgm
m2kgm
m2kgm
KörperoberflächeKörpergewichtKörpergrößeDatum
Lebensgewohnheiten
Kaffee-/ 
Teekonsum
Haustiere
AlkoholkonsumHobbies
Rauchen
GesellschaftsdrogenKörperliche Ertüchtigung
Art der Ernährung
> 5 
Gläser/Tag
3 – 5 
Gläser/Tag
< 3 
Gläser/Tag
Flüssigkeitszufuhr
Obst, Gemüse (zweimal täglich)
Fleisch, Fisch, Geflügel (täglich)
Hülsenfrüchte/Eier (wöchentlich)
Milchprodukte (täglich)
neinjaLebensmittelauswahl
321Wie viele Hauptmahlzeiten isst der Patient pro Tag?
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Medication file 
Bemerkung
Bemerkung
Bemerkung
Bemerkung
ReichdauerPackungs-
größe
Therapie-
zeitraum
IndikationDosierungStärkeWirkstoffePräparat
 
Medication profile 
BemerkungDosierungArzneimittel/Stärke
 
Care plan 
BeobachtungsparameterP
Empfehlung
A
Problemanalyse
O
Objektive Parameter
S
Subjektive Beschwerden
Datum
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Appendix L 
Platinum analysis 
Tab. L-1  Instrumentation and operating conditions 
Atomic absorption spectrometer SpectrAA® Zeeman 220, Varian, Darmstadt, 
Germany 
Graphite tube atomizer  GTA 100 
Autosampler  PSD 100 
Data evaluation Software SpectrAA® 220 Version 2.20 
Hollow cathode lamp UltrAA® lamp, platinum 
UltrAA® lamp control module 
Graphite tubes  Partition tubes coated 
Sample vials Polyethylen vials, 2 mL, conical 
Wavelength 265.9 nm 
Monochromator 0.5 nm slit width with reduced slit height 
Lamp current 10 mA 
Background correction Zeeman 
Injection volume 20 µl  
Purelab Plus® pure water system USF Reinstwassersysteme, Ransbach-Baumbach, 
Germany 
VoluMate® Pipettes Mettler-Toledo GmbH & Co, Gießen, Germany 
Eppendorf® Pipettes Eppendorf AG, Hamburg, Germany 
Centrifuge Rotanta RP Hettich GmbH & Co KG, Tuttlingen, Germany 
Centrifuge Universal 30RF Hettich GmbH & Co KG, Tuttlingen, Germany 
Centrifuge Megafuge 1.0R Heraeus GmbH & Co KG, Hanau, Germany 
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Tab. L-2 Chemicals and Reagents 
Chemicals 
 
Carboplatin Sigma, Taufkirchen, Germany 
Nitric acid ‘Suprapur’ 65 % Merck, Darmstadt, Germany 
Triton® X-100 Serva, Heidelberg, Germany 
Purelab Plus®-water USF Reinstwassersysteme, Ransbach Baumbach, 
Germany 
Argon 4.6 Air Product, Hattingen, Germany 
Solutions 
 
Triton-X-solution 1% 2,5 mL Triton-X 
water ad 250 mL   
Nitric acid 6.5% 100 mL Nitric acid 65 % 
water ad 1000 mL 
Carboplatin stock solution  
[1 mg Pt/mL] 
19.0 mg Carboplatin 
water ad 10.0 mL 
Carboplatin work solution 1  
[10 µg Pt/mL] 
100 µl stock solution 
water ad 10.0 mL 
Consumables 
 
Cellstar® tubes (15 mL)  Greiner Labortechnik, Frickenhausen, Germany 
PP-  reaction tubes (1.5 mL)  Greiner Labortechnik, Frickenhausen, Germany 
Pipette tips Greiner Labortechnik, Frickenhausen, Germany 
Graphite tubes  
(Partition tubes coated) 
Varian, Darmstadt, Germany 
Sample vials  
(Polyethylen vials, 2 mL, conical) 
Varian, Darmstadt, Germany 
S-Monovettes® 9 mL EDTA KE Sarstedt, Nümbrecht, Germany 
Centrifree® Millipore Amicon, Bedford, MA, USA 
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Tab. L-3 Validation of the FAAS method 
  Plasma Ultrafiltrate 
LLOQ [ng/mL] 20 5 
Recovery [%] Concentration 
[ng/mL] 
Recovery 
[%] 
Concentration 
[ng/mL] 
Recovery  
[%] 
  50  100.3  5  83.3  
  200  97.1  20  87.3  
  500  96.2  50  88.8  
Linearity  
Calibration set 
F value  
[< 34.12] 
Correlation 
coefficient r  
[> 0.99] 
F value  
[< 34.12] 
Correlation 
coefficient r 
[> 0.99] 
1  4.37  0.9987  4.37  0.9998  
2  0.58  0.9996  3.09  0.9985  
3  3.13  0.9993  1.94  0.9997  
4  4.07  0.9997  0.08  0.9994  
5  4.35  0.9995  24.38  0.9989  
Accuracy RE [%]* Between-day plasma Between-day ultrafiltrate 
Calibrators  0.3 - 2.3  0.6 - 3.4  
PQC  0.5 - 0.7  0.5 - 10.7  
SQC  1.6 - 6.4  1.6 - 8.0  
Precision RSD [%]*     
Calibrators  0.9 - 5.8  1.2 - 7.1   
PQC  2.7 - 3.6  1.5 - 4.7   
SQC  5.8 - 7.8  1.6 - 4.9   
*Presented are the absolut values of the smallest and highest values of all performed   
  measurements. 
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Tab. L-4 Accuracy assessment using QC samples 
Plasma 
Concentration 
[ng/mL] 
Nominal concentration 
[ng/mL] 
RE  
[%] 
PQC 500 439.9  500.0  -12.0  
PQC 500 464.1  500.0  -7.2  
PQC 2500 2358.3  2500.0  -5.7  
PQC 2500 2431.2  2500.0  -2.8  
PQC 5000 4801.3  5000.0  -4,0  
SQC 500 439.9  500.0  -12.0  
SQC 2000 2144.6  2000.0  7.2  
SQC 2000 2338.9  2000.0  16.9  
SQC 4000 4271.9  4000.0  6.8  
SQC 4000 4271.9  4000.0  6.8  
SQC 20000 4407.9  4000.0  10.2  
SQC 20000 4519.6  4000.0  13.0  
Ultrafiltrate 
Concentration 
[ng/mL] 
Nominal concentration 
[ng/mL] 
RE  
[%] 
PQC 500 394.0  500.0  -21.2  
PQC 500 447.2  500.0  -10.6  
PQC 2500 2339.0  2500.0  -6.4  
PQC 2500 2547.0  2500.0  1.9  
PQC 5000 4951.7  5000.0  -1.0  
SQC 500 514.9  500.0  3.0  
SQC 2000 1705.2  2000.0  -14.7  
SQC 2000 1850.3  2000.0  -7.5  
SQC 4000 3582.5  4000.0  -10.4  
SQC 4000 3640.5  4000.0  -9.0  
SQC 20000 3480.9  4000.0  -13.0  
SQC 20000 3480.9  4000.0  -13.0  
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Appendix M 
Monitoring of carboplatin 
Tab. M-1 Platinum concentrations and resulting AUCs 
  Pt conc. [µg/mL] Carboplatin conc. 
[µg/mL] 
AUC [mg⋅min/mL] 
Code Sample Plasma UF Plasma UF Plasma UF 
KOM01 BKHZIP1 16.41  13.65 31.22 25.98 7.03  4.85 
 BKHZIP2 6.22  3.72 11.84 7.08      
 BKHZIVP1 8.15  5.36 15.51 10.19 5.91  3.96 
 BKHZIVP2 5.84  3.66 11.12 6.96      
 BKHZVIP1 9.02  7.27 17.17 13.83 3.89  2.82 
 BKHZVIP2 3.09  1.91 5.87 3.64      
KOD01 MLKHZIP1 11.74  11.31 22.35 21.52 4.84  3.93 
 MLKHZIP2 3.97  2.83 7.56 5.38      
 MLKHZIIIP1 17.11  15.40 32.56 29.30 5.29  4.64 
 MLKHZIIIP2 3.85  3.22 7.33 6.14      
 MLKHZVIP1 11.09  9.71 21.10 18.48 4.32  3.08 
 MLKHZVIP2 3.37  1.93 6.42 3.68      
KOK11 IKUKZIP1 10.07  8.62 19.16 16.41 4.97  4.09 
 IKUKZIP2 4.36  3.40 8.30 6.48      
 IKUKZIIIP1 8.00  7.90 15.23 15.03 4.61  3.66 
 IKUKZIIIP2 4.16  2.93 7.91 5.58      
 IKUKZVIP1 9.36  7.29 17.82 13.88 5.46  3.90 
 IKUKZVIP2 5.09  3.33 9.69 6.33      
KOS01 KBNZIP1 13.08  9.52 24.89 18.11 5.13  3.83 
 KBNZIP2 4.17  2.94 7.94 5.59      
 KBNZIIIP1 10.53  7.99 20.04 15.21 4.57  3.94 
 KBNZIIIP2 3.78  3.28 7.19 6.24      
 KBNZVIP1 10.04  7.36 19.11 14.01 4.91  3.37 
 KBNZVIP2 4.29  2.61 8.16 4.98      
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Tab. M-2  Serum creatinine and GFR-estimation 
 KOM01 KOD01 KOK11 KOS01 
Serum creatinine pre-treatment 
[mg/dL] 
0.6 
 
0.56 
 
1  0.81 
GFR [mL/min] according to CG 108.61  127.31  57.00  61.02 
GFR [mL/min] according to Jelliffe 109.20  128.76  52.09  62.68 
Serum creatinine pre-cycle III [mg/dL] n.s.  0.59  0.85  n.s. 
GFR [mL/min] according to CG n.s.  120.84  67.06  n.s. 
GFR [mL/min] according to Jelliffe n.s.  122.21  61.28  n.s. 
Serum creatinine pre-cycle VI [mg/dL] 0.6  n.s.  0.86  n.s. 
GFR [mL/min] according to CG 108.61  n.s.  66.28  n.s. 
GFR [mL/min] according to Jelliffe 109.20  n.s.  60.57  n.s. 
Normal ratio Serum creatinine [ng/mL] 0.49-0.9     
CG = Cockroft-Gault     
 
Tab. M-3 NCI Common toxicity criteria  
Grade 0 1 2 3 4 
Platelets (⋅109/L) WNL <LLN - 75.0 ≥50.0-<75.0 ≥10.0-<50.0  <10.0 
Leukocytes (⋅109/L) WNL <LLN - 3.0 ≥2.0 - <3.0 ≥1.0 - <2.0 <1.0 
WNL = Within normal limits   
LLN = Lower limit of normal   
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